Amin M. Alousi, M.D.

Peer-Reviewed Articles

1. Smallbone, PI, Mendt Vilchez, MC, Sackstein, R, Tanner, MR, Kaur, I, Basar, R, Rafei, H, Daher, M, Overman, B, Al-Atrash, G, Alousi, AM, Bashir, Q, Hosing, C, Im, JS, Kebriaei, P, Banerjee, PP, Patel, KP, Zou, J, Cao, K, Khouri, IF, Mehta, RS, Molldrem, JJ, Nieto, Y, Oran, B, Popat, UR, Qazilbash, MH, Rondon, G, Saini, N, Srour, S, Champlin, RE, Rezvani, K, Shpall, E, Olson, AL. Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftment. Cytotherapy 28(3), 2026. e-Pub 2026. PMID: 41396090.
2. Louloudis, IE, Chen, YB, Spyrou, N, Alousi, AM, Katsivelos, N, Ayuk, F, Weber, D, Hogan, WJ, Etra, AM, Qayed, M, Aguayo-Hiraldo, P, Akahoshi, Y, Malki, MM, Bolaños-Meade, J, Chanswangphuwana, C, Diniz, MA, Eder, M, Hexner, E, Kitko, C, Kraus, S, Merli, P, Olson, T, MacMillan, ML, Pidala, J, Reshef, R, Schechter, T, Wölfl, M, Baez, J, Eng, G, Gleich, S, Young, R, Nakamura, R, Ferrara, JL, Levine, JE. Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity. Transplantation and Cellular Therapy 32(1):63.e1-63.e11, 2026. e-Pub 2026. PMID: 41015085.
3. Jen, WY, Croden, J, Almanza-Huante, E, DiNardo, C, Chien, KS, Hammond, DE, Qiao, W, Alvarado, Y, Masarova, L, Quesada, AE, Pierce, S, Bataller Torralba, A, Garcia-Manero, G, Alousi, AM, Short, NJ, Daver, N, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia. HemaSphere 9(10), 2025. e-Pub 2025. PMID: 41132245.
4. Brehm, V, Wang, Z, Rocha, L, Jones, B, Jenq, RR, Chang, C, Cheng, GS, Hsu, JL, Sharifi, H, Yanik, G, Luna, L, Waqar, A, Zaveri, JS, Dickey, BF, Bashoura, L, Shpall, E, Zinter, MS, O'Dwyer, D, Champlin, RE, Chen, GL, Alousi, AM, Paczesny, S, Peterson, CB, Sheshadri, A. Inflammatory Markers and Microbiome Dysbiosis in Hematopoietic Cell Transplant Recipients with Lung Graft-versus-Host Disease. Transplantation and Cellular Therapy 31(9):668.e1-668.e12, 2025. e-Pub 2025. PMID: 40543709.
5. Kadia, TM, Jen, WY, Bataller Torralba, A, Bazinet, A, Borthakur, G, Jabbour, EJ, Qiao, W, Short, NJ, Takahashi, K, Issa, GC, DiNardo, C, Montalban Bravo, G, Pemmaraju, N, Tran, A, Bharathi, V, Loghavi, S, Alousi, AM, Popat, UR, Daver, N, Ravandi-Kashani, F, Kantarjian, HM. A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia. American journal of hematology 100(8):1365-1373, 2025. e-Pub 2025. PMID: 40401707.
6. Smallbone, PI, Shigle, TL, Paslovsky, O, Hosing, C, Alousi, AM, Bashir, Q, Aljawai, YM, Ramdial, JL, Popat, UR, Champlin, RE, Shpall, E, Oran, B. Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndrome. Haematologica 110(8):1798-1807, 2025. e-Pub 2025. PMID: 40013380.
7. Oran, B, Thall, PF, Alousi, AM, Al-Atrash, G, Mehta, RS, Marin, D, Kebriaei, P, Popat, UR, Bassett Jr, R, Bashir, Q, Im, JS, Olson, AL, Jewell, J, Smallbone, PI, Shpall, E, Champlin, RE. Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant. Haematologica 111(1):149-157, 2025. e-Pub 2025. PMID: 40702903.
8. Sharma, R, Holtzman, NG, Pusic, I, Cutler, C, Treister, NS, Mehta, RS, Alousi, AM, Vigneswaran, N, Javaid, A, Boksa, F, Mody, DP, Costa-Da-Silva, AC, Schueller, O, Macé, S, Yao, Y, Ji, R, Hu, B, Marshall, K, Blazar, BR, Lee, SJ, Pavletic, S, Mays, JW. Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis. Blood Advances 9(14):3479-3494, 2025. e-Pub 2025. PMID: 40311075.
9. Abedin, S, Martens, M, Bolaños-Meade, J, Al Malki, MM, Lian, Q, Runaas, L, Elmariah, H, Gooptu, M, Larkin, K, Shaffer, BC, Loren, A, Solh, MM, Alousi, AM, Jamy, O, Perales, MA, Rezvani, A, Bhatt, AS, Jurdi, NE, Yao, JM, Applegate, K, Kean, LS, Efebera, Y, Reshef, R, Clark, WB, Leifer, ES, Saber, W, Horowitz, MM, JONES, RJ, Holtan, SG, Hamadani, M. Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older. Blood Advances 9(14):3495-3501, 2025. e-Pub 2025. PMID: 40305657.
10. Nieto, Y, Banerjee, PP, Kaur, I, Basar, R, Li, YE, Daher, M, Rafei, H, Kerbauy, LN, Kaplan, M, Marin, D, Griffin, L, Barnett, M, Bassett Jr, R, Uprety, N, Shrestha, R, Silva, FR, Islam, S, Ganesh, C, Borneo, Z, Ramdial, JL, Ramirez, A, Hosing, C, Alousi, AM, Popat, UR, Qazilbash, MH, Ahmed, S, Iyer, SP, Sainz, TP, Vega Vazquez, F, Fowlkes, NW, Alexis, K, Emig, M, Harstrick, A, Overesch, A, Shpall, E, Rezvani, K. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma. Nature medicine 31(6):1987-1993, 2025. e-Pub 2025. PMID: 40186077.
11. Alkhunaizi, M, Soto-Lanza, F, Leung, CH, Bhan, N, Bashoura, L, Dickey, BF, Sharifi, H, Cheng, GS, Yanik, G, Rondon, G, Saliba, RM, Chen, GL, Al-Atrash, G, Hosing, C, Kebriaei, P, Popat, UR, Shpall, E, Champlin, RE, Li, L, Alousi, AM, Sheshadri, A. Restrictive Ventilatory Defects Following Hematopoietic Stem Cell Transplant Are Associated With Increased Mortality. Transplantation and Cellular Therapy 31(4):255.e1-255.e10, 2025. e-Pub 2025. PMID: 39921208.
12. Nieto, Y, Ramdial, JL, Valdez, B, Thall, PF, Bassett Jr, R, Barnett, M, Srour, S, Hosing, C, Alousi, AM, Qazilbash, MH, Popat, UR, Gulbis, A, Shigle, TL, Ahmed, S, Pacheco, MG, Champlin, RE, Shpall, E, Andersson, BS. Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clinical Cancer Research 31(6):975-982, 2025. e-Pub 2025. PMID: 39804167.
13. Holtan, SG, Bolaños-Meade, J, Al Malki, MM, Wu, J, Kitko, C, Reshef, R, Rezvani, A, Shaffer, BC, Solh, MM, Yao, JM, Runaas, L, Elmariah, H, Larkin, K, El-Jurdi, N, Gooptu, M, Loren, A, Hall, AC, Alousi, AM, Jamy, O, Clark, WB, Kean, LS, Bhatt, AS, Perales, MA, Applegate, K, Efebera, Y, Leifer, ES, JONES, RJ, Horowitz, MM, Mattila, D, Saber, W, Hamadani, M, Martens, M. Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide. Journal of Clinical Oncology 43(8):912-918, 2025. e-Pub 2025. PMID: 39752608.
14. Senapati, J, Kantarjian, HM, Haddad, FG, Short, NJ, Borthakur, G, Kanagal Shamanna, R, Tang, G, Jabbour, EJ, DiNardo, C, Daver, N, Montalban Bravo, G, Shah, V, Alousi, AM, Shpall, E, Popat, UR, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia. American journal of hematology 100(2):249-259, 2025. e-Pub 2025. PMID: 39718824.
15. Bashir, Q, Konopleva, M, Abueg, G, Ramdial, JL, Hosing, C, Srour, S, Alousi, AM, Popat, UR, Nieto, Y, Al-Atrash, G, Champlin, RE, Shpall, E, Qazilbash, MH, Pemmaraju, N. Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasm. Leukemia Research Reports 24, 2025. e-Pub 2025. PMID: 40612021.
16. Ramdial J, Lin R, Thall PF, Valdez BC, Hosing C, Srour S, Popat U, Qazilbash M, Alousi A, Barnett M, Gulbis A, Shigle TL, Shpall EJ, Andersson BS, Nieto Y. High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas. Bone Marrow Transplant 59(12):1754-1762, 2024. e-Pub 2024. PMID: 39341929.
17. Marcoux CM, Alousi AM, Im J, Hill LC, Smallbone P, Popat U, Hosing C, Kebriaei P, Olson A, Mehta R, Chen G, Qazilbash M, Shpall E, Champlin RC, Saliba RM. Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease. Bone Marrow Transplant 59(11):1594-1600, 2024. e-Pub 2024. PMID: 39187601.
18. Wallis W, Gulbis AM, Wang T, Lee CJ, Sharma A, Williams KM, Nishihori T, Prestidge T, Gowda L, Byrne M, Krem MM, MacMillan ML, Kitko CL, Pidala J, Spellman SR, Lee SJ, Alousi AM. Incidence of bacterial blood stream infections in patients with acute GVHD. Bone Marrow Transplant 60(1):52-57, 2024. e-Pub 2024. PMID: 39420192.
19. Sharifi H, Bertini CD, Alkhunaizi M, Hernandez M, Musa Z, Borges C, Turk I, Bashoura L, Dickey BF, Cheng GS, Yanik G, Galban CJ, Guo HH, Godoy MCB, Reinhardt JM, Hoffman EA, Castro M, Rondon G, Alousi AM, Champlin RE, Shpall EJ, Lu Y, Peterson S, Datta K, Nicolls MR, Hsu J, Sheshadri A. CT strain metrics allow for earlier diagnosis of bronchiolitis obliterans syndrome after hematopoietic cell transplant. Blood Adv 8(19):5156-5165, 2024. e-Pub 2024. PMID: 39163616.
20. Senapati J, Kantarjian HM, Bazinet A, Reville P, Short NJ, Daver N, Borthakur G, Bataller A, Jabbour E, DiNardo C, Haddad F, Sasaki K, Popat U, Oran B, Alousi AM, Loghavi S, Shpall E, Garcia-Manero G, Ravandi F, Kadia TM. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer 130(19):3333-3343, 2024. e-Pub 2024. PMID: 38809547.
21. Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, Hamadani M, Arai S, Salhotra A, Perez-Simon JA, Alousi A, Choe H, Kwon M, Bermudez A, Kim I, Socie G, Chhabra S, Radojcic V, O'Toole T, Tian C, Ordentlich P, DeFilipp Z, Kitko CL. Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease. N Engl J Med 391(11):1002-1014, 2024. e-Pub 2024. PMID: 39292927.
22. Nebgen DR, Cheng L, Alousi AM, Ferrajoli A. Decreased Transfusions in Premenopausal Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation Given Leuprolide According to an Abnormal Uterine Bleeding Algorithm. JCO Oncol Pract 21(4):OP2400169, 2024. e-Pub 2024. PMID: 39284100.
23. Hayase E, Hayase T, Mukherjee A, Stinson SC, Jamal MA, Ortega MR, Sanchez CA, Ahmed SS, Karmouch JL, Chang CC, Flores II, McDaniel LK, Brown AN, El-Himri RK, Chapa VA, Tan L, Tran BQ, Xiao Y, Fan C, Pham D, Halsey TM, Jin Y, Tsai WB, Prasad R, Glover IK, Enkhbayar A, Mohammed A, Schmiester M, King KY, Britton RA, Reddy P, Wong MC, Ajami NJ, Wargo JA, Shelburne S, Okhuysen PC, Liu C, Fowler SW, Conner ME, Katsamakis Z, Smith N, Burgos da Silva M, Ponce DM, Peled JU, van den Brink MRM, Peterson CB, Rondon G, Molldrem JJ, Champlin RE, Shpall EJ, Lorenzi PL, Mehta RS, Martens EC, Alousi AM, Jenq RR. Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease. Cell Host Microbe 32(9):1621-1636.e6, 2024. e-Pub 2024. PMID: 39214085.
24. Saliba RM, Lee SJ, Carpenter PA, Hill GR, Lee CJ, Alousi A, Daher M, Chen G, Champlin RE, Rezvani K, Shpall EJ, Mehta RS. Mycophenolate mofetil is associated with inferior overall survival in cytomegalovirus seropositive patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. Haematologica 109(7):2321-2325, 2024. e-Pub 2024. PMID: 38426274.
25. Saengboon S, Ciurea S, Popat U, Ramdial J, Bashir Q, Alousi A, Chen J, Rondon G, Olson A, Im J, Hosing C, Shpall E, Champlin R, Srour SA. Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies. Blood Adv 8(12):3237-3245, 2024. e-Pub 2024. PMID: 38607399.
26. Febres-Aldana A, Khawaja F, Morado-Aramburo O, Shigle TL, Rondon G, Sassine J, Spallone A, Srinivasan K, Ramdial J, Alousi A, Champlin R, Chen G, Daher M, Rezvani K, Ariza-Heredia EJ, Shpall EJ, Chemaly RF. Mortality in recipients of allogeneic hematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: A single center retrospective Experience. Clin Microbiol Infect 30(6):803-809, 2024. e-Pub 2024. PMID: 38460821.
27. Malek AE, Al-Juhaishi T, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Faisal MS, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich VE, Ahmed S. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone Marrow Transplant 59(5):699-704, 2024. e-Pub 2024. PMID: 38355908.
28. Pasvolsky O, Saliba RM, Popat UR, Alousi A, Mehta R, Yeh J, Al-Atrash G, Adeel M, Ramdial J, Marin D, Rondon G, Kebriaei P, Champlin R, Daver N, Dinardo C, Short NJ, Shpall EJ, Oran B. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 24(5):e196-e204, 2024. e-Pub 2024. PMID: 38403505.
29. Ahmed S, Bashir Q, Bassett RL, Ullah F, Aung F, Valdez BC, Alousi AM, Hosing C, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Rezvani K, Mehta R, Shpall EJ, Ciurea S, Andersson BS, Champlin RE, Popat UR. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. Am J Hematol 99(4):562-569, 2024. e-Pub 2024. PMID: 38314663.
30. Marcoux C, Saliba RM, Wallis W, Khazal S, Ragoonanan D, Rondon G, Tewari P, Popat U, Oran B, Olson A, Bashir Q, Qazilbash M, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin D, Rezvani K, Khouri I, Srour S, Champlin R, Shpall E, Kebriaei P. Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation. Blood Adv 8(5):1128-1136, 2024. e-Pub 2024. PMID: 38266155.
31. McCarthy PL, Attwood KM, Liu X, Chen GL, Minderman H, Alousi A, Bashey A, Lowsky R, Miklos DB, Hansen J, Westervelt P, Yanik G, Waller EK, Howard A, Blazar BR, Wallace PK, Reshef R, Horowitz MM, Maziarz RT, Levine JE, Mohammadpour H. Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study. Bone Marrow Transplant 59(3):334-343, 2024. e-Pub 2024. PMID: 38110620.
32. Yalniz FF, Greenbaum U, Pasvolsky O, Milton DR, Kanagal-Shamanna R, Ramdial J, Srour S, Mehta R, Alousi A, Popat UR, Nieto Y, Kebriaei P, Al-Atrash G, Oran B, Hosing C, Ahmed S, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation. Transplant Cell Ther 30(2):205.e1-205.e12, 2024. e-Pub 2024. PMID: 37437764.
33. Dickey, JS, Dickey, BF, Alousi, AM, Champlin, RE, Sheshadri, A. Early and rapid development of bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation. Respiratory Medicine Case Reports 49, 2024. e-Pub 2024. PMID: 38745870.
34. Im A, Pusic I, Onstad L, Kitko CL, Hamilton BK, Alousi AM, Flowers ME, Sarantopoulos S, Carpenter P, White J, Arai S, El Jurdi N, Chen G, Cutler C, Lee S, Pidala J. Patient-reported treatment response in chronic graft-versus-host disease. Haematologica 109(1):143-150, 2024. e-Pub 2024. PMID: 37226713.
35. Joseph J, Srour SA, Milton DR, Ramdial JL, Saini NY, Olson AL, Bashir Q, Oran B, Alousi AM, Hosing C, Qazilbash MH, Kebriaei P, Shpall EJ, Champlin RE, Popat UR. Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplant Cell Ther 29(12):770.e1-770.e6, 2023. e-Pub 2023. PMID: 37742746.
36. Marinos A, Ramdial J, Khawaja F, Saliba RM, Shigle TL, Alousi AM, Rondon G, Chen J, Ledesma C, Champlin RE, Daher M, Chen G, Marin D, Rezvani K, Shpall EJ, Chemaly RF. Hematopoietic cell transplantation can be safely performed after COVID-19. Bone Marrow Transplant 58(12):1410-1412, 2023. e-Pub 2023. PMID: 37726490.
37. Alkhaldi H, Reinhardt A, Barnett M, Kundu S, Hosing C, Ramdial J, Saini N, Srour S, Alousi A, Kebriaei P, Popat U, Qazilbash M, Champlin R, Shpall EJ, Gulbis A, Shigle TL, Dabaja B, Pinnix C, Ahmed S, Steiner R, Andersson BS, Nieto Y. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Transplant Cell Ther 29(11):690-694, 2023. e-Pub 2023. PMID: 37607645.
38. Popat UR, Pasvolsky O, Bassett R, Mehta RS, Olson A, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Saini N, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. Blood Adv 7(20):6196-6205, 2023. e-Pub 2023. PMID: 37611156.
39. Button JE, Cosetta CM, Reens AL, Brooker SL, Rowan-Nash AD, Lavin RC, Saur R, Zheng S, Autran CA, Lee ML, Sun AK, Alousi AM, Peterson CB, Koh AY, Rechtman DJ, Jenq RR, McKenzie GJ. Precision modulation of dysbiotic adult microbiomes with a human-milk-derived synbiotic reshapes gut microbial composition and metabolites. Cell Host Microbe 31(9):1523-1538.e10, 2023. e-Pub 2023. PMID: 37657443.
40. Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica 108(9):2331-2342, 2023. e-Pub 2023. PMID: 36951163.
41. Mehta RS, Ali H, Dai Y, Yao B, Overman B, Ratanatharathorn V, Gill S, Socié G, Anderson K, Cahn JY, Mujeebuddin A, Champlin R, Shpall E, Holtan SG, Alousi A. A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement. Bone Marrow Transplant 58(9):1-9, 2023. e-Pub 2023. PMID: 37202544.
42. Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, DiNardo CD, Daver N, Yilmaz M, Abbas HA, Short NJ, Issa G, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia T. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol 98(9):1383-1393, 2023. e-Pub 2023. PMID: 37334870.
43. Ostrin EJ, Rider NL, Alousi AM, Irajizad E, Li L, Peng Q, Kim ST, Bashoura L, Arain MH, Noor LZ, Patel N, Mehta R, Popat UR, Hosing C, Jenq RR, Rondon G, Hanash SM, Paczesny S, Shpall EJ, Champlin RE, Dickey BF, Sheshadri A. A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept. Immunohorizons 7(6):421-430, 2023. e-Pub 2023. PMID: 37289498.
44. Mehta RS, Ramdial J, Marin D, Alousi A, Kanakry CG, Champlin RE, Rezvani K, Shpall EJ, Page K, Gadalla SM, Kebriaei P, Weisdorf D. Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia. Transplant Cell Ther 29(6):377.e1-377.e7, 2023. e-Pub 2023. PMID: 36990221.
45. Khawaja F, Srinivasan K, Spallone A, Feldman A, Cantu S, Ariza-Heredia E, Dvordak T, Alousi A, Ahmed S, George M, Frenzel E, Bhatti M, Chemaly RF. Nosocomial COVID-19 at a comprehensive cancer center during the first year of the pandemic: Lessons learned. Am J Infect Control 51(5):506-513, 2023. e-Pub 2023. PMID: 35901993.
46. Marcoux C, Marin D, Ramdial J, AlAtrash G, Alousi AM, Oran B, Kebriaei P, Popat UR, Rezvani K, Champlin RE, Shpall EJ, Mehta RS. Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS. Am J Hematol 98(5):712-719, 2023. e-Pub 2023. PMID: 36734029.
47. Mehta RS, Marin D, Alousi A, Kanakry CG, Champlin RE, Rezvani K, Shpall EJ, Page K, Gadalla SM, Weisdorf D, Kebriaei P. Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type. Blood Adv 7(8):1594-1603, 2023. e-Pub 2023. PMID: 36630564.
48. Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rezvani K, Champlin RE, Shpall EJ. HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther 29(3):189-198, 2023. e-Pub 2023. PMID: 36470579.
49. Ponce DM, Alousi AM, Nakamura R, Slingerland J, Calafiore M, Sandhu KS, Barker JN, Devlin S, Shia J, Giralt S, Perales MA, Moore G, Fatmi S, Soto C, Gomes A, Giardina P, Marcello L, Yan X, Tang T, Dreyer K, Chen J, Daley WL, Peled JU, van den Brink MRM, Hanash AM. A phase 2 study of Interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract. Blood 141(12):1389-1401, 2023. e-Pub 2023. PMID: 36399701.
50. Ngo-Huang A, Ombres R, Saliba RM, Szewczyk N, Adekoya L, Soones TN, Ferguson J, Fontillas RC, Gulbis AM, Hosing C, Kebriaei P, Lindsay R, Marin DC, Mehta RS, Alousi AM, Srour S, Oran B, Olson AL, Qazilbash MH, Rivera Z, Champlin RE, Shpall EJ, Popat UR. Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematologic Stem-Cell Transplant. JCO Oncol Pract 19(3):OP2200520, 2023. e-Pub 2023. PMID: 36626702.
51. Alkhunaizi M, Patel B, Bueno L, Bhan N, Ahmed T, Arain MH, Saliba R, Rondon G, Dickey BF, Bashoura L, Ost DE, Li L, Wang S, Shpall E, Champlin RE, Mehta R, Popat UR, Hosing C, Alousi AM, Sheshadri A. Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment. Transplant Cell Ther 29(3):204.e1-204.e7, 2023. e-Pub 2023. PMID: 36503180.
52. Etra A, Capellini A, Alousi A, Al Malki MM, Choe H, DeFilipp Z, Hogan WJ, Kitko CL, Ayuk F, Baez J, Gandhi I, Kasikis S, Gleich S, Hexner E, Hoepting M, Kapoor U, Kowalyk S, Kwon D, Langston A, Mielcarek M, Morales G, Özbek U, Qayed M, Reshef R, Rösler W, Spyrou N, Young R, Chen YB, Ferrara JLM, Levine JE. Effective treatment of low risk acute GVHD with itacitinib monotherapy. Blood 141(5):481-489, 2023. e-Pub 2023. PMID: 36095841.
53. Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi A, Olson A, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short NJ, Ravandi F, Champlin R, Shpall EJ, Kebriaei P. Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. Am J Hematol 98(2):E35-E37, 2023. e-Pub 2023. PMID: 36502492.
54. Bolaños-Meade, J, Hamadani, M, Wu, J, Al Malki, MM, Martens, M, Runaas, L, Elmariah, H, Rezvani, A, Gooptu, M, Larkin, K, Shaffer, BC, El-Jurdi, N, Loren, A, Solh, MM, Hall, AC, Alousi, AM, Jamy, O, Perales, MA, Yao, JM, Applegate, K, Bhatt, AS, Kean, LS, Efebera, Y, Reshef, R, Clark, WB, DiFronzo, NL, Leifer, ES, Horowitz, MM, JONES, RJ, Holtan, SG. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. New England Journal of Medicine 388(25):2338-2348, 2023. e-Pub 2023. PMID: 37342922.
55. Jenq R, Hayase E, Hayase T, Mukherjee A, Stinson S, Jamal M, Ortega M, Sanchez C, Ahmed S, Karmouch J, Chang CC, Flores I, McDaniel L, Brown A, El-Himri R, Chapa V, Tan L, Tran B, Pham D, Halsey T, Jin Y, Tsai WB, Prasad R, Glover I, Ajami N, Wargo J, Shelburne S, Okhuysen P, Liu C, Fowler S, Conner M, Peterson C, Rondon G, Molldrem JJ, Champlin R, Shpall E, Lorenzi P, Mehta R, Martens E, Alousi A. Bacteroides ovatus alleviates dysbiotic microbiota-induced intestinal graft-versus-host disease. Res Sq, 2023. e-Pub 2023. PMID: 36778495.
56. Schwabkey ZI, Wiesnoski DH, Chang CC, Tsai WB, Pham D, Ahmed SS, Hayase T, Ortega Turrubiates MR, El-Himri RK, Sanchez CA, Hayase E, Frenk Oquendo AC, Miyama T, Halsey TM, Heckel BE, Brown AN, Jin Y, Raybaud M, Prasad R, Flores I, McDaniel L, Chapa V, Lorenzi PL, Warmoes MO, Tan L, Swennes AG, Fowler S, Conner M, McHugh K, Graf T, Jensen VB, Peterson CB, Do KA, Zhang L, Shi Y, Wang Y, Galloway-Pena JR, Okhuysen PC, Daniel-MacDougall CR, Shono Y, Burgos da Silva M, Peled JU, van den Brink MRM, Ajami N, Wargo JA, Reddy P, Valdivia RH, Davey L, Rondon G, Srour SA, Mehta RS, Alousi AM, Shpall EJ, Champlin RE, Shelburne SA, Molldrem JJ, Jamal MA, Karmouch JL, Jenq RR. Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med 14(671):eabo3445, 2022. e-Pub 2022. PMID: 36383683.
57. Saliba RM, Alousi AM, Pidala J, Arora M, Spellman SR, Hemmer MT, Wang T, Abboud C, Ahmed S, Antin JH, Beitinjaneh A, Buchbinder D, Byrne M, Cahn JY, Choe H, Hanna R, Hematti P, Kamble RT, Kitko CL, Laughlin M, Lekakis L, MacMillan ML, Martino R, Mehta PA, Nishihori T, Patel SS, Perales MA, Rangarajan HG, Ringdén O, Rosenthal J, Savani BN, Schultz KR, Seo S, Teshima T, van der Poel M, Verdonck LF, Weisdorf D, Wirk B, Yared JA, Schriber J, Champlin RE, Ciurea SO. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplant Cell Ther 28(10):681-693, 2022. e-Pub 2022. PMID: 35853610.
58. Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour SA, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation. Transplant Cell Ther 28(10):695.e1-695.e10, 2022. e-Pub 2022. PMID: 35902049.
59. Popat UR, Andersson BS, Bassett R, Kawedia J, Valdez BC, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Nieto Y, Oran B, Olson A, Qazilbash MH, Srour SA, Shpall EJ, Champlin RE, Mehta RS. A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study. Haematologica 107(10):2496-2500, 2022. e-Pub 2022. PMID: 35770531.
60. Hayase E, Hayase T, Jamal MA, Miyama T, Chang CC, Ortega MR, Ahmed SS, Karmouch JL, Sanchez CA, Brown AN, El-Himri RK, Flores II, McDaniel LK, Pham D, Halsey T, Frenk AC, Chapa VA, Heckel BE, Jin Y, Tsai WB, Prasad R, Tan L, Veillon L, Ajami NJ, Wargo JA, Galloway-Peña J, Shelburne S, Chemaly RF, Davey L, Glowacki RWP, Liu C, Rondon G, Alousi AM, Molldrem JJ, Champlin RE, Shpall EJ, Valdivia RH, Martens EC, Lorenzi PL, Jenq RR. Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease. Cell 185(20):3705-3719.e14, 2022. e-Pub 2022. PMID: 36179667.
61. Sheshadri A, Huang HJ, Bashoura L, Alousi AM, Alkhunaizi M, Sharifi H, Hsu JL. Graft-versus-host disease may cause pulmonary restriction, but not all restriction is graft-versus-host disease. Blood Adv 6(17):4984-4986, 2022. e-Pub 2022. PMID: 35793452.
62. Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, Daher M, Valdez BC, Kawedia J, Popat U, Mehta R, Oran B, Nieto Y, Olson A, Anderlini P, Marin D, Hosing C, Alousi AM, Shpall EJ, Rondon G, Chen J, Qazilbash M, Champlin RE, Kebriaei P. Vorinostat combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-term Study Outcomes. Transplant Cell Ther 28(8):501.e1-501.e7, 2022. e-Pub 2022. PMID: 35618218.
63. Andersson BS, Thall PF, Ma J, Valdez BC, Bassett R, Chen J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Gulbis A, Cool R, Kawedia J, Hosing C, Kebriaei P, Kornblau S, Myers A, Oran B, Rezvani K, Shah N, Shpall E, Parmar S, Popat UR, Nieto Y, Champlin RE. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan?±?clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant 57(8):1295-1303, 2022. e-Pub 2022. PMID: 35610308.
64. Mehta RS, Saliba RM, Hayase E, Jenq RR, Abraham S, Rashid A, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour S, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Mycophenolate Mofetil: A Friend or a Foe with PTCy and Tacrolimus Prophylaxis in HLA-Matched donors?. Transplant Cell Ther 28(8):500.e1-500.e10, 2022. e-Pub 2022. PMID: 35662592.
65. Saliba, RM, Srour, S, Greenbaum, U, Ma, Q, Carmazzi, Y, Moller, M, Wood, J, Ciurea, SO, Kongtim, P, Rondon, G, Li, D, Saengboon, S, Alousi, AM, Rezvani, K, Shpall, E, Cao, K, Champlin, RE, Zou, J. SIRPα Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies. Frontiers in immunology 13, 2022. e-Pub 2022. PMID: 35874659.
66. Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Saini N, Srour SA, Champlin RE, Rezvani K, Shpall EJ. Haploidentical vs Matched Unrelated vs Matched Sibling Donor HCT with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 28(7):395.e1-395.e11, 2022. e-Pub 2022. PMID: 35513252.
67. Button JE, Autran CA, Reens AL, Cosetta CM, Smriga S, Ericson M, Pierce JV, Cook DN, Lee ML, Sun AK, Alousi AM, Koh AY, Rechtman DJ, Jenq RR, McKenzie GJ. Dosing a synbiotic of human milk oligosaccharides and B. infantis leads to reversible engraftment in healthy adult microbiomes without antibiotics. Cell Host Microbe 30(5):712-725.e7, 2022. e-Pub 2022. PMID: 35504279.
68. Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi AM, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica 107(4):899-908, 2022. e-Pub 2022. PMID: 33951890.
69. Akin S, Hosing C, Khouri I, Ahmed S, Alousi AM, Fowler N, Joseph J, Truxillo J, Ramdial JL, Maadani F, Rondon G, Daher M, Im JS, Steiner R, Westin J, Iyer SP, Dabaja B, Anderlini P, Popat UR, Qazilbash MH, Flowers CR, Shpall E, Champlin RE, Nieto Y, Srour SA. Autologous Stem Cell Transplantation for Large B-cell Lymphoma with Secondary Central Nervous System Involvement. Blood Adv 6(7):2267-2274, 2022. e-Pub 2022. PMID: 35008100.
70. Gaballa MR, Banerjee P, Milton DR, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi AM, Mehta R, Alatrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi F, Kantarjian H, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P. Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia. Blood 139(12):1908-1919, 2022. e-Pub 2022. PMID: 34914826.
71. Sheshadri A, Makhnoon S, Alousi AM, Bashoura L, Andrade R, Miller CJ, Stolar KR, Arain MH, Noor L, Balagani A, Jain A, Blanco D, Ortiz A, Taylor MS, Stenzler A, Mehta R, Popat UR, Hosing C, Ost DE, Champlin RE, Dickey BF, Peterson SK. Home-Based Spirometry Telemonitoring After Allogeneic Hematopoietic Cell Transplantation: Mixed Methods Evaluation of Acceptability and Usability. JMIR Form Res 6(2):e29393, 2022. e-Pub 2022. PMID: 35129455.
72. Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia 36(1):298, 2022. e-Pub 2022. PMID: 34876697.
73. Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia 36(1):257-262, 2022. e-Pub 2022. PMID: 34135465.
74. Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Saini N, Srour SA, Rezvani K, Shpall EJ, Champlin RE, Alousi AM. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 27(12):1003.e1-1003.e13, 2021. e-Pub 2021. PMID: 34537419.
75. Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol 96(12):E455-E457, 2021. e-Pub 2021. PMID: 34559916.
76. Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther 27(11):913.e1-913.e12, 2021. e-Pub 2021. PMID: 34329753.
77. Pidala J, Onstad L, Martin PJ, Hamilton BK, Cutler C, Kitko CL, Carpenter PA, Chen GL, Arora M, Flowers MED, Arai S, Alousi A, White J, Jacobsohn D, Pusic I, Lee SJ. Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. Blood Adv 5(22):4549-4559, 2021. e-Pub 2021. PMID: 34535015.
78. DeFilipp Z, Alousi AM, Pidala JA, Carpenter PA, Onstad LE, Arai S, Arora M, Cutler CS, Flowers MED, Kitko CL, Chen GL, Lee SJ, Hamilton BK. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. Blood Adv 5(20):4278-4284, 2021. e-Pub 2021. PMID: 34521116.
79. DeFilipp Z, Couriel DR, Lazaryan A, Bhatt VR, Buxbaum NP, Alousi AM, Olivieri A, Pulanic D, Halter JP, Henderson LA, Zeiser R, Gooley TA, MacDonald KPA, Wolff D, Schultz KR, Paczesny S, Inamoto Y, Cutler CS, Kitko CL, Pidala JA, Lee SJ, Socie G, Sarantopoulos S, Pavletic SZ, Martin PJ, Blazar BR, Greinix HT. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. Transplant Cell Ther 27(9):729-737, 2021. e-Pub 2021. PMID: 34147469.
80. Yalniz FF, Saliba RM, Greenbaum U, Ramdial J, Popat U, Oran B, Alousi A, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Mehta R, Qazilbash M, Joseph JJ, Rondon G, Kanagal-Shamanna R, Shpall E, Champlin R, Kebriaei P. Outcomes of second allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia. Transplant Cell Ther 27(8):689-695, 2021. e-Pub 2021. PMID: 34023569.
81. Alousi AM, Saliba RM. Pre-transplant Transfusion Burden and Transplant Outcomes, Is there a Case for Earlier Transplant?. Transplant Cell Ther 27(8):625-626, 2021. e-Pub 2021. PMID: 34304800.
82. Ramdial JL, Mehta RS, Saliba RM, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Andersson BS, Champlin RE, Popat U. Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. Bone Marrow Transplant 56(8):2005-2012, 2021. e-Pub 2021. PMID: 33846563.
83. Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):JCO2002608, 2021. e-Pub 2021. PMID: 33929874.
84. Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi A, Mehta R, Oran B, Olson A, Hosing C, Qazilbash M, Khouri I, Ciurea S, Shpall E, Jorgensen J, Wang S, Jain N, Jabbour E, Kantarjian H, Champlin R, Konopleva M, Kebriaei P. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 56(7):1746-1749, 2021. e-Pub 2021. PMID: 33767403.
85. Ponce DM, Politikos I, Alousi A, Carpenter PA, Milano F, MacMillan ML, Barker JN, Horwitz ME, for Transplantation AS, Interest Group CTCBS. Guidelines for the Prevention and Management of Graft-versus-Host Disease after Cord Blood Transplantation. Transplant Cell Ther 27(7):540-544, 2021. e-Pub 2021. PMID: 34210500.
86. Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver N, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol 193(5):1004-1008, 2021. e-Pub 2021. PMID: 33821472.
87. Mehta RS, Bassett R, Rondon G, Overman BJ, Popat UR, Hosing CM, Rezvani K, Qazilbash MH, Anderlini P, Jones RB, Kebriaei P, Marin D, Khouri IF, Oran B, Ciurea SO, Kondo K, Couriel DR, Shpall EJ, Champlin RE, Alousi AM. Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplant 56(6):1316-1324, 2021. e-Pub 2021. PMID: 33398094.
88. Joseph J, Ma J, Hennawy F, Abdulrazzaq MN, Saini N, Patel RD, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Srour S, Kebriaei P, Bashir Q, Nastoupil LJ, Westin JR, Rondon G, Champlin RE, Andersson BS, Nieto Y, Muzzafar T, Ahmed S. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther 27(5):404.e1-404.e5, 2021. e-Pub 2021. PMID: 33965178.
89. Oran B, Saliba RM, Mehta RS, Alousi AM, Marin D, Valdez BC, Chen J, Bashir Q, Ciurea SO, Olson AL, Hosing C, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Andersson BS, Popat UR. Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 127(10):1598-1605, 2021. e-Pub 2021. PMID: 33471943.
90. Ahmed S, Bashir Q, Bassett R, Poon MC, Valdez B, Konoplev S, Alousi AM, Andersson BS, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Kim S, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin R, Popat U. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther 27(5):430.e1-430.e7, 2021. e-Pub 2021. PMID: 33965187.
91. Ngo-Huang A, Yadav R, Bansal S, Williams J, Wu J, Fu JB, Alousi AM, Bruera E. An Exploratory Study on Physical Function in Stem Cell Transplant Patients Undergoing Corticosteroid Treatment for Acute Graft-Versus-Host-Disease. Am J Phys Med Rehabil 100(4):402-406, 2021. e-Pub 2021. PMID: 33278131.
92. Greenbaum U, Klein K, Martinez F, Song J, Thall PF, Ramdial JL, Knape C, Aung FM, Scroggins J, Knopfelmacher A, Mulanovich V, Borjan J, Adachi J, Muthu M, Leung C, Medina MC, Champlin R, Olson A, Alousi A, Rezvani K, Shpall EJ. High levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients. medRxiv, 2021. e-Pub 2021. PMID: 33758890.
93. Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Nieto Y, Ciurea SO, Oran B, Im J, Olson A, Marin D, Qazilbash M, Khouri I, Rondon G, Anderlini P, Rezvani K, Popat U, Kebriaei P, Shpall E, Champlin R, Alousi A. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplant Cell Ther 27(3):272.e1-272.e5, 2021. e-Pub 2021. PMID: 33781539.
94. Sheshadri A, Saliba R, Patel B, Ahmed T, Bueno LC, Arain MH, Mehta RS, Popat UR, Hosing CM, Rondon G, Bashoura L, Dickey BF, Champlin RE, Alousi AM. Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients. Bone Marrow Transplant 56(3):745-748, 2021. e-Pub 2021. PMID: 33009515.
95. Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschkus S, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, Gulbis AM, Konopleva M, Ohanian M, Ravandi F, Garcia-Manero G, Oran B, Popat UR, Mehta R, Alousi AM, Daver N, Champlin R, Diab A, Al-Atrash G. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer 9(2), 2021. e-Pub 2021. PMID: 33637601.
96. Saliba RM, Veltri L, Rondon G, Chen J, Al-Atrash G, Alousi A, Martinez C, Augustine L, Hosing CM, Oran B, Rezvani K, Shpall EJ, Kebriaei P, Khouri IF, Popat U, Champlin RE, Ciurea SO. Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. Haematologica 106(1):269-274, 2021. e-Pub 2021. PMID: 32107328.
97. Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol 144(1):1-8, 2021. e-Pub 2021. PMID: 32604096.
98. Greenbaum U, Klein K, Martinez F, Song J, Thall PF, Ramdial JL, Knape C, Aung FM, Scroggins J, Knopfelmacher A, Mulanovich V, Borjan J, Adachi J, Muthu M, Leung C, Medina MC, Champlin R, Olson A, Alousi A, Rezvani K, Shpall EJ. High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients. Front Immunol 12:675679, 2021. e-Pub 2021. PMID: 33995420.
99. Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, Woodworth G, Champlin RE. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv 4(21):5580-5588, 2020. e-Pub 2020. PMID: 33170934.
100. Sheshadri A, Alousi A, Bashoura L, Stolar K, Baghaie S, Arain MH, Noor L, Balagani A, Jain A, Blanco D, Ortiz A, Peterson SK, Langhals R, Taylor M, Stenzler A, Mehta RS, Popat UR, Hosing C, Rondon G, Shen F, Li L, Cheng GS, Ost DE, Champlin RE, Dickey BF. Feasibility and Reliability of Home-based Spirometry Telemonitoring in Allogeneic Hematopoietic Cell Transplant Recipients. Ann Am Thorac Soc 17(10):1329-1333, 2020. e-Pub 2020. PMID: 32614241.
101. Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, Bashir Q, Hosing CM, Nieto Y, Alousi AM, Qazilbash MH, Ciurea S, Shpall E, Khouri I, Kantarjian H, Jabbour E, Ravandi F, Champlin RE, Kebriaei P. Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia. Blood 136(15):1786-1789, 2020. e-Pub 2020. PMID: 32492706.
102. Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv 4(19):4834-4837, 2020. e-Pub 2020. PMID: 33027527.
103. Popat U, Mehta RS, Bassett R, Kongtim P, Chen J, Alousi AM, Anderlini P, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Lindsay R, Nieto Y, Olson A, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson BS, Champlin RE. Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant 26(8):1439-1445, 2020. e-Pub 2020. PMID: 32438043.
104. Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Agrawal V, Ahmed I, Al-Homsi AS, Aljurf M, Antin JH, Askar M, Auletta JJ, Bhatt VR, Chee L, Chhabra S, Daly A, DeFilipp Z, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Hogan WJ, Inamoto Y, Martino R, Majhail NS, Marks DI, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Rangarajan HG, Ringden O, Saad A, Savani BN, Schoemans H, Seo S, Schultz KR, Solh M, Spitzer T, Storek J, Teshima T, Verdonck LF, Wirk B, Yared JA, Cahn JY, Weisdorf DJ. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol 38(18):2062-2076, 2020. e-Pub 2020. PMID: 32364845.
105. Yalniz FF, Patel KP, Bashir Q, Marin D, Ahmed S, Alousi AM, Chen J, Ciurea SO, Rezvani K, Popat UR, Shpall EJ, Champlin RE, Oran B. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer 126(10):2183-2192, 2020. e-Pub 2020. PMID: 32101640.
106. Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer 126(10):2193-2205, 2020. e-Pub 2020. PMID: 32125707.
107. Varma A, Abraham SC, Mehta RS, Saini NY, Honhar M, Rashid M, Chen J, Srour SA, Bashir Q, Rondon G, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Anderlini P, Andersson BS, Shpall EJ, Champlin RE, Popat UR. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv 4(7):1296-1306, 2020. e-Pub 2020. PMID: 32236526.
108. Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma With Chromosome 1q Gain and 1p Deletion After Autologous Hematopoietic Stem Cell Transplantation: propensity-score matched analysis: Outcome of 1q+/1p- MM pts after auto-HCT. Biol Blood Marrow Transplant 26(4):665-671, 2020. e-Pub 2020. PMID: 31881283.
109. Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood 135(11):862-865, 2020. e-Pub 2020. PMID: 31961918.
110. Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta R, Oran B, Popat U, Hosing C, Olson A, Daver N, Konopleva M, Champlin RE. Is There an Optimal Conditioning for Older Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation?. Blood 135(6):449-452, 2020. e-Pub 2020. PMID: 31826244.
111. Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML. Randomized Multicenter Trial of Sirolimus vs. Prednisone as Initial Therapy for Standard Risk Acute GVHD: BMT CTN 1501. Blood 135(2):97-107, 2020. e-Pub 2020. PMID: 31738834.
112. Kongtim P, Hasan O, Perez JMR, Varma A, Wang SA, Patel KP, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash M, Mehta R, Shpall EJ, Alousi A, Khouri I, Kebriaei P, Popat U, Champlin RR, Ciurea SO. Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 26(1):197-203, 2020. e-Pub 2020. PMID: 31518645.
113. Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol 94(12):1382-1387, 2019. e-Pub 2019. PMID: 31595538.
114. Pidala JA, Hamilton BK, Martin PJ, Onstad L, Storer BE, Palmer J, Alousi A, Cutler C, Jagasia MH, Chen GL, Arora M, Flowers ME, Lee SJ. The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. Biol Blood Marrow Transplant 25(12):2468-2473, 2019. e-Pub 2019. PMID: 31394265.
115. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial. Haematologica 104(12):e555-e557, 2019. e-Pub 2019. PMID: 30948491.
116. Ciurea SO, Varma A, Kongtim P, Srour S, Bashir Q, Alousi AM, Mehta RS, Oran B, Popat U, Hosing C, Rondon G, Chen J, Olson AL, Konopleva MY, Champlin RE. Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis. Blood 134(Supplement_1):42, 2019. e-Pub 2019. PMID: 31724003.
117. Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
118. Saad A, Lamb L, Wang T, Hemmer MT, Spellman S, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Agrawal V, Aljurf M, Beitinjaneh AM, Bhatt VR, Buchbinder D, Byrne M, Cahn JY, Cairo M, Castillo P, Chhabra S, Diaz MA, Farhan S, Floisand Y, Frangoul HA, Gadalla SM, Gajewski J, Gale RP, Gandhi M, Gergis U, Hamilton BK, Hematti P, Hildebrandt GC, Kamble RT, Kanate AS, Khandelwal P, Lazaryan A, MacMillan M, Marks DI, Martino R, Mehta PA, Nishihori T, Olsson RF, Patel SS, Qayed M, Rangarajan HG, Reshef R, Ringden O, Savani BN, Schouten HC, Schultz KR, Seo S, Shaffer BC, Solh M, Teshima T, Urbano-Ispizua A, Verdonck LF, Vij R, Waller EK, William B, Wirk B, Yared JA, Yu LC, Arora M, Hashmi S. Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Transplant 25(9):1875-1883, 2019. e-Pub 2019. PMID: 31085303.
119. Hamilton BK, Liu Y, Hemmer MT, Majhail N, Ringden O, Kim D, Costa L, Stuart R, Alousi A, Pidala JA, Couriel DR, Aljurf M, Antin JH, Bredeson C, Cahn JY, Cairo M, Choi SW, Dandoy C, Gale RP, Gergis U, Hematti P, Inamoto Y, Kamble RT, MacMillan M, Marks DI, Nemecek E, Nishihori T, Saad A, Savani BN, Schriber J, Seo S, Socié G, Teshima T, Verdonck LF, Waller EK, Wirk M, Spellman SR, Arora M, Chhabra S. Inferior Outcomes with Cyclosporine and Mycophenolate mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 25(9):1744-1755, 2019. e-Pub 2019. PMID: 31158502.
120. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant 25(7):1340-1346, 2019. e-Pub 2019. PMID: 30763728.
121. Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SO. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 54(6):839-848, 2019. e-Pub 2019. PMID: 30258129.
122. Ghobadi A, Milton DR, Gowda L, Rondon G, Chemaly RF, Hamdi A, Alousi A, Afrough A, Oran B, Ciurea S, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Champlin RE, Bashir Q. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Curr Res Transl Med 67(2):51-55, 2019. e-Pub 2019. PMID: 30683577.
123. Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Adv 3(9):1441-1449, 2019. e-Pub 2019. PMID: 31053571.
124. Galloway-Peña JR, Peterson CB, Malik F, Sahasrabhojane PV, Shah DP, Brumlow CE, Carlin LG, Chemaly RF, Im JS, Rondon G, Felix E, Veillon L, Lorenzi PL, Alousi AM, Jenq RR, Kontoyiannis DP, Shpall EJ, Shelburne SA, Okhuysen PC. Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study. Open Forum Infect Dis 6(5):ofz173, 2019. e-Pub 2019. PMID: 31065565.
125. Shah MV, Saliba RM, Rondon G, Chen J, Soebbing D, Rus I, Alousi A, Oran B, Kebriaei P, Qazilbash M, Parmar S, Hosing C, Khouri IF, Popat UR, Champlin RE, Ciurea SO. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplant 54(4):601-606, 2019. e-Pub 2019. PMID: 30337700.
126. Sheshadri A, Chemaly RF, Alousi AM, Shah PK, Rondon G, Bashoura L, Kmeid J, Azzi J, Blanco DW, Kaous M, Dickey BF, Champlin RE, Shah DP. Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 25(4):800-809, 2019. e-Pub 2019. PMID: 30521974.
127. Khera N, Hamilton BK, Pidala JA, Wood WA, Wu V, Voutsinas J, Onstad L, Alousi AM, Broady R, Chen GL, Arora M, Cutler C, Flowers ME, Ganetsky A, Jagasia M, McCarthy PL, Sarantopoulos S, Abel GA, Majhail NS, Lee SJ. Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. Biol Blood Marrow Transplant 25(3):599-605, 2019. e-Pub 2019. PMID: 30296479.
128. Popat UR, Saliba R, Mehta RS, Olson A, Chen J, Ganesh C, Woodworth G, McMullin B, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour S, Rezvani K, Qazilbash MH, Shpall EJ, Andersson B, Champlin RE. Comparison of Post-Transplant Cyclophosphamide and Tacrolimus and Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2019. e-Pub 2019.
129. Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol 6(3):e132-e143, 2019. e-Pub 2019. PMID: 30824040.
130. Alousi A, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Pidala J, Anderlini P, Boyiadzis M, Bredeson CN, Cahn JY, Cairo MS, Gadalla SM, Hashmi SK, Gale RP, Kanda J, Kamble RT, Kharfan-Dabaja MA, Litzow MR, Ringden O, Saad AA, Schultz KR, Verdonck LF, Waller EK, Yared JA, Holtan SG, Weisdorf DJ. Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. Biol Blood Marrow Transplant 25(2):270-278, 2019. e-Pub 2019. PMID: 30292009.
131. Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biol Blood Marrow Transplant 25(1):73-85, 2019. e-Pub 2019. PMID: 30153491.
132. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol 94(1):E2-E5, 2019. e-Pub 2019. PMID: 30300461.
133. Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Yingst A, Couriel D, Alousi A, Pidala J, Knight JM, Verneris MR. Proinflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes. Biol Blood Marrow Transplant 25(1):12-18, 2019. e-Pub 2019. PMID: 30144561.
134. Carpenter PA, Logan BR, Lee SJ, Weisdorf DJ, Johnston L, Costa LJ, Kitko CL, Bolaños-Meade J, Sarantopoulos S, Alousi AM, Abhyankar S, Waller EK, Mendizabal A, Zhu J, O'Brien KA, Lazaryan A, Wu J, Nemecek ER, Pavletic SZ, Cutler CS, Horowitz MM, Arora M, BMT CTN. A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. Haematologica 103(11):1915-1924, 2018. e-Pub 2018. PMID: 29954931.
135. Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol 5(11):e532-e542, 2018. e-Pub 2018. PMID: 30389035.
136. Nikiforow S, Wang T, Hemmer M, Spellman S, Akpek G, Antin JH, Choi SW, Inamoto Y, Khoury HJ, MacMillan M, Marks DI, Meehan K, Nakasone H, Nishihori T, Olsson R, Paczesny S, Przepiorka D, Reddy V, Reshef R, Schoemans H, Waller N, Weisdorf D, Wirk B, Horowitz M, Alousi A, Couriel D, Pidala J, Arora M, Cutler C, Working Committee GWCOBOTCGD. Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. Haematologica 103(10):1708-1719, 2018. e-Pub 2018. PMID: 30076185.
137. Sheu T, Milgrom SA, Andraos TY, Gunther JR, Chi L, Nastoupil L, Fowler N, Oki Y, Fanale MA, Fayad LE, Hagemeister F, Neelapu SS, Medeiros LJ, Hosing C, Nieto Y, Ahmed S, Alousi AM, Dabaja B, Pinnix CC. Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol 3(4):639-646, 2018. e-Pub 2018. PMID: 30370365.
138. Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant 24(8):1602-1609, 2018. e-Pub 2018. PMID: 29501779.
139. Holtan SG, DeFor TE, Panoskaltsis-Mortari A, Khera N, Levine JE, Flowers MED, Lee SJ, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Cutler CS, Arai S, Lazaryan A, Newell LF, Jagasia MH, Pusic I, Wood WA, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Bunworasate U, Efebera YA, Ferrara JLM, Pidala J, Howard A, Wu J, Bolaños-Meade J, Ho V, Alousi A, Blazar BR, Weisdorf DJ, MacMillan ML. Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. Blood Adv 2(15):1882-1888, 2018. e-Pub 2018. PMID: 30087106.
140. Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, Chen J, Wallis W, Cao K, Konopleva M, Daver N, Cortes J, Ravandi F, Alousi A, Ahmed S, Popat U, Parmar S, Bashir Q, Betul O, Hosing C, Shpall EJ, Rezvani K, Khouri IF, Kebriaei P, Champlin RE. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 24(6):1232-1236, 2018. e-Pub 2018. PMID: 28918304.
141. Kumar AJ, Kim S, Hemmer MT, Arora M, Spellman SR, Pidala JA, Couriel DR, Alousi AM, Aljurf MD, Cahn JY, Cairo MS, Cutler CS, Farhan S, Gergis U, Hale GA, Hashmi SK, Inamoto Y, Kamble RT, Kharfan-Dabaja MA, MacMillan ML, Marks DI, Nakasone H, Norkin M, Qayed M, Ringden O, Schouten HC, Schultz KR, Solh MM, Teshima T, Urbano-Ispizua A, Verdonck LF, Gale RP, Hamilton BK, Majhail NS, Loren AW. Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. Blood Adv 2(9):1022-1031, 2018. e-Pub 2018. PMID: 29739773.
142. Abram TJ, Pickering CR, Lang AK, Bass NE, Raja R, Meena C, Alousi AM, Myers JN, McDevitt JT, Gillenwater AM, Vigneswaran N. Risk Stratification of Oral Potentially Malignant Disorders in Fanconi Anemia Patients Using Autofluorescence Imaging and Cytology-On-A Chip Assay. Transl Oncol 11(2):477-486, 2018. e-Pub 2018. PMID: 29481998.
143. Qayed M, Wang T, Hemmer MT, Spellman S, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Aljurf M, Ayas M, Bitan M, Cairo M, Choi SW, Dandoy C, Delgado D, Gale RP, Hale G, Frangoul H, Kamble RT, Kharfan-Dabaja M, Lehman L, Levine J, MacMillan M, Marks DI, Nishihori T, Olsson RF, Hematti P, Ringden O, Saad A, Satwani P, Savani BN, Schultz KR, Seo S, Shenoy S, Waller EK, Yu L, Horowitz MM, Horan J. Influence of Age on Acute and Chronic GVHD in Children Receiving HLA-Identical Sibling BMT for Acute Leukemia: Implications for Prophylaxis. Biol Blood Marrow Transplant 24(3):521-528, 2018. e-Pub 2018. PMID: 29155316.
144. Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant 53(3):315-325, 2018. e-Pub 2018. PMID: 29269797.
145. Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood 131(11):1248-1257, 2018. e-Pub 2018. PMID: 29386198.
146. Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant. e-Pub 2018. PMID: 29448058.
147. Chronic GVHD Consortium: Lee SJ, Hamilton BK, Pidala J, Alousi A, Kurukulasuriya, Onstad L, Jagasia M, Chen G, Cutler C, Broady R, Arora M, Arai S, Sarantopoulos S, Flowers ME. Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study. Biol Blood Marrow Transplant. e-Pub 2018. PMID: 29476954.
148. Andermann TM, Peled JU, Ho C, Reddy P, Riches M, Storb R, Teshima T, van den Brink MRM, Alousi A, Balderman S, Chiusolo P, Clark WB, Holler E, Howard A, Kean LS, Koh AY, McCarthy PL, McCarty JM, Mohty M, Nakamura R, Rezvani K, Segal BH, Shaw BE, Shpall EJ, Sung AD, Weber D, Whangbo J, Wingard JR, Wood WA, Perales MA, Jenq RR, Bhatt AS, Blood, Trials Network MTC. The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biol Blood Marrow Transplant. e-Pub 2018. PMID: 29471034.
149. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97-103, 2018. e-Pub 2018. PMID: 29097493.
150. Pasquini MC, Logan B, Jones RJ, Alousi AM, Appelbaum FR, Bolaños-Meade J, Flowers MED, Giralt S, Horowitz MM, Jacobsohn D, Koreth J, Levine JE, Luznik L, Maziarz R, Mendizabal A, Pavletic S, Perales MA, Porter D, Reshef R, Weisdorf D, Antin JH. Blood and Marrow Transplant Clinical Trials Network Report on Development of Novel Endpoints and Selection of Promising Approaches for Graft-Versus-Host Disease Prevention Trials. Biol Blood Marrow Transplant. e-Pub 2018. PMID: 29325830.
151. Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, Choi SW, DeFilipp Z, Gadalla SM, Gale RP, Gergis U, Hashmi S, Hematti P, Holmberg L, Inamoto Y, Kamble RT, Lehmann L, MacMillan MA, McIver Z, Nishihori T, Norkin M, O'Brien T, Olsson RF, Reshef R, Saad A, Savani BN, Schouten HC, Seo S, Solh M, Verdonck L, Vij R, Wirk B, Yared J, Horowitz MM, Knight JM, Verneris MR. Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplant. e-Pub 2018. PMID: 29382954.
152. Rondón G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, Hosing CM, Kebriaei P, Khouri IF, Shpall EJ, Popat UR, Champlin RE, Ciurea SO. Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem-Cell Transplant Outcomes. Biol Blood Marrow Transplant 23(12):2166-2171, 2017. e-Pub 2017. PMID: 28844946.
153. Im JS, Abraham SC, Saliba RM, Rondon G, Ross WA, Rashid A, Shpall EJ, Popat U, Qazilbash MH, Hosing C, Oran B, Shah N, Tewari P, Nieto Y, Kebriaei P, Champlin RE, Alousi AM. Histologic Grade 1 is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease. Am J Surg Pathol 41(11):1483-1490, 2017. e-Pub 2017. PMID: 28834808.
154. Khouri MR, Jabbour EJ, Gulbis AM, Turturro F, Ledesma C, Korbling M, Samuels BI, Ahmed S, Alousi AM, Ciurea SO, Marin D, Patel KK, Popat UR, Bueso-Ramos CE, Bassett RL, Khouri IF. Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. Biol Blood Marrow Transplant 23(8):1405-1410, 2017. e-Pub 2017. PMID: 28495642.
155. Srour SA, Li S, Popat UR, Qazilbash MH, Lozano-Cerrada S, Maadani F, Alousi A, Kebriaei P, Anderlini P, Nieto Y, Jones R, Shpall E, Champlin RE, Hosing C. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. Br J Haematol 178(4):561-570, 2017. e-Pub 2017. PMID: 28485023.
156. Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi A, Hosing C, Popat U, Kebriaei P, Champlin R, de Lima M, Skerrett D, Burke E, Shpall EJ, Oran B. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biol Blood Marrow Transplant 23(8):1359-1366, 2017. e-Pub 2017. PMID: 28506845.
157. Saliba RM, Sarantopoulos S, Kitko CL, Pawarode A, Goldstein SC, Magenau J, Alousi AM, Churay T, Justman H, Paczesny S, Reddy P, Couriel DR. B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality. Bone Marrow Transplant 52(7):1010-1015, 2017. e-Pub 2017. PMID: 28481353.
158. Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol 28(7):1554-1559, 2017. e-Pub 2017. PMID: 28379307.
159. Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi A, Bashir Q, Ciurea SO, Popat U, Khouri I, Marin D, Rezvani K, Kebriaei P, Shpall EJ, Champlin RE, Oran B. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogenic stem cell transplantation using reduced intensity conditioning. Cancer 123(14):2661-2670, 2017. e-Pub 2017. PMID: 28324640.
160. Pingali SR, Saliba RM, Anderlini P, Hosing C, Khouri I, Alousi AM, Nieto Y, Qazilbash MH, Champlin R, Popat UR. Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma. Biol Blood Marrow Transplant 23(7):1059-1063, 2017. e-Pub 2017. PMID: 28389254.
161. Krakow EF, Hemmer M, Wang T, Logan B, Arora M, Spellman S, Couriel D, Alousi A, Pidala J, Last M, Lachance S, Moodie EEM. Tools for the Precision Medicine Era: How to Develop Highly Personalized Treatment Recommendations From Cohort and Registry Data Using Q-Learning. Am J Epidemiol 186(2):160-172, 2017. e-Pub 2017. PMID: 28472335.
162. Bachegowda LS, Saliba RM, Ramlal R, Kongtim P, Chen J, Rondon G, Wallis W, Alousi A, Ahmed S, Hosing CM, Parmar S, Qazilbash M, Khouri IF, Bashir Q, Oran B, Popat U, Shpall EJ, Marin D, Rezvani K, Kebriaei P, Champlin RE, Ciurea SO. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood 129(22):3031-3033, 2017. e-Pub 2017. PMID: 28351938.
163. Peled JU, Devlin SM, Staffas A, Lumish M, Khanin R, Littmann ER, Ling L, Kosuri S, Maloy M, Slingerland JB, Ahr KF, Porosnicu Rodriguez KA, Shono Y, Slingerland AE, Docampo MD, Sung AD, Weber D, Alousi AM, Gyurkocza B, Ponce DM, Barker JN, Perales MA, Giralt SA, Taur Y, Pamer EG, Jenq RR, van den Brink MRM. Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. J Clin Oncol 35(15):JCO2016703348, 2017. e-Pub 2017. PMID: 28296584.
164. Khoury HJ, Wang T, Hemmer MT, Couriel D, Alousi A, Cutler C, Aljurf M, Antin JH, Ayas M, Battiwalla M, Cahn JY, Cairo M, Chen YB, Gale RP, Hashmi S, Hayashi RJ, Jagasia M, Juckett M, Kamble RT, Kharfan-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoemans H, Schouten HC, Socie G, Storek J, Verdonck L, Vij R, Wood WA, Yu L, Martino R, Carabasi M, Dandoy C, Gergis U, Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz KR, Wirk BM, Spellman S, Arora M, Pidala J. Improved survival after acute graft vs host disease diagnosis in the modern era. Haematologica 102(5):958-966, 2017. e-Pub 2017. PMID: 28302712.
165. Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplant 52(4):580-587, 2017. e-Pub 2017. PMID: 27991894.
166. Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO. Relapse Risk and Survival in Patients with FLT3 Acute Myeloid Leukemia Undergoing Stem Cell Transplantation. Am J Hematol 92(4):331-337, 2017. e-Pub 2017. PMID: 28052408.
167. Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann L, Yu L, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Kharfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hashmi S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transplant 52(3):400-408, 2017. e-Pub 2017. PMID: 27941764.
168. Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant 23(2):285-292, 2017. e-Pub 2017. PMID: 27816651.
169. Oran B, Jorgensen JL, Marin D, Wang S, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Bassett R, Lyons G, Chen J, Rezvani K, Popat U, Kebriaei P, Patel K, Rondon G, Shpall EJ, Champlin RE. Pretransplantion minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica 102(1):110-117, 2017. e-Pub 2017. PMID: 27540139.
170. Khoder A, Alsuliman A, Basar R, Sobieski C, Kondo K, Alousi AM, Szydlo R, Muftuoglu M, Shaim H, Apperley JF, Gokdemir E, Cooper N, Mehta RS, Marin D, Champlin R, Shpall E, Rezvani K. Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease. Front Immunol 8:1937, 2017. e-Pub 2017. PMID: 29375566.
171. Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer 122(21):3316-3326, 2016. e-Pub 2016. PMID: 27404668.
172. Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS. Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once Daily IV Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. Biol Blood Marrow Transplant 22(10):1792-1800, 2016. e-Pub 2016. PMID: 27377901.
173. Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer 122(17):2680-8, 2016. e-Pub 2016. PMID: 27203405.
174. Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest 126(9):3363-76, 2016. e-Pub 2016. PMID: 27482888.
175. Sarvaria A, Basar R, Mehta RS, Shaim H, Muftuoglu M, Khoder A, Sekine T, Gokdemir E, Kondo K, Marin D, Daher M, Alousi AM, Alsuliman A, Liu E, Oran B, Olson A, Jones RB, Popat U, Hosing C, Champlin R, Shpall EJ, Rezvani K. IL-10+ regulatory B cells are enriched in cord blood and may play a role in protection against GVHD after cord blood transplantation. Blood 128(10):1346-61, 2016. e-Pub 2016. PMID: 27439912.
176. Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 128(2):297-312, 2016. e-Pub 2016. PMID: 27247137.
177. Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Hagemeister FB, Oki Y, Neelapu S, Romaguera JE, Younes A, Champlin RE. Gemcitabine, fludarabine and melphalan for reduced-intensity conditioning and allogeneic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 22(7):1333-1337, 2016. e-Pub 2016. PMID: 27064056.
178. Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Anderlini P, Rondon G, Alousi A, Ciurea S, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing CM. Double Umbilical Cord Blood Transplantation (dUCB) is effective therapy for relapsed or refractory Hodgkin Lymphoma. Leuk Lymphoma 57(7):1-23, 2016. e-Pub 2016. PMID: 26472485.
179. Galloway-Peña JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, Chemaly RF, Marsh L, Ghantoji SS, Pemmaraju N, Garcia-Manero G, Rezvani K, Alousi AM, Wargo JA, Shpall EJ, Futreal PA, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer 122(14):2186-96, 2016. e-Pub 2016. PMID: 27142181.
180. Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi A, Qazilbash M, Bashir Q, Ahmed S, Popat U, Hosing C, Khouri I, Shpall EJ, Champlin RE, Ciurea SO. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol 173(3):444-55, 2016. e-Pub 2016. PMID: 26947769.
181. Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Shpall EJ, Champlin RE, Popat U. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant 22(5):961-5, 2016. e-Pub 2016. PMID: 26921820.
182. Varma A, Saliba RM, Torres HA, Afrough A, Hosing C, Khouri IF, Nieto Y, Shah ND, Parmar S, Bashir Q, Ahmed S, Jones RB, Kebriaei P, Olson AL, Shpall EJ, Alousi AM, Qazilbash MH, Champlin RE, Popat U. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplant. e-Pub 2016. PMID: 26950376.
183. Karuturi M, Younes A, Fayad L, Kwak L, Pro B, Shah J, Oki Y, Simien R, Liboon MJ, Hutto T, Feng L, Horowitz S, Nieto Y, Anderlini P, Alousi A, Popat U, Medeiros LJ, Miranda R, Fanale M. ICE (Ifosfamide, Carboplatin, Etoposide) with or without Bortezomib in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Randomized Phase II Trial. Leuk Lymphoma 57(2):1-8, 2016. e-Pub 2016. PMID: 25804933.
184. Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression Free Survival for Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant 22(1):47-53, 2016. e-Pub 2016. PMID: 26343946.
185. Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, Popat U, Qazilbash M, Shpall EJ, Oki Y, Nieto Y, Pinnix C, Fanale M, Maadani F, Donato M, Champlin R, Duvic M. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol 26(12):2490-5, 2015. e-Pub 2015. PMID: 26416896.
186. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant 21(11):1914-20, 2015. e-Pub 2015. PMID: 26071868.
187. Inamoto Y, Flowers ME, Wang T, Urbano-Ispizua A, Hemmer MT, Cutler CS, Couriel DR, Alousi AM, Antin JH, Gale RP, Gupta V, Hamilton BK, Kharfan-Dabaja MA, Marks DI, Ringdén OT, Socié G, Solh MM, Akpek G, Cairo MS, Chao NJ, Hayashi RJ, Nishihori T, Reshef R, Saad A, Shah A, Teshima T, Tallman MS, Wirk B, Spellman SR, Arora M, Martin PJ. Tacrolimus versus cyclosporine after hematopoietic cell transplantation for acquired aplastic anemia. Biol Blood Marrow Transplant 21(10):1776-82, 2015. e-Pub 2015. PMID: 26033280.
188. Konopleva M, Benton CB, Thall PF, Zeng Z, Shpall E, Ciurea S, Kebriaei P, Alousi A, Popat U, Anderlini P, Nieto Y, Parmar S, Qiao W, Chen J, Rondon G, McMullin B, Wang RY, Lu H, Schober W, Woodworth G, Gulbis A, Cool R, Andreeff M, Champlin R. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplant 50(7):939-46, 2015. e-Pub 2015. PMID: 25867648.
189. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Phase II Trial Of Gvhd Prophylaxis with Post-Transplantation Cyclophosphamide Following Reduced-Intensity Busulfan/Fludarabine (Bu/Flu) Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant 21(5):906-12, 2015. e-Pub 2015. PMID: 25667989.
190. Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, Fayad L, Fanale MA, Alousi AM, Anderlini P, Betul O, Popat UR, Pro B, Khouri IF. Comparison of Survival in Patients with T-cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease. Biol Blood Marrow Transplant 21(5):855-9, 2015. e-Pub 2015. PMID: 25652691.
191. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-92, 2015. e-Pub 2015. PMID: 25778529.
192. Arora M, Hemmer MT, Ahn KW, Klein JP, Cutler CS, Urbano-Ispizua A, Couriel DR, Alousi AM, Gale RP, Inamoto Y, Weisdorf DJ, Li P, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola LM, Jacobsohn DA, Jagasia M, Klumpp TR, Petersdorf EW, Santarone S, Schouten HC, Wingard JR, Spellman SR, Pavletic SZ, Lee SJ, Horowitz MM, Flowers ME. CIBMTR Chronic GVHD Risk Score Predicts Mortality in an Independent Validation Cohort. Biol Blood Marrow Transplant 21(4):640-5, 2015. e-Pub 2015. PMID: 25528390.
193. MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, Ho VT, Bolaños-Meade J, Ferrara JL, Jones R, Arora M, Blazar BR, Holtan SG, Jacobsohn D, Pasquini M, Socie G, Antin JH, Levine JE, Weisdorf DJ. A refined risk score for acute GVHD that predicts response to initial therapy, survival and transplant-related mortality. Biol Blood Marrow Transplant 21(4):761-7, 2015. e-Pub 2015. PMID: 25585275.
194. Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, Magenau J, Weisdorf DJ, Ho VT, Bolaños-Meade J, Alousi AM, Ferrara JL, Blood, Trials Network MTC. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol 2(1):e21-9, 2015. e-Pub 2015. PMID: 26687425.
195. Alousi A, Bruno VM, Futreal PA, Petrosino JF, Kontoyiannis DP. Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis. PLoS One 10(11):e0139851, 2015. e-Pub 2015. PMID: 26556047.
196. Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO. Similar Transplant Outcomes for AML/MDS Patients with Haploidentical versus 10/10 HLA Matched Unrelated and Related Donors. Biol Blood Marrow Transplant 20(12):1975-81, 2014. e-Pub 2014. PMID: 25263628.
197. Bolaños-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Goldstein SC, Hexner EO, Horowitz MM, Lee SJ, Levine JE, MacMillan ML, Martin PJ, Mendizabal AM, Nakamura R, Pasquini MC, Weisdorf DJ, Westervelt P, Ho VT. Phase III clinical trial steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute graft-versus-host disease: BMT CTN 0802. Blood 124(22):3221-7; quiz 3335, 2014. e-Pub 2014. PMID: 25170121.
198. Oran B, Kongtim P, Popat U, de Lima M, Jabbour E, Lu X, Chen J, Rondon G, Kebriaei P, Ahmed S, Andersson B, Alousi A, Ciurea S, Shpall E, Champlin RE. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. Biol Blood Marrow Transplant 20(10):1618-25, 2014. e-Pub 2014. PMID: 24953017.
199. Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A, Anderlini P, Ciurea S, Jabbour E, Oran B, Popat UR, Rondon G, Bassett RL, Gulbis A. BFR (bendamustine, fludarabine and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced risk of myelosuppression and severe graft-versus-host disease. Blood 124(14):2306-12, 2014. e-Pub 2014. PMID: 25145344.
200. Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, Mielke S, de Lavallade H, Muftuoglu M, Fernandez Curbelo I, Liu E, Muraro PA, Alousi A, Stringaris K, Parmar S, Shah N, Shaim H, Yvon E, Molldrem J, Rouce R, Champlin R, McNiece I, Mauri C, Shpall EJ, Rezvani K. Regulatory B-Cells Are Enriched Within the IgM Memory and Transitional Subsets in Healthy Donors but Deficient In Chronic Graft-Versus-Host Disease. Blood 124(13):2034-45, 2014. e-Pub 2014. PMID: 25051962.
201. Parmar S, de Lima M, Worth L, Petropoulos D, Lee D, Cooper L, Kongtim P, Alousi A, Hosing C, Popat U, Kebriaei P, McNiece I, Shpall E, Rondon G, Champlin R. Is there an expiration date for a cord blood unit in storage?. Bone Marrow Transplant 49(8):1109-12, 2014. e-Pub 2014. PMID: 24797184.
202. Zhou Y, Slack R, Jorgensen JL, Wang SA, Rondon G, de Lima M, Shpall E, Popat U, Ciurea S, Alousi A, Qazilbash M, Hosing C, O'Brien S, Thomas D, Kantarjian H, Medeiros LJ, Champlin RE, Kebriaei P. The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 14(4):319-26, 2014. e-Pub 2014. PMID: 24548609.
203. Ma Q, Li D, Carreño R, Patenia R, Tsai KY, Xydes-Smith M, Alousi AM, Champlin RE, Sale GE, Afshar-Kharghan V. Complement component C3 mediates Th1/Th17 polarization in human T-cell activation and cutaneous GVHD. Bone Marrow Transplant 49(7):972-6, 2014. e-Pub 2014. PMID: 24777193.
204. Mehta RS, Di Stasi A, Hosing C, Shah N, Rezvani K, Alousi A, O'Brien S, Wierda W, Keating M, Shpall EJ. Lenalidomide-Induced Graft-Vs.-Leukemia Effect in a Patient With Chronic Lymphocytic Leukemia Who Relapsed After Allogeneic Stem Cell Transplant. Clin Lymphoma Myeloma Leuk 14(3):e105-9, 2014. e-Pub 2014. PMID: 24502832.
205. Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ. The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. Clin Lymphoma Myeloma Leuk 14(1):e1-5, 2014. e-Pub 2014. PMID: 24169268.
206. Hart JW, Shiue LH, Shpall EJ, Alousi AM. Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion. Ther Adv Hematol 4(5):320-334, 2013. e-Pub 2013. PMID: 24082993.
207. Smith VR, Popat U, Ciurea S, Nieto Y, Anderlini P, Rondon G, Alousi A, Qazilbash M, Kebriaei P, Khouri I, de Lima M, Champlin R, Hosing C. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol 88(9):754-7, 2013. e-Pub 2013. PMID: 23749720.
208. Chakhachiro ZI, Saliba RM, Okoroji GJ, Korbling M, Alousi AM, Betul O, Anderlini P, Ciurea SO, Popat U, Champlin R, Samuels BI, Medeiros LJ, Bueso-Ramos C, Khouri IF. Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission. Cancer 119(18):3318-25, 2013. e-Pub 2013. PMID: 23775587.
209. Shiue LH, Alousi AM, Wei C, Hosing CM, Duvic M, Ni X. Augmentation of blood dendritic cells by extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma and graft-versus-host disease. J Invest Dermatol 133(8):2098-100, 2013. e-Pub 2013. PMID: 23519332.
210. Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, Qazilbash M, Hosing C, Jones RB, Popat UR, Nieto Y, Alousi A, Ciurea S, Shpall EJ, Champlin RE, Kebriaei P. Outcomes of adults with acute lymphoblastic leukemia (ALL) following relapse post allogeneic hematopoietic stem cell transplantation (HSCT). Biol Blood Marrow Transplant 11(4):1059-64, 2013. e-Pub 2013. PMID: 23644077.
211. Karuturi M, Hosing C, Fanale M, Medeiros LJ, Alousi AM, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson BS, Champlin R, Anderlini P, Popat U. High-dose Chemotherapy and Autologous Stem Cell Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Biol Blood Marrow Transplant 19(6):991-4, 2013. e-Pub 2013. PMID: 23507470.
212. Alousi AM, Le-Rademacher J, Saliba RM, Appelbaum FR, Artz A, Benjamin J, Devine SM, Kan F, Laughlin MJ, Lazarus HM, Liesveld J, Perales MA, Maziarz RT, Sabloff M, Waller EK, Eapen M, Champlin RE. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?. Blood 121(13):2567-73, 2013. e-Pub 2013. PMID: 23361908.
213. Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol 160(6):798-805, 2013. e-Pub 2013. PMID: 23330820.
214. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous Stem-Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. Biol Blood Marrow Transplant 19(3):410-7, 2013. e-Pub 2013. PMID: 23128322.
215. Bolaños-Meade J, Wu J, Logan BR, Levine JE, Ho VT, Alousi AM, Weisdorf DJ, Luznik L, Blood, Trials Network MTC. Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302. Biol Blood Marrow Transplant 19(3):481-5, 2013. e-Pub 2013. PMID: 23247045.
216. Alousi AM, Bolaños-Meade J, Lee SJ. Graft-versus-Host Disease: The State of the Science. Biol Blood Marrow Transplant 19(1 Suppl):S102-8, 2013. e-Pub 2013. PMID: 23110985.
217. Kebriaei P, Madden T, Wang X, Thall PF, Ledesma C, de Lima M, Shpall EJ, Hosing C, Qazilbash M, Popat U, Alousi A, Nieto Y, Champlin RE, Jones RB, Andersson BS. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplant 48(1):26-31, 2013. e-Pub 2013. PMID: 22732703.
218. Najera JE, A||B A, De Lima M, Ciurea SO. Akinetic mutism-a serious complication to tacrolimus-based GVHD prophylaxis. Bone Marrow Transplant 48(1):157-8, 2013. e-Pub 2013. PMID: 22705799.
219. Dhamne C, Chung Y, Alousi AM, Cooper LJ, Tran DQ. Peripheral and thymic Foxp3+ regulatory T cells in search of origin, distinction, and function. Front Immunol 4:253, 2013. e-Pub 2013. PMID: 23986762.
220. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture. N Engl J Med 367(24):2305-2315, 2012. e-Pub 2012. PMID: 23234514.
221. Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, Hosing C, Khouri I, Qazilbash M, Popat U, Alousi A, Nieto Y, Jones RB, de Lima M, Champlin RE, Andersson BS. Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 18(12):1819-26, 2012. e-Pub 2012. PMID: 22750645.
222. Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved Early Outcomes Using a T-cell Replete Graft Compared with T-cell Depleted Haploidentical Hematopoietic Stem-Cell Transplantation. Biol Blood Marrow Transplant 18(12):1835-44, 2012. e-Pub 2012. PMID: 22796535.
223. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplant in Patients with Refractory Lymphoid Malignancies. Biol Blood Marrow Transplant 18(11):1677-86, 2012. e-Pub 2012. PMID: 22643322.
224. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119(26):6373-8, 2012. e-Pub 2012. PMID: 22586182.
225. Levine JE, Logan BR, Wu J, Alousi AM, Bolaños-Meade J, Ferrara JL, Ho VT, Weisdorf DJ, Paczesny S. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 119(16):3854-60, 2012. e-Pub 2012. PMID: 22383800.
226. Hymes SR, Alousi AM, Cowen EW. Graft-versus-host disease: Part II. Management of cutaneous graft-versus-host disease. J Am Acad Dermatol 66(4):535.e1-535.e16, 2012. e-Pub 2012. PMID: 22421124.
227. Hymes SR, Alousi AM, Cowen EW. Graft-versus-host disease: Part I. Pathogenesis and clinical manifestations of graft-versus-host disease. J Am Acad Dermatol 66(4):515.e1-515.e18, 2012. e-Pub 2012. PMID: 22421123.
228. Anderlini P, Saliba RM, Ledesma C, Chancoco C, Alousi AM, Shpall EJ, Popat UR, Hosing CM, Khouri IF, Nieto Y, Ciurea S, Younes A, Fanale MA, Acholonu S, Valverde R, Champlin RE. Gemcitabine, fludarabine and melphalan (G-FM) as a reduced-intensity conditioning regimen for allogeneic stem cell transplantation in relapsed and refractory hodgkin lymphoma: preliminary results. Leuk Lymphoma 53(3):499-502, 2012. e-Pub 2012. PMID: 21859247.
229. Ross WA, Alousi AM. Making the diagnosis of gastrointestinal GVHD: is evaluation of the ileum necessary?. Bone Marrow Transplant 47(3):321-2, 2012. e-Pub 2012. PMID: 22395763.
230. Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SA. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant 47(2):212-6, 2012. e-Pub 2012. PMID: 21423123.
231. Saliba RM, Couriel DR, Giralt S, Rondon G, Okoroji GJ, Rashid A, Champlin RE, Alousi AM. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant 47(1):125-31, 2012. e-Pub 2012. PMID: 21383686.
232. Alatrash G, Pelosini M, Saliba RM, Koca E, Rondon G, Andersson BS, Chiattone A, Zhang W, Giralt SA, Cernosek AM, Kebriaei P, Alousi AM, Popat UR, Hosing C, Khouri IF, Champlin RE, de Lima MJ. Platelet Recovery Prior to Allogeneic Stem Cell Transplant Predicts Posttransplant Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 17(12):1841-5, 2011. e-Pub 2011. PMID: 21684343.
233. Joseph RW, Alousi A, Konda B, Komanduri K, Neumann J, Trevino C, Stolar K, Qazilbash M, Hosing C, Kebriaei P, Couriel DR, Champlin RE, Saliba R, Popat U. High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol 86(11):954-6, 2011. e-Pub 2011. PMID: 21948087.
234. Kim HN, Alousi AM, Lee JH, Qiao W, Xiao L, Ross WA. Role of ERCP in patients after hematopoietic stem cell transplantation. Gastrointest Endosc 74(4):817-24, 2011. e-Pub 2011. PMID: 21802682.
235. Khan H, Oberoi S, Mahvash A, Sharma M, Rondon G, Alousi A, Shpall EJ, Kontoyiannis DP, Champlin RE, Ciurea SO. Reversible Ureteral Obstruction due to Polyomavirus Infection after Percutaneous Nephrostomy Catheter Placement. Biol Blood Marrow Transplant 17(10):1551-5, 2011. e-Pub 2011. PMID: 21396475.
236. Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE. Clofarabine±Fludarabine with Once Daily IV Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. Biol Blood Marrow Transplant 17(6):893-900, 2011. e-Pub 2011. PMID: 20946966.
237. Parmar S, Andersson BS, Couriel D, Munsell MF, Fernandez-Vina M, Jones RB, Shpall EJ, Popat U, Anderlini P, Giralt S, Alousi A, Cano P, Bosque D, Hosing C, Silva Lde P, Westmoreland M, Wathen JK, Berry D, Champlin RE, de Lima MJ. Prophylaxis of Graft-Versus-Host Disease in Unrelated Donor Transplantation with Pentostatin, Tacrolimus, and "Mini"-Methotrexate: A Phase I/II Controlled, Adaptively Randomized Study. J Clin Oncol 29(3):294-302, 2011. e-Pub 2011. PMID: 21149654.
238. Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, Andersson BS, Champlin R, Couriel DR. Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol 2011:601953, 2011. e-Pub 2011. PMID: 22110505.
239. Levine JE, Logan B, Wu J, Alousi AM, Ho V, Bolaños-Meade J, Weisdorf D, Blood, Trials Network MTC. Graft-versus-Host Disease Treatment: Predictors of Survival. Biol Blood Marrow Transplant 16(12):1693-9, 2010. e-Pub 2010. PMID: 20541024.
240. Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma. Biol Blood Marrow Transplant 16(8):1122-1129, 2010. e-Pub 2010. PMID: 20178853.
241. Jacobson PA, Huang J, Wu J, Kim M, Logan B, Alousi A, Grimley M, Bolaños-Meade J, Ho V, Levine JE, Weisdorf D. Mycophenolate Pharmacokinetics and Association with Response to Acute Graft vs Host Disease (GVHD) Treatment From the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant 16(3):421-9, 2010. e-Pub 2010. PMID: 19925875.
242. Alousi AM, Uberti J, Ratanatharathorn V. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Leuk Lymphoma 51(3):376-389, 2010. e-Pub 2010. PMID: 20141428.
243. Hosing C, Munsell MF, Reuben JM, Popat U, Lee BN, Gao H, Körbling M, Shpall EJ, Kebriaei P, Alousi A, De Lima M, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I. A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas. J Blood Med 1:49-55, 2010. e-Pub 2010. PMID: 22282683.
244. Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B, Khouri I, Hosing C, Ippoliti C, Shpall EJ, Champlin R, Alousi A. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 15(12):1555-62, 2009. e-Pub 2009. PMID: 19896079.
245. Alousi AM, Weisdorf DJ, Logan BR, Bolaños-Meade J, Carter S, Difronzo N, Pasquini M, Goldstein SC, Ho VT, Hayes-Lattin B, Wingard JR, Horowitz MM, Levine JE, Blood, Trials Network MTC. Etanercept, mycophenolate, denileukin or pentostatin plus corticosteroids for acute graft vs. host disease: a randomized phase II trial from the BMT CTN. Blood 114(3):511-7, 2009. e-Pub 2009. PMID: 19443659.
246. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 15(7):812-6, 2009. e-Pub 2009. PMID: 19539212.
247. Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U. Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 84(6):335-7, 2009. e-Pub 2009. PMID: 19384931.
248. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15(6):718-23, 2009. e-Pub 2009. PMID: 19450756.
249. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA, Anderlini P, Popat U, Pro B, Samuels B, Hagemeister F, Medeiros LJ, Champlin RE, Khouri IF. Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113(18):4144-52, 2009. e-Pub 2009. PMID: 19168784.
250. Efebera YA, Thandi RS, Saliba RM, Popat U, De Lima M, Alousi A, Hosing C, Rondon G, Champlin R, Giralt S. The Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant Outcomes. Internet J Hematol 7(1), 2009. e-Pub 2009. PMID: 25356072.
251. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 14(12):1401-7, 2008. e-Pub 2008. PMID: 19041063.
252. Alousi AM, Saliba RM, Okoroji GJ, Macapinlac HA, Hosing C, Korbling M, Samuels BI, Popat U, Kebriaei P, Anderlini P, Qazilbash MH, de Lima M, Giralt SA, Champlin RE, Khouri IF. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol 142(5):786-92, 2008. e-Pub 2008. PMID: 18564354.
253. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. 8-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide and rituximab. Blood 111(12):5530-6, 2008. e-Pub 2008. PMID: 18411419.
254. Hosing C, Saliba RM, Okoroji GJ, Popat U, Couriel D, Ali T, De Padua Silva L, Kebriaei P, Alousi A, De Lima M, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Ann Oncol 19(6):1166-71, 2008. e-Pub 2008. PMID: 18272911.
255. Kebriaei P, Detry MA, Giralt S, Carrasco-Yalan A, Anagnostopoulos A, Couriel D, Khouri IF, Anderlini P, Hosing C, Alousi A, Champlin RE, de Lima M. Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation with Reduced Intensity Conditioning for Patients with Chronic Myeloid Leukemia. Blood 110(9):3456-3462, 2007. e-Pub 2007. PMID: 17652620.
256. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 13(9):1066-72, 2007. e-Pub 2007. PMID: 17697969.
257. Alousi AM, Boinpally R, Wiegand R, Parchment R, Gadgeel S, Heilbrun LK, Wozniak AJ, DeLuca P, LoRusso PM. A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor. Invest New Drugs 25(2):147-54, 2007. e-Pub 2007. PMID: 17103044.
258. Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 39(5):279-283, 2007. e-Pub 2007. PMID: 17262062.

Invited Articles

1. Alousi AM. Paraneoplastic Limbic Encephalitis in a Patient with Colon Cancer. MD Morning Report On-line Interactive Website, 2006. e-Pub 2006.
2. Alousi A, Stano M, Simon M. Economic Evaluation of aromatase inhibitors for the treatment of breast cancer. Pharmacoeconomics Outcomes Res 3:89-97, 2003. e-Pub 2003.

Review Articles

1. Smallbone, PI, Mehta, RS, Alousi, AM. Steroid Refractory Acute GVHD. American journal of hematology 100(S3):14-29, 2025. e-Pub 2025. PMID: 40123554.
2. Hill L, Alousi A, Kebriaei P, Mehta R, Rezvani K, Shpall E. New and emerging therapies for acute and chronic graft versus host disease. Ther Adv Hematol 9(1):21-46, 2018. e-Pub 2018. PMID: 29317998.
3. Thompson PA, Rezvani K, Hosing CM, Oran B, Olson AL, Popat UR, Alousi AM, Shah ND, Parmar S, Bollard C, Hanley P, Kebriaei P, Cooper L, Kellner J, McNiece IK, Shpall EJ. Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant 50 Suppl 2:S55-62, 2015. e-Pub 2015. PMID: 26039209.
4. Robinson SN, Simmons PJ, Yang H, Alousi AM, Marcos de Lima J, Shpall EJ. Mesenchymal stem cells in ex vivo cord blood expansion. Best Pract Res Clin Haematol 24(1):83-92, 2011. e-Pub 2011. PMID: 21396596.
5. Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cortés JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma 9(Supplement 3):S261-5, 2009. e-Pub 2009. PMID: 19778850.
6. Alousi A, de Lima M. Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. Clin Adv Hematol Oncol 5(7):560-70, 2007. e-Pub 2007. PMID: 17679930.

Other Articles

1. Nieto, Y, Banerjee, PP, Kaur, I, Basar, R, Li, YE, Daher, M, Rafei, H, Kerbauy, LN, Kaplan, M, Marin, D, Griffin, L, Barnett, M, Bassett Jr, R, Uprety, N, Shrestha, R, Silva, FR, Islam, S, Ganesh, C, Borneo, Z, Ramdial, JL, Ramirez, A, Hosing, C, Alousi, AM, Popat, UR, Qazilbash, MH, Ahmed, S, Iyer, SP, Sainz, TP, Vega Vazquez, F, Fowlkes, NW, Alexis, K, Emig, M, Harstrick, A, Overesch, A, Shpall, E, Rezvani, K Correction to. Nature medicine 31(8):2816, 2025. PMID: 40571757.
2. Alkhunaizi M, Patel B, Bueno L, Bhan N, Ahmed T, Arain MH, Saliba R, Rondon G, Dickey BF, Bashoura L, Ost DE, Li L, Wang S, Shpall E, Champlin RE, Mehta R, Popat UR, Hosing C, Alousi AM, Sheshadri A Corrigendum to 'Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation' [Transplantation and Cellular Therapy 29/3 (2023) 204-204]. Transplant Cell Ther, 2024. PMID: 39561968.
3. Alousi A, Ghosh S, Rice D, Moran C, Manning JT, Iliescu C, Hymes S, Kim S, Bashoura L, Kornblau S, Dickey BF Pleuropericarditis, obliterative bronchiolitis and lymphocytic interstitial pneumonitis after allogeneic haematopoietic stem cell transplantation. BMJ Case Rep 2011, 2011. PMID: 22707568.

Abstracts

1. Popat UR, Saliba RM, Mehta RS, Alousi AM, Alatrash, G, Bashir Q, Chen J, Gulbis A, Hosing CM, Im JS, Kebriaei P, Khouri IF, Kawedia JD, Marin D, Nieto Y, Olson A, Oran B, Ramdial JL, Saini NY, Srour SA, Rezvani K, Qazilbash MH, Kantarjian H, Andersson B, Champlin RE, Shpall EJ. Myeloablative Fractionated Busulfan Regimens in Matched Donor Transplantation. Transplant Cell Ther 2023 TCT Meetings of ASTCT and CIBMTR 29(Supplement 2), 2023. e-Pub 2023.
2. Marinos A, Ramdial JL, Saliba R, Khawaja F Alousi AM, Rondon G, Chen G, Ledesma C, Chemaly RF, Champlin RE, Marin D, Daher M, Rezvani K, Shpall EJ. Long-Term Follow-up Outcomes of Patients That Underwent Allogeneic or Autologous Hematopoietic Transplant Shortly after a COVID-19 Infection. Transplant Cell Ther 2023 TCT Meetings of ASTCT and CIBMTR 29(Supplement 2), 2023. e-Pub 2023.
3. Chi D, Hosing C, Khouri I F, Saengboon S, Saini NY, Ramdial JL, Akin S, Bashir Q, Steiner R, Dabaja B, Pinnix C, Ahmed S, Alousi AM, Anderlini P, Kebriaei P, Qazilbash MH, Popat UR Shpall EJ, Champlin RE, Nieto Y, Srour SA. Long-Term Outcomes after Autologous Stem Cell Transplant (ASCT) for Primary Central Nervous System Lymphoma (PCNSL). Transplant Cell Ther 2023 TCT Meetings of ASTCT and CIBMTR 29(Supplement 2), 2023. e-Pub 2023.
4. Popat UR, Saliba RM, Mehta RS, Alousi AM, Al-Atrash, G, Bashir Q, Chen J, Hosing CM, Gulbis AM, Im JS, Kebriaei P, Khouri IF, Kawedia JD, Marin D, Nieto Y, Olson A, Oran B, Ramdial JL, Saini NY, Shigle, TL, Srour SA, Rezvani K, Qazilbash MH, Andersson B, Shpall EJ, Champlin RE. Myeloablative Fractionated Busulfan Fludarabine and Thiotepa Regimen for Haploidentical Donor Transplantation. Transplant Cell Ther 2023 TCT Meetings of ASTCT and CIBMTR 29(Supplement 2), 2023. e-Pub 2023.
5. Saengboon S, Khouri I, Ramdial JL, Akin S, Steiner R, Ahmed S, Dabaja B, Alousi AM, Qazilbash MH, Champlin RE, Nieto Y, Hosing C, Saini NY, Shi D, Malpica L, Westin JR, Wu SY, Kebriaei P, Popat, UR, Shpall EJ, Srour SA. Timing of Autologous Stem Cell Transplantation (ASCT) in Patients with Primary Central Nervous System Lymphoma (PCNSL). Transplant Cell Ther 2023 TCT Meetings of ASTCT and CIBMTR 29(Supplement 2), 2023. e-Pub 2023.
6. Chan KH, Ramdial JL, Srour SA, Kebriaei P, Qazilbash MH, Iyer SP, Nair R, Strati P, Fang P, Pinnix C, Cuglievan B, Re C, Nieto Y, Hosing C, Alousi AM, Popat UR, Ahmed S, Lee HJ, Steiner R, Dabaja B, Gunther JR, Mahadeo KM, Shpall EJ. Outcome of Patients with Classical Hodgkin Lymphoma (cHL) Relapsing after an Autologous Stem-Cell Transplant (ASCT). Transplant Cell Ther 2023 TCT Meetings of ASTCT and CIBMTR 29(Supplement 2), 2023. e-Pub 2023.
7. Capellini A, Etra A, Alousi AM, Al Malki M, Choe H, Defilipp Z, Hogan WJ, Kitko CL, Ayuk FA, Baez J, Gandhi I, Kasikis, Gleich, Hexner EO, Hoepting M, Kapoor U, Kowalik S, Kwon D, Langston A, Mielcarek M, Morales G, Ozbek U, Qayed M, Reshef R, Roesler W, Spyrou N, Young R, Chen Y, Ferrara JL, Levine J. Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy. Blood 64th ASH Annual Meeting 140(Supplement 1), 2022. e-Pub 2022.
8. Nieto Y, Valdez BC, Thall, PF, Ramdial JL, Srour SA, Hosing C, Saini N, Alousi AM, Qazilbash MH, Popat UR, Gulbis A, Shigle TL, Bassett R, Guillermo-Pacheco M, Ledesma C, Strati P, Ahmed S, Steiner R, Westin J, Nair R, Iyer SP, Champlin RE, Shpall EJ, Andersson BS. High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas. Blood 64th ASH Annual Meeting 140(Supplement 1), 2022. e-Pub 2022.
9. Champlin RE, Bachar Lustig E, Bashir Q, Oran B, Kornblau SM, Hosing, Alousi AM, Popat UR, McCarty JM, Thall PF, Dabaja BS, Liu W, Dang G, Castro K, Ramirez A, Spiotto M, Wu S, Fang P, Kaur I, Rezvani K, Shpall EJ, Reisner Y. First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT). Blood 64th ASH Annual Meeting 140(Supplement 1), 2022. e-Pub 2022.
10. Nieto Y, Banerjee P, Kaur I, Bassett R, Kerbauy L, Basar R, Kaplan M, Griffin L, Esqueda D, Ganesh C, Barnett M, Alousi A, Hosing C, Ramdial J, Saini N, Srour S, Alexis K, Harstrick A, Shpall EJ, Rezvani K. Innate cell engager (ICE®) AFM13 combined with preactivated and expanded cord blood (CB)-derived NK cells for patients with refractory/relapsed CD30+ lymphoma. AACR Annual Meeting 2022 82(12_Supplement), 2022. e-Pub 2022.
11. Srinivasan K, Khawaja F, Cantu S, Alousi AM, Ramdial J, Champlin RE, Shpall EJ, Frenzel E, Chemaly RF. Outcomes of Hospital-Associated Covid-19 in Hematopoietic Cell Transplant (HCT) Recipients: A Single Center Experience. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S331-S332, 2022. e-Pub 2022.
12. Popat UR, Mehta RS, Thall P, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, ieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpall EJ, Champlin RE, Andersson BS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S78-S79, 2022. e-Pub 2022.
13. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis AM, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S82-S83, 2022. e-Pub 2022.
14. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, VAldez BC, Rezvani K, Qazilbash MH, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S293, 2022. e-Pub 2022.
15. Popat UR, Mehta RS, BAssett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, SAini NY, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement), 2022. e-Pub 2022.
16. Arora M, Lee SJ, Onstad L, Cutler C, Carpenter PA, Pidala JA, Hamilton BK, Jayani RV, Flowers MED, Arai S, Alousi AM, Bhatia S. Prevalence and Predictors of Frailty in Patients with Chronic Graft-Versus-Host Disease. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S296-S297, 2022. e-Pub 2022.
17. Ramdial JL, Saliba RM, Alousi AM, Rondon G, Chen J, Ledesma C, Shpall EJ, Chemaly, Champlin RE. Allogeneic and Autologous Hematopoietic Transplants Can be Safely Performed after COVID-19 Infections. Blood 63rd ASH Annual Meeting 138(Supplement 1):2855, 2021. e-Pub 2021.
18. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia J, Khouri I, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. Blood 63rd ASH Annual Meeting 138(Supplement 1):1803, 2021. e-Pub 2021.
19. Popat UR, Mehta RS, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis A, Marin D, Nieto D, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, rezvani K, Qazilbash MH, Kadia TM Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. Blood 63rd ASH Annual Meeting 138(Supplement 1):2879, 2021. e-Pub 2021.
20. Wallis, W, Gulbis A, Wang T, Kitko CL, MacMillan ML, Pidala J, Riches ML, Spellman SR, Arora M, Alousi AM. Bacterial Prophylaxis in Patients with Acute Gvhd; Who Is at Risk for Bloodstream Infections?. Blood 63rd ASH Annual Meeting 138(Supplement 1):2870, 2021. e-Pub 2021.
21. Popat UR, Bassett R, Thall PF, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpall EJ, Champlin RE, Andersson BS, Mehta RS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. Blood 63rd ASH Annual Meeting 138(Supplement 1):556, 2021. e-Pub 2021.
22. Al-Juhaishi T, Malek AE, Milton DR, Ramdial JL, Daher, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Chitra Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto, Anderlini, Alousi AM, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich V, Ahmed S. Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. Blood 63rd ASH Annual Meeting 138(Supplement 1):1779, 2021. e-Pub 2021.
23. Popat, UR, Mehta, RS, Bassett, R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im, JS, Kebriaei, P, Kawedia, JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Blood 63rd ASH Annual Meeting 138(Supplement 1):1802, 2021. e-Pub 2021.
24. Mehta R, Bassett R, Olson A, Chen J, Ganesh C, Alousi A, Anderlini P, Al-Atrash G, Bashir Q, Ciurea S, Hosing C, Im J, Kebriaei P, Khouri I, Marin D, Molldrem J, Nieto Y, Oran B, Rezvani K, Qazilbash M, Srour S, Shpall E, Champlin R, Andersson B, Popat U. CT-046: Post-Transplant Cyclophosphamide in HLA-Matched and Haploidentical Transplant Recipients Receiving a Myeloablative Fractionated Busulfan Conditioning Regimen: Results of a Phase II Study. Clin Lymphoma Myeloma Leuk 2021 SOHO Meeting 21(Supplement 1):S446-S447, 2021. e-Pub 2021.
25. Mehta R, Bassett R, Olson A, Chen J, Ganesh C, Alousi A, Anderlini P, Al-Atrash G, Bashir Q, Ciurea S, Hosing C, Im J, Kebriaei P, Khouri I, Marin D, Molldrem J, Nieto Y, Oran B, Rezvani K, Qazilbash M, Srour S, Shpall E, Champlin R, Andersson B, Popat U. Poster: CT-046: Post-Transplant Cyclophosphamide in HLA-Matched and Haploidentical Transplant Recipients Receiving a Myeloablative Fractionated Busulfan Conditioning Regimen: Results of a Phase II Study. Clin Lymphoma Myeloma Leuk 2021 SOHO Annual Meeting 21(Supplement 1):S258, 2021. e-Pub 2021.
26. DeFilipp Z, Onstad L, Arai S, Arora M, Cutler C, Flowers MED, Kitko CL, Carpenter PA, Pidala JA, Alousi AM, Chen GL, Lee SJ, Hamilton BK. Non-Relapse Mortality Among Patients Diagnosed with Chronic Graft-Versus-Host Disease: An Updated Analysis from the Chronic Gvhd Consortium. Transplant Cell Ther 2021 TCT Meetings of ASTCT and CIBMTR 27(3, Supplement):S79-S80, 2021. e-Pub 2021.
27. Oran B, Alousi AM, Mehta RS, Marin D, Kebriaei P, Popat UR, Olson AL, McCarty JM, Ramos JD, Bassett R, Keer HN, Thall PF, Champlin RE. Minimal Residual Disease Eradication with Guadecitabine (SGI-110) in the Post-Transplant Setting. Blood 62nd ASH Annual Meeting 136(Supplement 1):10-11, 2020. e-Pub 2020.
28. Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Rondon G, Nieto Y, Ciurea S, Oran, B, Im JS, Olson AL, Marin D, Qazilbash MH, Khouri IF, Anderlini P, Rezvani K, Popat UR, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease. Blood 62nd ASH Annual Meeting 136(Supplement 1):39-40, 2020. e-Pub 2020.
29. Saini N, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS, Srour SA, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE Qazilbash MH. African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. Blood 62nd ASH Annual Meeting 136(Supplement 1):9-10, 2020. e-Pub 2020.
30. Nieto Y, Gruschkus SK, Jones RB, Valdez BC, Timmons M, Hosing C, Anderlini P, Kebriaei P, Popat UR, Qazilbash MH, Alousi AM, Srour SA, Saini N, Ramdial J, Im JS, Shpall EJ, Rezvani K, Gulbis A, Shigle TL, Mahadeo KM, Khazal S, Khouri IF, Dabaja BS, Pinnix CC, Gunther JR, Lee H, Ahmed S, Steiner RE, Iyer SP, Nair R, Parmar S, Cuglievan B, Maadani F, Rondon G, Champlin RE, Andersson BS. Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. Blood 62nd ASH Annual Meeting 136(Supplement 1):17-18, 2020. e-Pub 2020.
31. Mehta RS, Bassett, R, Chen J, Valdez BC, Kswedisa J, Alousi AM, Al-Atrash Gm Bashir Q, Ciurea S, Hosing C, Im JS, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial. Blood 62nd ASH Annual Meeting 136(Supplement 1):10-11, 2020. e-Pub 2020.
32. Oran B, Al-Atrash G, Alousi AM, Mehta RS, Hosing C, Popat UR, Im JS, McCarty JM, Ramos JD, Keer HN, Thall PF, Champlin RE. Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation. Blood 62nd ASH Annual Meeting 136(Supplement 1):29-30, 2020. e-Pub 2020.
33. Mukherjee A, Milton DR, Jabbour E, Daver N, Gulbis A, Ledesma C, Konopleva M, DiNardo CD, Ravandi F, Kadia TM, Al-Atrash G, Alousi AM, Daher M, Marin D, Olson AL Oran B, Kebriaei P, Saini N, Srour SA, Popat UR, Im JS, Mehta RS, Rondon G, Kantarjian HM, Champlin RE, Khouri IF. Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy. Blood 62nd ASH Annual Meeting 136(Supplement 1):13-14, 2020. e-Pub 2020.
34. Saini, N, Ma J, Timmons M, Alousi AM, Anderlini P, Andersson BS, Hosing C, Ramdial J, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Srour SA, Valdez BC, Daaja BS, Pinnix CC, Gunther JR, Maadani F, Rondon G, Champlin RE, Nieto Y. High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC). Blood 62nd ASH Annual Meeting 136(Supplement 1):32-33, 2020. e-Pub 2020.
35. Andersson, BS, Thall P, Valdez BC, MA J, Chen J, Ahmed S, Alousi AM, Bashir Q, Ciurea SO, Gulbis A, Hosing C, Jones RB, Kawedia J, Kebriaei P, Kornblau SM Myers A, Oran B, Rezvani K, Shah N, Shpall EJ, Parmar S, Popat UR, Nieto Y, Champlin RE. A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS. Blood 62nd ASH Annual Meeting 136(Supplement 1):37-38, 2020. e-Pub 2020.
36. Kadia TM, Borthakur G, Takahashi K, DiNardo C, Daver N, Pemmaraju N, Jabbour E, Jain N, Short N, Qiao W, Adewale L, Rausch C, Pierce SA, Alvarado Y, Alousi AM, Popat UR, Khouri IF, Garcia-Manero G, Konopleva M, Cortes JE, Ravandi F, Kantarjian HM. Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML). Blood 62nd ASH Annual Meeting 136(Supplement 1):20-22, 2020. e-Pub 2020.
37. Oran B, Ciurea SO, Mehta RS, Alousi AM, Rondon G, Popat UR, Marin D, Daher M, Im JS, Kebriaei P, Al-Atrash G, Champlin RE. Transplant Outcomes with Fludarabine and Melphalan in High Risk AML Patients By Donor Types. Blood 62nd ASH Annual Meeting 136(Supplement 1):20-21, 2020. e-Pub 2020.
38. Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Daher M, Gruschkus SK, Knape C, Whited L, Gulbis A, Marcotulli M, Rondon G, Popat UR, Mehta RS, Konopleva M, Oran B, Ohanian M, Ravandi F, Garcia-Manero G, Alousi AM, Daver M, Champlin RE, Al-Atrash G. Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis. Blood 62nd ASH Annual Meeting 136(Supplement 1):1, 2020. e-Pub 2020.
39. Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Daher M, Gruschkus S, Knape C, Whited L, Gulbis A, Cornelison-Marcotulli M, Rondon G, Popat U, Mehta R, Konopleva M, Oran B, Ohanian M, Ravandi F, Garcia-Manero G, Alousi A, Daver N, Champlin R, Diab A, Al-Atrash G. Post-Transplant Cyclophosphamide Reduces the Incidence of Acute Graft Versus Host Disease in AML/MDS Patients Who Receive Checkpoint Inhibitors After Allogeneic Stem Cell Transplant. Clin Lymphoma Myeloma Leuk 2020 SOHO Annual Meeting 20(Supplement 1):S201-S202, 2020. e-Pub 2020.
40. Yalniz F, Saliba R, Greenbaum U, Ramdial J, Alousi A, Joseph J, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Shpall E, Mehta R, Qazilbash M, Popat U, Oran B, Champlin R, Kebriaei P. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 2020 SOHO Annual Meeting 20(Supplement 1):S202, 2020. e-Pub 2020.
41. Joseph J, Milton D, Al-Atrash G, Alousi A, Bashir Q, Daher M, Im J, Mehta R, Olson A, Oran B, Saini N, Srour S, Bose P, Pemmaraju N, Verstovsek S, Andersson B, Champlin R, Popat U. Myeloablative Fludarabine and Busulfan Regimen in Myelofibrosis (MF): Long-Term Outcomes and Analysis of Prognostic Factors. Clin Lymphoma Myeloma Leuk 2020 SOHO Annual Meeting 20(Supplement 1):S333, 2020. e-Pub 2020.
42. Joseph J, Milton DR, Chen J, Alatrash G, Alousi AM, Bashir Q, Ciurea SO, Daher M, Im JS, Mehta RS, Oran B, Olson AL, Saini N, Srour SA, Andersson B, Champlin RE, Popat UR. Myeloablative fludarabine and busulfan regimen in myelofibrosis: Long term outcomes and analysis of prognostic factors. J Clin Oncol 2020 ASCO Virtual Scientific Program 38(15_suppl):e19520, 2020. e-Pub 2020.
43. Qazilbash MH, Ramdial J, Bashir Q, Milton DR, Patel RD, Popat UR, Hosing CM, Kebriaei P, Alousi AM, Ciurea SO, Konopleva M, Champlin RE, Pemmaraju N. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for BPDCN. Biol Blood Marrow Transplant 2020 TCT Meetings 26(3, Supplement):S106-S107, 2020. e-Pub 2020.
44. Popat UR, Saliba RM, Mehta RS, Olson A, Chen J, Ganesh C, Woodworth G, McMullin B, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour SA, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE. Comparison of Post-Transplant Cyclophosphamide and Tacrolimus and Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. Biol Blood Marrow Transplant 2020 TCT Meetings 26(3, Supplement):S125, 2020. e-Pub 2020.
45. Popat UR, Mehta RS, Bassett R, Olson A, Chen J, Ganesh C, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour SA, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Champlin RE, Andersson BS. Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study. Biol Blood Marrow Transplant 2020 TCT Meetings 26(3, Supplement):S6-S7, 2020. e-Pub 2020.
46. Ponce DM, Alousi AM, Nakamura R, Sandhu KS, Barker JN, Shia J, Yan X, Daley WL, Moore G, Fatmi S, Soto C, Gomes A, Singerland J, Giardina P, Peled JU, van den Brink MRM, Hanash AM. A Phase 2 Study of F-652, a Novel Tissue-Targeted Recombinant Human Interleukin-22 (IL-22) Dimer, for Treatment of Newly Diagnosed Acute Gvhd of the Lower GI Tract. Biol Blood Marrow Transplant 2020 TCT Meetings 26(3, Supplement):S51-S52, 2020. e-Pub 2020.
47. Kebriaei P, Banerjee PP, Ganesh C, Kaplan M, Nandivada VD, Cortes AKN, Alousi AM, Marin D, Shpall EJ, Mehta RS, Ravandi F, Kantarjian H, Jabbour E, Champlin RE, Rezvani K. Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant 2020 TCT Meetings 26(3, Supplement):S102-S103, 2020. e-Pub 2020.
48. Saliba RM, Arora M, Spellman SR, Hemmer MT, Wang T, Alousi AM, Pidala JA, Jagasia M, MacMillan ML, Horowitz MM, Schriber J, Champlin RE, Ciurea SO. Acute Graft-Versus-Host Disease Is Less Severe and Associated with Lower Non-Relapse Mortality after Haploidentical Transplantation with Post-Cyclophosphamide Prophylaxis. Biol Blood Marrow Transplant 2020 TCT Meetings 26(3, Supplement):S26-S27, 2020. e-Pub 2020.
49. Koller P, Saliba RM, Ledesma C, Rondon G, Popat UR, Alousi AM, Mehta RS, Oran B, Olson AL, Hosing C, Qazilbash MH, Khouri IF, Ciurea SO, Shpall EJ, Jorgensen J, Wang SA, Jain N, Jabbour E, Kantarjian H, Champlin RE, Konopleva MY, Kebriaei P. Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression. Blood 61st ASH Annual Meeting 134(Supplement_1):4598, 2019. e-Pub 2019.
50. Ciurea SO, Varma A, Kongtim P, Srour S, Bashir Q, Alousi AM, Mehta R, Oran B, Popat UR, Hosing C, Rondon G, Chen J, Olson AL, Konopleva MY, Champlin RE. Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis. Blood 61st ASH Annual Meeting 134(Supplement_1):42, 2019. e-Pub 2019.
51. Oran B, Champlin RE, Wang F, Jeyakumar N, Garcia-Manero G, Kantarjian HM, Saliba RM, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat UR, Futreal A, Takahashi K. Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients. Blood 61st ASH Annual Meeting 134(Supplement 1), 2019. e-Pub 2019.
52. Oran B, Champlin RE, Wang F, Jeyakumar N, Garcia-Manero G, Kantarjian H, Saliba RM, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat UR, Futreal A, Takahashi K. Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients. Blood 61st ASH Annual Meeting 134(Supplement_1):47, 2019. e-Pub 2019.
53. Popat UR, Mehta RS, Bassett R, Olson A, Chen J, Ganesh C, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea S, Hosing C, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Saini N, Srour S, Rezvani K, Qazilbash MH, Molldrem J, Shpall EJ, Andersson BJ, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study. Blood 61st ASH Annual Meeting 134(Supplement_1):256, 2019. e-Pub 2019.
54. Champlin RE, Popat UR, Oran B, Ciurea SO, Kebriaei P, Alousi AM, Al-Atrash G, Bashir Q, Khouri IF, Hosing C, Anderlini P, Jones R, Marin D, Mehta RS, Nieto Y, Olson AL, Qazilbash MH, Rezvani K, Shpall EJ, Chen J, Rondon G, McMullin B, Al Jahdhami VP, Kawedia J, Valdez BC, Ma J, Thall, PF, Andersson B. A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. Blood 61st ASH Annual Meeting 134(Supplement_1):257, 2019. e-Pub 2019.
55. Yalniz F, Saliba R, Yucel O, Garcia-Manero G, Ramdial J, Popat UR, Ciurea S, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Hosing C, Marin D, Mehta RS, Olson A, Rezvani K, Shpall EJ, Rondon EJ, Champlin RE, Oran B. Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation. Blood 61st ASH Annual Meeting 134(Supplement_1):512, 2019. e-Pub 2019.
56. Kebriaei P, Banerjee P, Ganesh C, Kaplan M, Nandivada V, Nunez Cortes A, Alousi AM, Marin D, Shpall EJ, Mehta RS, Ravandi F, Jabbour E, Kantarjian H, Champlin RE, and Rezvani K. Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia. Blood 61st ASH Annual Meeting 134(Supplement_1):1298, 2019. e-Pub 2019.
57. Wang Y, Young K, Milton D, Ledesma C, Jabbour E, Xu-Monette Y, Molldrem J, Anderlini P, Alousi AM, Bashir Q, Daher M, Fayad L, Iyer S, Kebriaei P, Marin D, Mehta RS, Olson AL, Popat UR, Samaniego F, Westin J, Qazilbash MH, Im JS, Rondon G, Gulbis A, Champlin RE, Khouri IF. Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation. Blood 61st ASH Annual Meeting 134(Supplement_1):2021, 2019. e-Pub 2019.
58. Olson A, Lin R, Bdaiwi M, Thall PF, Rafei H, Kaur I, Abueg G, Timmons M, Chemaly R, Marin D, Alousi AM, Ahmed S, Ciurea SO, Hosing C, Kebriaei P, Jones RB, Andersson BS, Oran B, Abuddayeh, Popat UR, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. Blood 61st ASH Annual Meeting 134(Supplement_1):3596, 2019. e-Pub 2019.
59. Popat UR, Saliba R, Mehta RS, Olson A, Chen J, Ganesh C, Rondon G, Woodworth G, McMullin B, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour S, Rezvani K, Qazilbash MH, Molldrem J, Shpall EJ, Andersson BS, Champlin RE. Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. Blood 61st ASH Annual Meeting 134(Supplement_1):3296, 2019. e-Pub 2019.
60. Mukherjee A, Milton D, Gulbis A, Ledesma C, Jabbour E, Alousi AM, Bashir Q, Daher M, Oran B, Olson A, Marin D, Srour S, Kebriaei P, Mehta RS, Nemeth KP, Popat UR, Im JS, Champlin RE, Khouri IF. Post-Transplant Cyclophosphamide (PT-Cy) Based Haploidentical Cell Transplantation (Haplo) Versus Rabbit Anti-Thymocyte Globulin (r-ATG) Based HLA Matched Unrelated Donor (MUD) Transplantation in Patients (pts) with Relapsed/Refractory Lymphoma. Blood 61st ASH Annual Meeting 134(Supplement_1):4530, 2019. e-Pub 2019.
61. Popat UR, Mehta RS, Bassett R, Olson AL, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Shpall EJ, Champlin RE, Andersson B. Post-transplant cyclophosphamide in matched and haploidentical transplant recipients receiving myeloablative timed sequential busulfan conditioning regimen: Results of a phase II study. J Clin Oncol 2019 ASCO Annual Meeting 37(15_suppl):7007, 2019. e-Pub 2019.
62. Kongtim P, Hasan O, Perez JMR, Varma A, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash MH, Mehta R, Shpall EJ, Alousi AM, Khouri IF, Kebriaei P, Popat UR, Champlin RE, Ciurea SO. Development and validation of a novel disease risk model for patients with AML receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2019 ASCO Annual Meeting 37(15_suppl):7016, 2019. e-Pub 2019.
63. Popat UR, Saliba RM, Olson A, Mehta RS, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Molldrem JJ, Nieto Y, Oran B, Qazilbash MH, Rezvani K, Rondon G, Shpall EJ, Varma A, Andersson BS, Champlin RE. Comparison of Tacrolimus and Post-Transplant Cyclophosphamide (PTCy) with Tacrolimus and Methotrexate (Tac/MTX) Gvhd Prophylaxis in Patients with AML Undergoing Transplantation from Matched Related or Unrelated Donors. Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT and CIBMTR 25(3, Supplement):S235-S236, 2019. e-Pub 2019.
64. Pidala JA, Hamadani M, Dawson P, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan S, Ferrara J, Levine JE, Anasetti C, Pritchard T, Martens M, Horowitz MM, MacMillan ML. Sirolimus Vs. Prednisone As Initial Systemic Therapy for Minnesota Standard Risk (MN-SR), Ann Arbor 1/2 Acute Graft-Vs-Host Disease (GVHD): Primary Results of the Multi-Center Randomized Phase II BMT CTN 1501 Trial. Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT and CIBMTR 25(3, Supplement):S50-S51, 2019. e-Pub 2019.
65. Patel B, Sheshadri A, Saliba RM, Rondon G, Ahmed T, Arain MH, Mehta RS, Popat UR, Hosing CM, Bashoura L, Dickey BF, Champlin RE, Alousi AM. Azithromycin Exposure Following Hematopoietic Stem Cell Transplantation Is Associated with an Increased Risk of Cancer Relapse in Acute Leukemia. Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT and CIBMTR 25(3, Supplement):S231-S232, 2019. e-Pub 2019.
66. Saliba RM, Alousi AM, Andersson BS, Chen J, Mehta RS, Molldrem JJ, Champlin RE, Popat UR. Higher Pre-Transplant IL-2 Levels Correlate with Higher Incidence of Acute Graft-Versus-Host Disease. Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT and CIBMTR 25(3, Supplement):S245, 2019. e-Pub 2019.
67. Rashid A, Hamilton BK, Wang T, Hemmer MT, Spellman SR, Alousi AM, Jagasia M, Pidala JA, Arora M, Im AP. Risk Factors for Graft-Versus-Host Disease (GVHD) in Haploidentical Hematopoietic Cell Transplantation (HCT) Using Post-Transplant Cyclophosphamide (PTCy). Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT and CIBMTR 25(3, Supplement):S256, 2019. e-Pub 2019.
68. Mukherjee A, Milton D, Ledesma C, Olson A, Alatrash G, Anderlini P, Alousi A, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Molldrem JJ, Oran B, Popat UR, Qazilbash MH, Rondon G, Champlin RE, Gulbis AM, Khouri IF. Idiopathic Portal Hypertension Related Refractory Ascites (IPHRA) after Allogeneic Stem Cell Transplant. Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT and CIBMTR 25(3, Supplement):S144–S145, 2019. e-Pub 2019.
69. Neumann JL, Alousi AM. Nursing Challenges Caring for HSCT Patients with Gvhd. Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT and CIBMTR 25(3, Supplement):S436, 2019. e-Pub 2019.
70. Saini N, Saliba RM, Patel RD, Abdulrazzaq MN, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Kebriaei P, Nastoupil LJ, Westin JR, Rondon G, Andersson BS, Champlin RE, Muzzafar TR, Nieto Y, Ahmed S. Does Cell of Origin Classification Impact Outcomes in Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplant. Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT and CIBMTR 25(3, Supplement):S394-S395, 2019. e-Pub 2019.
71. Mukherjee A, Milton D, Ledesma C, Olson A, Alatrash G, Anderlini P, Alousi AM, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Molldrem JJ, Oran B, Popat UR, Qazilbash MH, Rondon G, Champlin RE, Gulbis AM, Khouri IF. Influence of the Intensity of the Allogeneic Conditioning Regimen on the Risk of Hemorrhagic Cystitis (HC) in Patients Receiving Post- Transplant Cyclophosphamide (PT-Cy) As Gvhd Prophylaxis. Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT and CIBMTR 25(3, Supplement):S147-S148, 2019. e-Pub 2019.
72. Kongtim P, Parmar S, Milton DR, Ramos Perez JM, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi AM, Andersson BS, Im JS, Hosing C, Bashir Q, Khouri IF, Kebriaei P, Oran B, Popat UR, Champlin RE, Ciurea SO. Hematopoietic Cell Transplant-Composite Risk (HCT-CR) — a Novel Prognostic Model to Predict Transplant Outcomes. Blood 60th ASH Annual Meeting 132(Supplement 1):2141, 2018. e-Pub 2018.
73. Oran B, Garcia-Manero G, Saliba RM, Al-Atrash G, Jabbour EJ, Popat UR, Ravandi F, Kadia TM, Cortes JE, Alousi AM, Konopleva MY, DiNardo CD, Rezvani K, Alfayez M, Shpall EJ, Sharma P, Champlin RE, Kantarjian HM, Daver NG. Post Allogeneic Stem Cell Transplant (SCT) Cyclophosphamide Improves Progression Free Survival (PFS) in Pts with AML/MDS Treated with CTLA-4 or PD-1 Blockade Prior to SCT. Blood 60th ASH Annual Meeting 132(Supplement 1):483, 2018. e-Pub 2018.
74. Popat UR, Mehta RS, Bassett RL, Olson AL, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Shpall EJ, Champlin RE, Andersson BS. Timed Sequential Busulfan and Post-Transplantation Cyclophosphamide in Matched and Haploidentical Transplantation: Results of a Phase II Study. Blood 60th ASH Annual Meeting 132(Supplement 1):3373, 2018. e-Pub 2018.
75. Saini N, Patel R, Varma A, Bashir Q, Delgado R, Popat UR, Hosint C, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mukherjee A, Mehta RS, Khouri IF, Ciurea SO, Shpall EJ, Hasan O, Weber DM, Thoas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-Based Autologous Transplantation in the Octogenarian Multiple Myeloma Patient Population. Blood 60th ASH Annual Meeting 132(Supplement 1):4606, 2018. e-Pub 2018.
76. Oran B, de Lima M, Garcia-Manero G, Thall P, Alousi AM, Hosing C, Kebriaei P, Popat UR, Giralt S, Ahmed S, Shpall EJ, Andersson BS, Bashir Q, Ciurea S, Rezvani K, Woodworth G, Champlin RE. Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. Blood 60th ASH Annual Meeting 132(Supplement 1):971, 2018. e-Pub 2018.
77. Khouri IF, Milton DR, Jabbour EJ, Al-Atrash G, Anderlini P, Alousi AM, Bashir Q, Ciurea SO, Hymes S, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Qazilbash MH, Rondon G, Champlin RE, Gulbis A. Influence of the Intensity of the Conditioning Regimens on the Risks of Gvhd in Patients Receiving Rituximab Prophylaxis during Allogeneic Stem Cell Transplantation (alloSCT). Blood 60th ASH Annual Meeting 132(Supplement 1):4584, 2018. e-Pub 2018.
78. Saini, N, Varma A, Ma J, Milton DR, Patel R, Hasan O, Bashir Q, Nieto Y, Mukherjee A, Delgado R, Popat UR, Hosing C, Kebriaei P, Alousi AM, Ahmed S, Mehta RS, Ciurea SO, Khouri IF, Shpall EJ, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. Blood 60th ASH Annual Meeting 132(Supplement 1):4607, 2018. e-Pub 2018.
79. Saini N, Saliba RM, Rondon G, Maadani F, Popat UR, Oran B, Hosing C, Bashir Q, Olson AL, Nieto Y, Alousi AM, Kebriaei P, Srour S, Mehta RS, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad LF, Lee HJ, Fowler NH, Parmar S, Westin J, Hagemesiter FB Champlin RE, Ciurea SO. Allogeneic Transplantation for Lymphoid Malignancies with Fludarabine and Melphalan Conditioning and Different Donor Types. Blood 60th ASH Annual Meeting 132(Supplement 1):3356, 2018. e-Pub 2018.
80. Varma, A, Saini NY, Sui D, Milton DR, Mukherjee A, Bashir Q, Rondon G, Srour SA, Popat UR, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS, Khouri I, Weber DM, Thomas SK, Manasanch EE, Lee HC, Patel KK, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin ER, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. Blood 60th ASH Annual Meeting 132(Supplement 1):4609, 2018. e-Pub 2018.
81. Chhabra S, Liu Y, Hemmer M, Wang T, Hamilton BK, Costa LJ, Kim DD, Majhail NS, Stuart RK, Alousi AM, Couriel DR, Pidala JA, Spellman SR, Ringden O, Arora M. Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation: Comparing the Efficacy of Mycophenolate Mofetil and Methotrexate in Combination with Calcineurin Inhibitor. Biol Blood Marrow Transplant 2018 BMT Tandem Meetings 24(3, Supplement):S170-S171, 2018. e-Pub 2018.
82. Khera N, Hamilton BK, Wood WA, Wu V, Onstad L, Alousi AM, Broady R, Chen GL, Arora M, Cutler C, Flowers ME, Ganetsky, Jagasia M, McCarthy PL, Pidala JA, Sarantopoulos S, Abel GA, Majhail NS, Lee SJ. Employment, Insurance and Financial Experiences of Patients with Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant 2018 BMT Tandem Meetings 24(3, Supplement):S30-S31, 2018. e-Pub 2018.
83. Shah MV, Saliba RM, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Ahmed S, Alousi AM, Mehta RS, Pemmaraju N, Verstovsek S, Popat UR. Transplant Outcomes for Patients with Secondary Acute Myeloid Leukemia (AML) Arising From Myeloproliferative Neoplasms (MPN). Biol Blood Marrow Transplant 2018 BMT Tandem Meetings 24(3, Supplement):S322-S323, 2018. e-Pub 2018.
84. Srour SA, Desai P, Ciurea SO, Bashir Q, Oran B, Olson A, Ahmed S, Bose P, Mehta RS, Pemmaraju N, Alousi AM, Verstovsek S, Champlin RE, Popat UR. Immunosuppression Withdrawal Is an Effective Treatment of Relapse after Allogeneic Stem Cell Transplant for Myelofibrosis. Biol Blood Marrow Transplant 2018 BMT Tandem Meetings 24(3, Supplement):S196-S197, 2018. e-Pub 2018.
85. Hamilton BK, Liu Y, Hemmer M, Wang T, Chhabra S, Costa LJ, Kim DD, Ringden O, Stuart RK, Alousi AM, Couriel DR, Pidala JA, Spellman SR, Majhail NS, Arora M. Cyclosporine in Combination with Mycophenolate Mofetil Leads to Increased Incidence of Graft-Versus-Host Disease and Inferior Outcomes after Myeloablative Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis. Biol Blood Marrow Transplant 2018 BMT Tandem Meetings 24(3, Supplement):S185,, 2018. e-Pub 2018.
86. Holtan SG, Defor TE, Howard A, Pidala JA, Levine JE, Wu JM, Khera N, Lee SJ, Bolanos-Meade J, Ho VT, Alousi AM, Inamoto Y, Chen GL, Arora M, Palmer J, Flowers ME, Cutler C, Renteria AS, Lukez A, Arai S, Lazaryan A, Hogan WJ, Newell LF, Jagasia M, Wood WA, Krupski MC, Yanik GA, Bunworasate U, Hexner EO, Ayuk F, Holler E, Mayer S, Pusic I, Duong HK, Efebera YA, Ferrara J, Blazar BR, Mortari A, Weisdorf DJ, MacMillan ML. Amphiregulin Modifies the Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN Acute Gvhd Therapy Trials. Biol Blood Marrow Transplant 2018 BMT Tandem Meetings 24(3, Supplement):S177-S178, 2018. e-Pub 2018.
87. Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Weisdorf DJ. Graft-Versus-Host Disease (GVHD)-Free Relapse-Free Survival (GRFS) and Chronic Gvhd (CRFS) in Alternative Donor Hematopoietic Cell Transplantation (HCT) in Adults. Blood 59th ASH Annual Meeting 130(Supplement 1):517, 2017. e-Pub 2017.
88. Khouri IF, Gulbis AM, Milton DR, Korbling M, Ledesma C, Ahmed S, Alousi A, Oran B, Anderlini P, Ciurea SO, Bassett Jr RL, Jabbour EJ. Safety of Addition of Inotuzumab Ozogamicin (CMC 544) to Bendamustine, Fludarabine, and Rituximab (BFR) Allogeneic Conditioning for Lymphoid Malignancies. Blood 59th ASH Annual Meeting 130(Supplement 1):3240, 2017. e-Pub 2017.
89. Gowda L, Saliba RM, Shah MV, Rondon G, Badar I, Olson AL, Ciurea SO, Kebriaei P, Srour SA, Parmar S, Nieto Y, Ahmed S, Mehta RS, Alatrash G, Marin DC, Andersson BS, Oran B, Bashir Q, Qazilbash MH, Hosing C, Khouri IF, Alousi AM, Anderlini P, Shpall EJ, Rezvani K, Champlin RE, Popat U. Graft Failure Post Allogeneic Stem Cell Transplant: Conditioning Regimen Improves Engraftment and Survival. Blood 59th ASH Annual Meeting 130(Supplement 1):32, 2017. e-Pub 2017.
90. Oran B, Garcia-Manero G, Saliba RM, Alatrash G, Jabbour EJ, Popat U, Ravandi F, Alousi AM, Kadia T, Konopleva M, DiNardo CD, Pierce S, Rezvani K, Shpall EJ, Sharma P, Champlin RE, Kantarjian HM, Daver N. Post-Transplant Cyclophosphamide Improves Progression Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients with Prior CTLA-4 or PD-1 Blockade. Blood 59th ASH Annual Meeting 130(Supplement 1):3209, 2017. e-Pub 2017.
91. Khouri IF, Jabbour EJ, Ledesma C, Korbling M, Alousi AM, Anderlini P, Oran B, Ciurea SO, Fayad LE, Bassett Jr RL, Gulbis AM. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning for Lymphoid Malignancies: 8-Year Results. Blood 59th ASH Annual Meeting 130(Supplement 1):2036, 2017. e-Pub 2017.
92. Gowda L, Alijadayeh M, Marin DC, Rondon G, Popat UR, Alousi AM, Oran B, Shah MV, Ahmed S, Kanagal-Shamanna R, Ciurea SO, Shpall EJ, Luthra R, Qazilbash MH, Rezvani K, Jabbour EJ, Patel KP, Ravandi F, Kantarjian HM, Champlin RE, Kebriaei P. Early Maintenance with Tyrosine Kinase Inhibitors Post Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Improves Survival in Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Blood 59th ASH Annual Meeting 130(Supplement 1):1992, 2017. e-Pub 2017.
93. Oran B, Saliba RM, Jorgensen JL, Shah MV, Marin DC, Wang SA, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Rezvani K, Popat UR, Rondon G, Kebriaei P Shpall EJ, Champlin RE. The Prognostic Impact of Minimal Residual Disease on Risk of Progression and Progression Free Survival in Acute Myeloid Leukemia. Blood 59th ASH Annual Meeting 130(Supplement 1):2031, 2017. e-Pub 2017.
94. Nieto Y, Thall PF, Valdez BC, Ma J, Timmons M, Trapp M, Ahmed S, Shpall EJ, Jones RB, Hosing C, Anderlini P, Popat U, Qazilbash MH, Alousi AM, Gulbis AM, Ledesma C, Champlin RE, Andersson BS. Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas. Blood 59th ASH Annual Meeting 130(Supplement 1):1966, 2017. e-Pub 2017.
95. Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Weisdorf DJ. Graft-Versus-Host Disease (GVHD)-Free Relapse-Free Survival (GRFS) and Chronic Gvhd (CRFS) in Alternative Donor Hematopoietic Cell Transplantation (HCT) in Pediatric Patients. Blood 59th ASH Annual Meeting 130(Supplement 1):2053, 2017. e-Pub 2017.
96. Kebriaei P, Huls H, Olivares S, Orozco AF, Su S, Maiti SN, De Groot E, Smith A, Yang Y, Rondon G, Qazilbash MH, Ciurea SO, Alousi AM, Nieto Y, Marin DC, Popat U, Hosing C, Kantarjian HM, Rezvani K, Shpall EJ, Champlin RE, Cooper LJN, Singh H. Long Term Follow up after Adoptive Transfer of CD19-Specific CAR + T Cells Genetically Modified Via Non-Viral Sleeping Beauty System Following Hematopoietic Stem Cell Transplantation (HSCT). Blood 59th ASH Annual Meeting 130(Supplement 1):2059, 2017. e-Pub 2017.
97. Ciurea SO, Saliba RM, Chen J, Rondon G, Popat U, Parmar S, Andersson B, Alousi AM, Ahmed S, Bashir Q, Alatrash G, Hosing C, Olson AL, Mehta RS, Rezvani K, Shpall EJ, Khouri IF, Kebriaei P, Champlin RE. Allogeneic Transplantation for TP53+ AML: Prognostic Factors for Survival. Blood 59th ASH Annual Meeting 130(Supplement 1):1938, 2017. e-Pub 2017.
98. Khera N, Jagasia M, Broady R, Onstad LE, Hamilton BK, Chen G, Alousi AM, Sarantopoulos S, Pidala J, Flowers ME, McCarthy PL, Arora M, Cutler C, Wood WA, Ganestsky A, Abel GA, Majhail NS, Lee SJ. Prevalence and Risk-Factors for Financial Burden in Patients with Chronic Graft-Versus-Host Disease: A Cross-Sectional Survey from the Chronic Gvhd Consortium. Blood 59th ASH Annual Meeting 130(Supplement 1):530, 2017. e-Pub 2017.
99. Oran B, Garcia-Manero G, Saliba RM, Al-Atrash G, Jabbour E, Popat U, Ravandi F, Alousi A, Kadia T, Konopleva M, Dinardo C, Rezvani K, Shpall EJ, Sharma P, Champlin RE, Kantarjian HM, Daver N. Improved Acute Graft-versus Host Disease (aGVHD) and Progression Free Survival with Post-Transplant Cyclophosphamide in AML/MDS Patients (pts) with Prior CTLA-4 or PD-1 Blockade. Clin Lymphoma Myeloma Leuk 2017 XXVIII International Association for Comparative Research on Leukemia & Related Diseases Symposium Meeting 17(10_Supplement):S11, 2017. e-Pub 2017.
100. Oran B, Garcia-Manero G, Saliba RM, Al-Atrash G, Jabbour E, Popat U, Ravandi F, Alousi A, Kadia T, Konopleva M, Dinardo C, Rezvani K, Shpall EJ, Sharma P, Champlin RE, Kantarjian HM, Daver N. Improved Acute Graft-versus Host Disease (aGVHD) and Progression Free Survival with Post-Transplant Cyclophosphamide in AML/MDS Patients (pts) with Prior CTLA-4 or PD-1 Blockade. Clin Lymphoma Myeloma Leuk 2017 XXVIII International Association for Comparative Research on Leukemia & Related Diseases Symposium Meeting 17(10_Supplement):S11, 2017. e-Pub 2017.
101. Popat U, Saliba R, Oran B, Ahmed S, Alousi AM, Bashir Q, Ciurea SO, Hosing C, Kebriaei P, Khouri IF, Marin D, Nieto Y, Olson AL, Qazilbash MH, Rezvani K, Valdez B, Jones RB, Shpall EJ, Andersson B, Champlin RE. Better survival with fludarabine and timed sequential busulfan regimen in older patients with AML/MDS. J Clin Oncol 2017 ASCO Annual Meeting 35(15_suppl):7046, 2017. e-Pub 2017.
102. Shah MV, Saliba RM, Jorgensen JL, Wang SA, Alousi AM, Andersson BS, BAshir Q, Ciurea SO, Kebriaei P, Marin D, Patel K, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia Patients. Biol Blood Marrow Transplant 2018 BMT Tandem Meetings 23(3, Supplement):S40-S41, 2017. e-Pub 2017.
103. Nieto Y, Bassett R, Ahmed S, Anderlini P, Hosing CM, Popat UR, Andersson BS, Valdez BC, Shpall EJ, Qazilbash MH, Kebriaei P, Alousi AM, Guillermo M, Oki Y, Fanale MA, Hagemeister F, Dabaja B, Pinnix C, Milgrom S, Champlin RE, Jones RB. Prospective PHASE 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (GEM/BU/MEL) with Autologous Stem Cell Transplant (ASCT) in Hodgkin’s Lymphoma Patients at High Risk of Post-transplant Recurrence – Comparison with a Concurrent Matched Cohort. Biol Blood Marrow Transplant 2018 BMT Tandem Meetings 23(3, Supplement):S268, 2017. e-Pub 2017.
104. Reshma R, Rondon G, Lahoti A, Champlin RE, Alousi AM. Improved Renal Outcomes in Patients Converted From Tacrolimus to Sirolimus after Developing Acute Kidney Injury Post Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 2018 BMT Tandem Meetings 23(3, Supplement):S293-S294, 2017. e-Pub 2017.
105. Hill L, Saliba RM, Chen J, Rondon G, Qazilbash MH, Popat UR, Shah N, Neumann JL, Hymes SR, Hosing CM, Kebriaei P, Oran B, Nieto Y, Olson A, Ciurea SO, Marin D, Champlin RE, Shpall EJ, Alousi AM. Predictors for Steroid Tapering in Patients with Acute Graft-Versus-Host Disease and Their Impact on Graft-Versus-Host Disease Response and Non-Relapse Mortality: Older Age and Co-Morbidities Are Associated with Quicker Tapering and Worse Outcomes. Biol Blood Marrow Transplant 2018 BMT Tandem Meetings 23(3, Supplement):S371, 2017. e-Pub 2017.
106. Srour SA, Khour IF, Lozano-Cerrada S, Nieto Y, Alousi AM, Popat UR, Qazilbash MH, Anderlini P, Kebriaei P, Shpall EJ, Champlin RE, Hosing C. Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas. Blood 58th ASH Annual Meeting 128(22):2270, 2016. e-Pub 2016.
107. Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi A, Bashir Q, Ciurea SO, Popat UR, Marin D, Rezvani K, Kebriaei P, Shpall EJ, Champlin RE, Oran B. Hematopoietic Stem Cell Transplantation with Reduced Intensity Conditioning in Older Patients with Myelodysplastic Syndromes. Blood 58th ASH Annual Meeting 128(22):5847, 2016. e-Pub 2016.
108. Qayed M, Horan J, Spellman SR, Arora M, Wang T, Hemmer M, Pidala JA, Couriel D, Alousi AM. Influence of Age on Risk for Acute and Chronic Graft Versus Host Disease in Children Receiving HLA Identical Sibling Bone Marrow Transplantation. Blood 58th ASH Annual Meeting 128(22):2228, 2016. e-Pub 2016.
109. Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Khouri IF, Nieto Y, Popat UR, Marin D, Rezvani K, Kebriaei P, Shah N, Olson AL, Shpall EJ, Champlin RE, Oran B. Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Blood 58th ASH Annual Meeting 128(22):2276, 2016. e-Pub 2016.
110. Kumar AJ, Kim S, Hemmer M, Arora M, Spellman S, Pidala JA, Couriel D, Alousi AM, Loren AW. Unrelated Male Donors Versus Sibling Parous Female Donors: Impact on Transplant-Related Outcomes. Blood 58th ASH Annual Meeting 128(22):70, 2016. e-Pub 2016.
111. Maher OM, Saliba RM, Alousi AM, Champlin RE, Shpall EJ, Tewari P, Hymes SR, Neumann JL, Overman BJ, Chen J, Rondon G, Song HW, Hofferek CJ, Tran DQ. High TCR Vbeta Skewing in CD4+ and Low in CD8+ Is Associated with Development of Chronic Graft-Versus-Host Disease. Blood 58th ASH Annual Meeting 128(22):4570, 2016. e-Pub 2016.
112. Hill L, Saliba RM, Chen J, Rondon G, Qazilbash MH, Popat UR, Shah N, Neumann JL, Hymes SR, Hosing C, Kebriaei P, Nieto Y, Oran B, Olson A, Ciurea SO, Rezvani K, Marin D, Champlin RE, Shpall EJ, Alousi AM. Predictors for Steroid Tapering in Patients with Acute Graft-Versus-Host Disease and Their Impact on Graft-Versus-Host Disease Response and Non-Relapse Mortality: Older Age and Co-Morbidities Are Associated with Quicker Tapering and Worse Outcomes. Blood 58th ASH Annual Meeting 128(22):3424, 2016. e-Pub 2016.
113. Kebriaei P, Wei W, Thall PF, Ledesma C, Valdez BC, Popat UR, Olson AL, Alousi AM, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Marin D, Rezvani K, Nieto Y, Champlin RE, Andersson BS. Busulfan (Bu) in Combination with Double Nucleoside Analogues Fludarabine (Flu) and Clofarabine (Clo) Plus Vorinostat As a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia. Blood 58th ASH Annual Meeting 128(22):64, 2016. e-Pub 2016.
114. Olson AL, Muftuoglu M, Kaur I, LiL, Abueg G, Chemaly R, Yvon E, Thall PF, Marin D, Alousi AM, Ahmed S, Ciurea SO, Hosing C, Kebriaei P, Jones R, Andersson BS, Shah N, Oran, Abudayyeh A, Popat UR, Champlin RE, Shpall EJ, Rezvani K. Efficacy of Third Party BK Virus (BKV) Specific Cytotoxic T-Lymphocytes Generated By Ex Vivo Expansion for the Treatment of BKV Infection in Stem Cell Transplant Recipients, a Phase 2 Trial. Blood 58th ASH Annual Meeting 128(22):504, 2016. e-Pub 2016.
115. Oran B, Muftuoglu M, Kaur I, Li L, Yvon E, Abueg G, Bassett R, Thall PF, Marin D, Alousi AM, Ahmed S, Ciurea SO, Nina S, Hosing C, Olson AL, Parmar S, Jones R, Popat UR, Andersson BS, Champlin RE, Shpall EJ, Rezvani K. Most Closely HLA-Matched Third Party Allogeneic CMV Specific T-Cells Generated Using the Cytokine Capture System for the Treatment of CMV Infections after Allogeneic Stem Cell Transplantation. Blood 58th ASH Annual Meeting 128(22):4547, 2016. e-Pub 2016.
116. Cerrada SL, Marin D, Rondon G, Ledesma C, Popat UR, Olson AL, Alousi AM, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Rezvani K, Jabbour E, Kantarjian HM, Champlin RE, Kebriaei P. Impact of New Anti-Leukemia Agents on Transplant Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) in Second Complete Remission. Blood 58th ASH Annual Meeting 128(22):4676, 2016. e-Pub 2016.
117. Cerrada SL, Marin D, Rondon G, Ledesma C, Popat UR, Olson A, Alousi A, Oran B, Ahmed A, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Rezvani K, Jabbour E, Kantarjian HM, Champlin RE, Kebriaei P. Additional Consolidation after Attaining Second Complete Remission Results in Superior Outcomes after Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. Blood 58th ASH Annual Meeting 128(22):4680, 2016. e-Pub 2016.
118. Khouri IF, Wang X, Turturro F, Jabbour E, Carballo-Zarate AA, Korbling M, Alousi AM, Oran B, Anderlini P, Ciurea SO, Patel KK, Marin D, Nastoupil LJ, Fanale MA, Samuels BI, Gulbis AM, Medeiros LJ, Khoury J. Long-term outcomes of non-myeloablative allogeneic stem cell transplantation (alloSCT) in patients with relapsed mantle cell lymphoma (MCL). J Clin Oncol 2016 ASCO Annual Meeting 34(15_suppl):7551, 2016. e-Pub 2016.
119. Nieto Y, Bassett R, Hosing C, Jones RB, Valdez BC, Kingham A, Ahmed S, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Kebriaei P, Brammer JE, Oki Y, Fanale MA, Maadani F, Rondon G, Champlin RE, Andersson BS. Comparison of High-Dose Gemcitabine, Busulfan and Melphalan (GEM/BU/MEL) and BEAM in Concurrent Patient Cohorts with Mature T-CELL NON-Hodgkin's Lymphoma (T-NHL) Receiving an Autologous Stem Cell Transplantation (ASCT). Biol Blood Marrow Transplant 2016 BMT Tandem Meetings 22(3, Supplement):S227-S228, 2016. e-Pub 2016.
120. Lindsay R, Saliba R, Choi H, Ping Z, Ramlal R, Alousi AM, Jones RB, Champlin RE. Transfusion History Is the Most Significant Predictor of Iron Overload after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 2016 BMT Tandem Meetings 22(3, Supplement):S336-S337, 2016. e-Pub 2016.
121. Popat UR, Lyons G, Bassett R, Chen J, Valdez, Kawedia JD, Ahmed S, Alousi AM, Anderlini P, Bashir Q, Ciurea SO, Hosing C, Jones RB, Kebriaei P, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Patel K, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Timed Sequential Busulfan is Safe and Appears Promising in Older Patients with AML/MDS. Biol Blood Marrow Transplant 2016 BMT Tandem Meetings 22(3):S33-S34, 2016. e-Pub 2016.
122. Carpenter PA, Logan BR, Lee SJ, Weisdorf DJ, Johnston L, Costa LJ, Kitko CL, Bolanos-Meade J, Alousi AM, Horowitz MM, Ahyankar S, Waller E, Mendizabal A, Wang Y, Lazaryan A, Carter SL, Nemecek E, Pavletic SZ, Cutler CS, Arora M. Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized Phase II Study from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant 2016 BMT Tandem Meetings 22(3, Supplement):S50-S52, 2016. e-Pub 2016.
123. Li D, Patenia R, Molldrem J, Alousi AM, Champlin RE, Ma Q. 2-Methoxyestradiol Treatment Prevents Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Effect in Mice. Biol Blood Marrow Transplant 2016 BMT Tandem Meetings 22(3, Supplement):S405-S406, 2016. e-Pub 2016.
124. Mehta, R, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi AM, Popat UR, Kebriaei P, Champlin RE, McNiece IK, De Lima M, Skerrett D, Burke E, Shpall EJ, Oran B. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation Following Reduced Intensity Conditioning Regimens. Blood 57th ASH Annual Meeting 126(23):1190, 2015. e-Pub 2015.
125. Nieto Y, Bassett R, Anderlini P, MD, Hosing C, Alousi AM, Popat UR, Andersson BS, Valdez BC, Shpall, EJ, Ahmed S, Qazilbash M, Guillermo M, Oki Y, Fanale MA, Hagemeister FB, Dabaja BS, Pinnix CC, Milgrom SA, Tewari P, MD, Champlin RE, Jones R. Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM. Blood 57th ASH Annual Meeting 126(23):1980, 2015. e-Pub 2015.
126. Khoury HJ, Wang T, Arora M, Hemmer M, Spellman SR, Cutler CS, Couriel DR, Alousi AM, Joseph JA, MD. Outcomes of Grades II-IV Acute Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: How Much Progress Was Achieved?. Blood 57th ASH Annual Meeting 126(23):3132, 2015. e-Pub 2015.
127. Nieto, Y, Valdez, BC, Thall PF, Wei W, Jones R, Hosing CM, Ahmed S, Popat UR, Shpall EJ, Qazilbash M, Gulbis AM, Anderlini P, Shah N, Bashir W Alousi AM, Oki Y, Hagemeister FB, Champlin RE, Andersson BS. Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma. Blood 57th ASH Annual Meeting 126(23):1992, 2015. e-Pub 2015.
128. Kebriaei P, Ciurea SO, Huls MH, Singh H, Olivares S, Su S, Figliola MJ, Kumar P, Jena B, Forget MA, Ang S, Jackson R, Liu T, McNiece IK, Rondon G, Hackett P, Kantarjian HM, Lee DA, Popat UR, Alousi A, Oran B, Shah N, Hosing CM, Marin D, Rezvani K, Shpall EJ, Champlin RE. Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19 + Malignancies. Blood 57th ASH Annual Meeting 126(23):862, 2015. e-Pub 2015.
129. Ramlal R, Gaballa S, Chen J, Rondon G, Oran B, Ahmed S, Bashir Q, Rezvani K, Marin D, Alousi AM, Kebriaei P, Qazilbash M, Hosing C, Popat UR, Shpall EJ, Champlin R, Ciurea SO. Outcomes of Haploidenitical Stem Cell Transplants for De Novo Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia Arising from MDS: The MD Anderson Experience. Blood 57th ASH Annual Meeting 126(23):3225, 2015. e-Pub 2015.
130. Pingali SR, Saliba R, Anderlini P, Hosing CM, Khouri IF, Alousi AM, Kebriaei P, Nieto Y, Qazilbash MH, Fanale MA, Shpall EJ, Champlin RE, Popat UR. Age over 55 Years at Diagnosis Increases Risk of Second Malignancies after Auto-Transplantation for Hodgkin's Lymphoma Patients. Blood 57th ASH Annual Meeting 126(23):3186, 2015. e-Pub 2015.
131. Khouri IF, Sui D, Turturro F, Erwin WD, Bassett Jr RL, Korbling M, Valverde R, Ahmed S, Alousi AM, Anderlini P, Bashir Q, Ciurea SO, Oran B, Olson A, Popat UR, Patel KK, Qazilbash MH, Fanale MA, Fayad LE, Nastoupil L, Westin JR, Gulbis AM, Medeiros J, Young KH, Jessop A. In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials. Blood 57th ASH Annual Meeting 126(23):3192, 2015. e-Pub 2015.
132. Desai P, Chen J, Liu D, Wu J, Ahmed S, Oran B, Ciurea SO, Alousi AM, Verstovsek S, Champlin RE, Popat UR. Patient Choice and Lack of Medicare Coverage for HCT Are the Major Reasons Why Transplant Eligible Myelofibrosis Patients Do Not Undergo Transplant. Blood 57th ASH Annual Meeting 126(23):3324, 2015. e-Pub 2015.
133. Alousi AM, Bassett Jr R, Chen J, Overman BJ, Hosing CM, Popat UR, Shpall EJ, Nieto Y, Qazilbash MH, Khouri IF, Kebriaei P, Ahmed S, Shah N, Rezvani K, Kondo K, Ciurea SO, Hymes SR, Neumann JL, Molldrem JL, Plair TR, Champlin RE. A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. Blood 57th ASH Annual Meeting 126(23):854, 2015. e-Pub 2015.
134. Nikiforow S, Hemmer M, Spellman SR, Alousi AM, Couriel DR, Pidala JA, Arora M, Cutler CS, Wang T. Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value When Present in Isolation or in Addition to Grade I or Other Grade II-Defining GvHD Manifestations. Blood 57th ASH Annual Meeting 126(23):857, 2015. e-Pub 2015.
135. Popat UR, Ray G, Bassett Jr RL, Poon MYC, Valdez BC, Konopleva S, Ahmed S, Alousi AM, Andersson B, Bashir Q, Ciurea SO, Hosing CM, Jones R, Kebriaei P, Khouri IF, Kim S, Nieto Y, Olson AL, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin RE. Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial. Blood 57th ASH Annual Meeting 126(23):738, 2015. e-Pub 2015.
136. Im JS, Saliba RM, Abraham SC, Ross W, Rondon G, Rashid A, Shpall EJ, Popat UR, Qazilbash M, Hosing CM, Oran B, Shah N, Champlin RE, Alousi AM. Histologic Confirmation for Patients Presenting with Gastrointestinal Graft Versus Host Disease: How to Interpret Histologic Grade 1 ( Does It Matter )?. Blood 57th ASH Annual Meeting 126(23):1933, 2015. e-Pub 2015.
137. Kebriaei P, Basset Jr RL, Ledesma C, Rondon G, Oran B, Ciurea SO, Alousi AM, Popat UR, Patel KK, Ahmed S, Olson AL, Bashir Q, Shah N, Jones R, Rezvani K, Nieto Y, Khouri IF, Qazilbash MH, Hosing CM, Shpall EJ, Champlin RE, Andersson BS. Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results. Blood 57th ASH Annual Meeting 126(23):4376, 2015. e-Pub 2015.
138. Kongtim P, Popat UR, Jimenez AM, Gabella S, El Fakih RO, Rondon G, Chen J, Bueso-Ramos CE, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian HM, Alousi AM, Hosing CM, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Survival for Patients with Chronic Myelomonocytic Leukemia. Blood 57th ASH Annual Meeting 126(23):4347, 2015. e-Pub 2015.
139. Rondon G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, Hosing CM, Kebriaei P, Khouri IF, Shpall EJ, Popat UR, Champlin RE, Ciurea SO. Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation. Blood 57th ASH Annual Meeting 126(23):4321, 2015. e-Pub 2015.
140. Im JS, Saliba RM, Abraham SC, Rashid A, Ross W, Nieto Y, Shpall EJ, Oran B, Olson A, Ahmed S, Popat UR, Rondon G, Qazilbash MH, Shah N, Champlin RE, Alousi AM. Gastrointestinal Acuity Score (GAS): A Comprehensive Risk Score Incorporating Histologic Grade and Clinical Factors to Predict Need for Second Line Therapy, Non-Relapse Mortality, and Overall Survival in Lower Gastrointestinal Graft Vs. Host Disease. Blood 57th ASH Annual Meeting 126(23):3128, 2015. e-Pub 2015.
141. Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi AM, Qazilbash MH, Bashir Q, Ahmed S, Popat UR, Hosing CM, Khouri IF, Shpall EJ, Champlin RE, Ciurea SO. Post-Transplantation High Dose Cyclophosphamide As Gvhd Prophylaxis in 9/10 HLA-Matched Unrelated Donors Hematopoietic Stem Cell Transplantation. Blood 57th ASH Annual Meeting 126(23):3135, 2015. e-Pub 2015.
142. Ragon BK, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin Therapy for Steroid-Refractory Acute Graft Versus Host Disease: Identifying Those Who May Benefit. Blood 57th ASH Annual Meeting 126(23):3136, 2015. e-Pub 2015.
143. Gaballa S, Ge I, El Fakih RO, Brammer JE, Wang SA, Lee DA, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom AE, Al-Atrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi AM, Nieto Y, Qazilbash MH, Hosing CM, Popat UR, Shpall EJ, Khouri IF, Champlin RE, Ciurea SO. Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation. Blood 57th ASH Annual Meeting 126(23):152, 2015. e-Pub 2015.
144. Popat UR, Bassett RL, Chen J, Alousi A, Anderlini P, Ciurea SO, Hosing C, Jones RB, Kebriaei P, Khouri IF, Konoplev S< De Lima MJG, Nieto Y, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson B, Champlin RE. Allogeneic transplantation for myelofibrosis: Final analysis of a prospective study after a median follow up of 5 years. J Clin Oncol 2015 ASCO Annual Meeting 33(15_suppl):7008, 2015. e-Pub 2015.
145. Thompson PA, Perera T, Marin D, Oran B, Popat UR, Qazilbash MH, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Rondon G, Alousi AM, Ciurea SO, Champlin RE, Bajel A, Szer J, Shpall EJ, Hosing C. Results of Allogeneic Double Umbilical Cord Blood Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant 2015 BMT Meetings 21(2, Supplement):S48, 2015. e-Pub 2015.
146. Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Champlin RE, Ciurea SO. Minimal Residual Disease By PCR Testing Is a Significant Predictor of Disease Relapse in Patients with FLT3 Positive AML after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2015 BMT Meetings 21(2, Supplement):S81-S82, 2015. e-Pub 2015.
147. Popat UR, Saliba R, Oran B, Chen J, Alousi AM, Ahmed S, Bashir Q Ciurea SO, Hosoing C, Jones RB, Kebriaei P, Khouri IF, Nieto YL, Olson A, Parmar S, Shah N, Shpall EJ, Qazilbash MH, Andersson BS, Champlin RE. Cytogenetics and Blast Count Determine Transplant Outcomes in Advanced AML. Biol Blood Marrow Transplant 2015 BMT Meetings 21(2, Supplement):S304, 2015. e-Pub 2015.
148. Hosing C, Munsell M, Armitage S, Sadeghi T, Rezvani K, Oran B, Marin D, Dworsky S, Popat UR, Wilson J, Alousi AM, Shah N, Olson A, Jones RB, Kebriaei P, Qazilbash MH, Parmar S, McNiece I, Champlin RE, Shpall EJ. Ex-Utero Plus in Utero Collection of Umbilical Cord Blood (CB) for Banking Yields Higher Total Nucleated Cell Counts (TNC) Compared to Either Procedure Alone. Biol Blood Marrow Transplant 2015 BMT Meetings 21(2, Supplement):S154-S155, 2015. e-Pub 2015.
149. Pingali S, Milton D, Popat U, Hosing C, Bashir Q, Alousi A, Jones R, Nieto Y, Kebriaei P, Qazilbash M, Andersson B, Shpall E, Khouri I, Champlin R, Ciurea C. Transplant Outcomes of 9/10 HLA Matched Unrelated Donors (MUD) Treated with Post-Transplant Cyclophosphamide for Prevention of Graft Versus Host Disease. Blood 56th ASH Annual Meeting 124(21):2486, 2014. e-Pub 2014.
150. Inamoto Y, Martin P, Flowers M, Urbano-Ispizua A, Wang T, Hemmer M, Cutler C, Couriel D, Alousi A, Arora M, Spellman S. Comparison of Tacrolimus Versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia: A CIBMTR Analysis. Blood 56th ASH Annual Meeting 124(21):4383, 2014. e-Pub 2014.
151. Popat U, Fox P, Bassett R, Chen J, Valdez B, Kawedia J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash M, Shah N, Shpall E, Andersson B, Champlin R. Myeloablative Timed Sequential Busulfan Is Safe in Older Patients. Blood 56th ASH Annual Meeting 124(21):3859, 2014. e-Pub 2014.
152. MacMillan M, Robin M, Harris A, Defor T, Martin P, Alousi A, Ho V, Bolanos-Meade J, Ferrara J, Jones R, Arora M, Blazar B, Holtan S, Jacobsohn D, Pasquini M, Socie G, Antin J, Levine J, Weisdorf D. A Refined Clinical Risk Score at Onset of Treatment for Acute Gvhd That Predicts Response to Initial Therapy, Survival and Transplant-Related Mortality. Blood 56th ASH Annual Meeting 124(21):188, 2014. e-Pub 2014.
153. Ahmed S, Shpall E, Gulbis A, Jones R, Martinez C, Rondon G, Rezvani K, Oran B, Olson A, Shah N, Parmar S, Popat U, Alousi A, Nieto Y, Hosing C, Bashir Q, Kebriaei P, Qazilbash M, Champlin R, Mulanovich V. Assessment of Incidence Toxoplasma Gondii Infection and Outcomes in Allogeneic Stem Cell Patients. Blood 56th ASH Annual Meeting 124(21):1187, 2014. e-Pub 2014.
154. Levine J, Braun T, Harris A, Holler E, Taylor A, Miller H, Magenau J, Weisdorf D, Ho V, Bolanos-Meade J, Alousi A, Ferrara J. A Biomarker Algorithm Defines Onset Grades of Acute Graft-Vs-Host Disease with Distinct Non-Relapse Mortality. Blood 56th ASH Annual Meeting 124(21):661, 2014. e-Pub 2014.
155. Khouri I, Saliba R, Xu-Monette Z, Korbling M, Rondon G, Valverde R, Alousi A, Anderlini P, Ahmed S, Ciurea S, Fayad L, Oran B, Parmar S, Popat U, Westin J, Turturro F, Medeiros J, Gulbis A, Young K. Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL). Blood 56th ASH Annual Meeting 124(21):2563, 2014. e-Pub 2014.
156. Oran B, Cao K, Saliba R, Hosing C, Popat U, de Lima M, Carmazzi Y, Alousi A, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Champlin R, Rezvani K, Shpall E. Higher Allele Level HLA Matching Improves Prognostication after Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies. Blood 56th ASH Annual Meeting 124(21):2532, 2014. e-Pub 2014.
157. Ma Q, Li D, Alousi AM, Champlin RE, Sale GE, Afshar-Kharghan V. Complement Component C3 Mediates Th1/Th17 Polarization in Human T Cell Activation and Cutaneous Graft-Versus-Host Disease. Biol Blood Marrow Transplant 2014 BMT Meetings 20(2, Supplement):S274, 2014. e-Pub 2014.
158. Pingali SR, Milton D, de Stasi A, Patel RD, Kebriaei P, Popat UR, Alousi AM, Anderlini P, Qazilbash MH, Hosing C, Rezvani K, Bashir Q, Oran B, Shpall EJ, Khouri IF, Champlin RE, Ciurea SO. Haploidentical Transplantation for Advanced Hematologic Malignancies Using Melphalan-Based Conditioning – Mature Results from a Single Center. Biol Blood Marrow Transplant 2014 BMT Meetings 20(2, Supplement):S40-S41, 2014. e-Pub 2014.
159. Anderlini P, Saliba R, Ledesma C, Chancoco CM, Alexander TR, Alousi AM, Hosing C, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Oki Y, Romaguera JE, Neelapu SS, Younes A, Champlin RE. Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation For Relapsed/Refractory Hodgkin Lymphoma In The Brentuximab Vedotin Era. Biol Blood Marrow Transplant 2014 BMT Meetings 20(2, Supplement):S72, 2014. e-Pub 2014.
160. Chu D, Valdez BC, Fox PS, Thall P, Worth L, Popat UR, Jones RB, Shpall EJ, Hosing C, Alousi AM, Rondon G, Kebriaei P, Champlin RE, Andersson BS. Clofarabine ± Fludarabine with IV Busulfan and Allogeneic Stem Cell Transplantation for Advanced Myeloid Leukemia (ML) and MDS. Biol Blood Marrow Transplant 2014 BMT Meetings 20(2, Supplement):S152-S153, 2014. e-Pub 2014.
161. Sarvaria A, Khoder A, Alsuliman A, Chew C, Sekine T, Cooper N, de Lavallade H, Muftuoglu M, Yvon E, Hamdi A, Alousi AM, St John L, Marin D, Stringaris K, Liu E, Molldrem J, Shah N, Parmar S, McNiece I, Champlin RE, Shpall EJ, Rezvani K. Immunoregulatory B Cells Are Enriched within Transitional and IgM Memory B Cell Subsets in Healthy Donors but Are Reduced and Functionally Impaired in Patients with Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant 2014 BMT Meetings 20(2, Supplement):S55, 2014. e-Pub 2014.
162. Oran B, Kongtim P, de Lima M, Popat UR, Garcia-Manero G, Jabbour EJ, Abruzzo LV, Chen J, Rondon G, Andersson BS, Alousi A, Ciurea SO, Shpall EJ, Champlin RE. Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS. Blood 55th ASH Annual Meeting 122(21):305, 2013. e-Pub 2013.
163. Anderlini P, Saliba RM Ledesma C, Chancoco CM, Alexander T, Alousi A, Hosing CM, Khouri I, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Oki Y, Romaguera JE, Neelapu S, Younes A, Champlin RE. Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM). Blood 55th ASH Annual Meeting 122(21):410, 2013. e-Pub 2013.
164. Khouri IF, Wei W, Valverde R, Korbling M, Turturro F, Gulbis AM, Guillermo-Pacheco M, Ahmed S, Alousi A, Oran B, Anderlini P, Ciurea SO, Hosing CM< Popat UR, Jabbour E, Champlin RE, Bassett R. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression. Blood 55th ASH Annual Meeting 122(21):541, 2013. e-Pub 2013.
165. Popat UR, Oran B, Hosing CM, Kebriaei P, Rezvani K, Parmar S, Shah N, Bollard CM, Molldrem JJ, Nieto Y, Andersson BS, Alousi A, Jones RB, Cooper LJN, Qazilbash MH, Bashir Q, Ahmed S, Bosque D, Chen J, McCarty J, Rondon G, Munsell M, McNiece IK, Kaur I, Yvon E, Annandale K, Olchesky S, de Lima MJ, Champlin RE, Miller L, Paradiso L, Koh L, Zweidler-McKay P, Shpall EJ. Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment. Blood 55th ASH Annual Meeting 122(21):691, 2013. e-Pub 2013.
166. Ghobadi A, Hamdi A, Kongtim P, Milton D, Alousi A, Anderlini P, Ciurea SO, Oran B, Khouri I, Parmar S, Qazilbash MH, Kebriaei P, Popat UR, Rezvani K, Chemaly RF, Shpall EJ, Champlin RE, Bashir Q. The Effect Of CMV Reactivation On Relapse and Survival In Patients With AML and MDS After Allogeneic Stem Cell Transplant (allo-HCT). Blood 55th ASH Annual Meeting 122(21):4531, 2013. e-Pub 2013.
167. Oran B, Poon M, Chen J, rondon G, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing CM, Parmar S, Qazilbash MH, Popat UR, Nieto Y, Alousi A, Jones RB, Rezvani K, de Lima M, Shpall EJ, Champlin RE, Kebriaei P. Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblatic Leukemia (ALL) With First Complete Remission (CR). Blood 55th ASH Annual Meeting 122(21):2142, 2013. e-Pub 2013.
168. Di Stasi A, Poon LM, Ferro R, Milton D, Rondon G, Wang SA, Hamdi A, Qazilbash MH, Ahmed S, Khouri I, Oran B, Hosing CM, Kebriaei P, Alousi A, Popat UR, Shpall EJ, Lee DA, Rezvani K, Champlin RE, Ciurea SO. Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning. Blood 55th ASH Annual Meeting 122(21):2167, 2013. e-Pub 2013.
169. Sarvaria A, Khoder A, Alsuliman A, Chew C, Sekine T, Cooper N, de Lavallade H, Muftuoglu M, Yvon E, Hamdi A, Alousi A, St John LS, Marin D, Stringaris K, Liu E, Molldrem JJ, Shah N, Parmar S, McNiece IK, Champlin RE, Shpall EJ, Rezvani K. B Cell With Regulatory Function Are Enriched Within Transitional and IgM Memory B Cell Subsets In Healthy Donors But Are Reduced and Functionally Impaired In Patients With Chronic Graft-Versus-Host Disease. Blood 55th ASH Annual Meeting 122(21):4478, 2013. e-Pub 2013.
170. Nieto Y, Thall PF, Valdez BC, Hosing CM, Ahmed S, Jones RB, Shah N, Anderlini P, Qazilbash MH, Popat UR, Bashir Q, Shpall EJ, Alousi A, Kebriaei P, Fox P, Bassett R, Chancoco C, Oki Y, Fanale MA, Fowler N, Hagemeister F, Romaguera JE, Champlin RE, Andersson BS. Vorinostat (SAHA) Combined With High-Dose Gemcitabine/Busulfan/Melphalan (SAHA/Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Patients With Refractory Lymphomas. Blood 55th ASH Annual Meeting 122(21):2095, 2013. e-Pub 2013.
171. Aung FM, Lichtiger B, Alousi A, Ahmed S, Anderlini P, Andersson BS, Bashir Q, Ciurea SO, Jones RB, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash MH, Shah N, Khouri I, Shpall EJ, Champlin RE, Popat UR. Pure Red Cell Aplasia In Major ABO Mismatched Allogeneic Hematopoietic Cell Transplantation Is Associated With Severe Pancytopenia. Blood 55th ASH Annual Meeting 122(21):5449, 2013. e-Pub 2013.
172. Ahmed S, Di Stasi A, Shpall EJ, Khouri IF, Alousi AM, Ciurea SO, Bashir Q, Qazilbash M, Jones RB, Nieto Y, Parmar S, Kebriaei P, Shah N, Rezvani K, Hosing CM, Oran B, Andreeff M, Anderlini P, Andersson BS, Champlin RE, Popat UR. Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant. Blood 55th ASH Annual Meeting 122(21):2083, 2013. e-Pub 2013.
173. Pingali SR, Denai M, Di Stasi A, Kebriaei P, Popat UR, Alousi A, Anderlini P, Parmar S, Hosing CM, Andersson BS, Bashir Q, Ahmed S, Oran B, Shpall EJ, Khouri I, Konopleva M, Alatrash G, Champlin RE, Ciurea SO. Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial. Blood 55th ASH Annual Meeting 122(21):4523, 2013. e-Pub 2013.
174. Popat UR, Bassett R, Chen J, Alousi AM, Anderlini P, Ciurea SO, Hosing C, Jones RB, Kebriaei P, Khouri IF, Konoplev S, De Lima M, Nieto Y, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson B, Champlin RE. Allogeneic transplantation for myelofibrosis: Benefit of dose intensity. J Clin Oncol 2013 ASCO Annual Meeting 31(15_suppl):7011, 2013. e-Pub 2013.
175. Bolaños-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Hexner EO, Horowitz MM, Levine JE, MacMillan ML, Martin PJ, Nakamura R, Pasquini MC, Weisdorf DJ, Westervelt P, Ho VT. A Multi-Center, Randomized, Double Blind, Phase III Clinical Trial Comparing Steroids/Placebo Vs. Steroids/Mycophenolate Mofetil As Initial Therapy for Acute Graft-Versus-Host Disease. Blood and Marrow Transplant Clinical Trials Network Study 0802. Biol Blood Marrow Transplant 2013 BMT Tandem Meetings 19(2, Supplement):S137, 2013. e-Pub 2013.
176. Benton CB, Konopleva M, Saliba RM, Shpall EJ, Ciurea SO, Kebriaei P, Alousi AM, Popat UR, Anderlini PA, Nieto Y, Parmar S, Zeng Z, Chen JJ, Rondon G, McMullin B, Wang RY, Lu H, Schober WD, Woodworth GG, Gulbis A, Cool R, Qiao W, Thall PF, Andreeff M, and Champlin RE. Leukemia Cell Mobilization with Plerixafor Plus G-CSF with Busulfan/Fludarabine and Allogeneic Hematopoietic Cell Transplantation in Patients with AML/MDS Is Associated with Decreased Complete Chimerism and GvHD, and Increased Risk of Relapse. Blood 54th ASH Annual Meeting 120(21):360, 2012. e-Pub 2012.
177. Khouri IF, Saliba RM, Turturro F, Korbling M, Ledesma C, Rondon G, Alousi AM, Anderlini P, Bashir Q, Ciurea SO, Hosing CM, Popat UR, Charafeddine Y, Oki Y, Fayad LE, and Champlin RE. Bortezomib and BEAM-Rituximab Reduced-Intensity Conditioning for High-Risk Lymphoma Patients Who Are Not Eligible for Nonmyeloablative Allogeneic Stem Cell Transplantation. Blood 54th ASH Annual Meeting 120(21):4157, 2012. e-Pub 2012.
178. Alousi AM, Saliba RM, Chen J, Andersson BS, Khouri I, Qazilbash MH, Popat UR, Hosing CM, Ciurea SO, Shpall EJ, Jones RB, Kebriaei P, Nieto Y, Anderlini P, de Lima M, Rondon G, and Champlin RE. A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. Blood 54th ASH Annual Meeting 120(21):4200, 2012. e-Pub 2012.
179. Hamdi A, Poon LM, Saliba RM, Rondon G, Ledesma C, Qazilbash M, Hosing CM, Jones RB, Popat UR, Nieto Y, Alousi AM, Ciurea SO, Shpall EJ, Champlin RE, and Kebriaei P. Outcomes of Adults with Acute Lymphoblastic Leukemia (ALL) Following Relapse After First Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood 54th ASH Annual Meeting 120(21):4215, 2012. e-Pub 2012.
180. Ahmed S, Saliba RM, De Lima M, Fisher TD, Rondon G, Kebriaei P, Alousi AM, Hosing CM, Bashir Q, Andersson B, Champlin RE. International Consensus Criteria for Tyrosine Kinase Inhibitor Response and Outcome of Allogeneic Stem Cell Transplantation for CML. Blood 54th ASH Annual Meeting 120(21):1997, 2012. e-Pub 2012.
181. Ahmed S, Saliba RM, de Lima M, Rondon G, Kebriaei P, Fisher TD, Jabbour E, Chen J, Kantarjian H, Anderlini P, Alousi AM, Hosing CM, Andersson B, Jones RB, Qazilbash MH, Shpall EJ, Giralt S, and Champlin RE. Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia. Blood 54th ASH Annual Meeting 120(21):3129, 2012. e-Pub 2012.
182. de Lima M, Parmar S, Chen JJ, Giralt SA, Rondon G, Popat UR, Alousi AM, Lee HC, Woodworth GG, Hosing CM, Shpall EJ, Kebriaei P, Manero GG, Champlin RE, and Saliba RM. Low Dose Azacitidine (AZA) Reduces the Incidence of Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood 54th ASH Annual Meeting 120(21):742, 2012. e-Pub 2012.
183. Hosing C, Saliba R, Singh L, Popat U, Qazilbash M, Anderlini P, Nieto Y, Alousi A, Frazier E, Dabaja E, Champlin R, Duvic M. Total Skin Electron Beam radiation therapy and allogeneic haematopoietic stem cell transplantation in advanced mycosis fungoides and Sezary syndrome. Nature/2012 EBMT Abstract Book 47(Supplement 1):S85, 2012. e-Pub 2012.
184. Nieto Y, Jones RB, Liu P, Anderlini P, Popat U, Andersson B, Shpall EJ, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Chancoco C, Bashir Q, Ciurea S, Parmar S, Champlin R. Comparison of Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) with BEAM and Busulfan/Melphalan (Bu/Mel) in Concur-Rent Cohorts of Refractory Hodgkin's Lymphoma (HL) Patients Receiving an Autologous Stem-Cell Transplant. Biol Blood Marrow Transplant 2012 BMT Tandem Meetings 18(2, Supplement):S206-S207, 2012. e-Pub 2012.
185. Nieto Y, Jones RB, Popat U, Andersson B, Valdez B, Thall P, Shpall EJ, Chancoco C, Alousi A, Anderlini P, Hosing C, Qazilbash M, Bashir Q, Kebriaei P, Khouri I, Ciurea S, Parmar S, Rondon G, Champlin R. Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity in Refractory or Poor-Risk Relapsed Non-Hodgkin's Lymphoma (NHL) Patients Receiving an Autologous Stem-Cell Transplant (ASCT). Biol Blood Marrow Transplant 2012 BMT Tandem Meetings 18(2, Supplement):S206, 2012. e-Pub 2012.
186. Zhou Y, Jorgensen JL, Saliba RM, Wang SA, Rondon G, Ledesma C, Andersson BS, de Lima MJ, Shpall EJ, Popat U, Ciurea SO, Alousi AM, Qazilbash M, Hosing CM, Medeiros LJ, Champlin R, Kebriaei P. Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation. Blood 53rd ASH Annual Meeting 118(21):3072, 2011. e-Pub 2011.
187. Nieto Y, Thall PF, Andersson BS, Popat UR, Anderlini P, Valdez BC, Shpall EJ, Qazilbash M, Alousi AM, Chancoco C, Hosing CM, Kebriaei P, Bashir Q, Shah N, Khouri I, Ciurea SO, McMullin B, Rondon G, Champlin R, Jones R. High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies. Blood 53rd ASH Annual Meeting 118(21):3083, 2011. e-Pub 2011.
188. De Lima M, Ahmed S, Shpall EJ, Rondon G, Chen J, Woodworth GG, Chiattone A, Chu DT, Popat UR, Campos SR, Alousi AM, Hosing CM, Parmar S, Kebriaei P, Khouri IF, Cortes JE, Issa JPJ, Champlin R. Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors. Blood 53rd ASH Annual Meeting 118(21):3106, 2011. e-Pub 2011.
189. Popat U, Bassett R, Silva LD, Alousi AM, Anderlini P, Hosing CM, Jones R, Kebriaei P, Khouri I, Shpall EJ, Qazilbash MH, Garcia-Manero G, Andersson BS, Champlin R, de Lima MJ. Long Term Results of Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome: Analysis of Prognostic Factors. Blood 53rd ASH Annual Meeting 118(21):4531, 2011. e-Pub 2011.
190. Ciurea SO, Saliba RM, Bayraktar UD, Xie S, Rondon G, Parmar S, Kebriaei P, Montes N, Sharma M, Konopleva M, Nieto Y, Qazilbash MH, Alousi AM, Andersson BS, Hosing CM, Shpall EJ, Khouri IF, de Lima M, Champlin R. Improved Early Outcomes with T-Cell Replete (TCR) Compared with T-Cell Depleted (TCD) Haploidentical Stem Cell Transplantation (HaploSCT). Blood 53rd ASH Annual Meeting 118(21):320, 2011. e-Pub 2011.
191. Zipp L, Saliba RM, Valverde R, Okoroji GJ, Korbling M, Samuels BI, Abruzzo LV, Alousi AM, Andersson BS, Hosing CM, Erwin B, Anderlini P, Popat UR, Kebriaei P, Macapinlac HA, Champlin R, Khouri IF. Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies. Blood 53rd ASH Annual Meeting 118(21):2005, 2011. e-Pub 2011.
192. Khouri IF, Saliba RM, Korbling M, Alousi AM, Popat UR, Anderlini P, Ciurea SO, Kebriaei P, Qazilbash MH, Champlin R, Bassett RL, Jr. Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd. Blood 53rd ASH Annual Meeting 118(21):894, 2011. e-Pub 2011.
193. Anderlini P, Saliba RM, Ledesma C, Chancoco CM, Acholonu S, Valverde R, Popat UR, Hosing CM, Alousi AM, Shpall EJ, Nieto Y, Ciurea SO, Khouri I, Champlin R. Gemcitabine, Fludarabine, and Melphalan (G-FM) as Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Relapsed and Refractory Hodgkin Lymphoma (HL). Blood 53rd ASH Annual Meeting 118(21):3003, 2011. e-Pub 2011.
194. Khouri IF, Saliba RM, Valverde R, Samuels BI, Korbling M, Alousi AM, Anderlini P, Bashir Q, De Lima M, Hosing C, Kebriaei P, Nieto Y, Popat UR, Qazilbash M, Neelapu S, Fowler NH, Samaniego F, Wang L, Champlin R, Macapinlac HA. Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90yttrium Ibritumomab Tiuxetan (90YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results. Blood 53rd ASH Annual Meeting 118(21):662, 2011. e-Pub 2011.
195. Beitinjaneh A, Saliba RM, Okoroji GJ, Korbling M, Alousi AM, Popat U, Anderlini P, Bashir Q, Andersson BS, Kebriaei P, Hosing CM, Qazilbash M, Fanale MA, Pro B, Champlin R, Khouri I. Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience. Blood 53rd ASH Annual Meeting 118(21):1760, 2011. e-Pub 2011.
196. Chakhachiro ZI, Saliba RM, Okoroji GJ, Korbling M, Alousi AM, Hosing CM, De Lima M, Anderlini P, Popat U, Samuels BI, Medeiros LJ, Bueso-Ramos CE, Champlin R, Khouri IF. 12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years. Blood 53rd ASH Annual Meeting 118(21):4138, 2011. e-Pub 2011.
197. Andersson BS, de Lima MJ, Saliba RM, Shpall EJ, Popat U, Jones R, Nieto Y, Hosing CM, Kebriaei P, Alousi AM, Worth LL, Madden T, Gulbis A, Chen JJ, Rondon G, McAdams P, McMullin B, Andreeff M, Champlin R. Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS; Results of a Randomized Phase III Study. Blood 53rd ASH Annual Meeting 118(21):892, 2011. e-Pub 2011.
198. Popat U, Andersson BS, Bassett R, Ciurea S, Rondon G, Alousi AM, Anderlini P, Hosing C, Jones R, Kebriaei P, Nieto Y, Khouri I, Shpall EJ, Verstovsek S, Qazilbash M, de Lima MJ, Champlin R. Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. Blood 53rd ASH Annual Meeting 118(21):2006, 2011. e-Pub 2011.
199. Beitinjaneh A, Saliba R, Okoroji G, Alousi AM, Popat UR, Korbling M, Anderlini P, Qazilbash M, Kebriaei P, Hosing C, Champlin RE, Khouri IF. Autologous stem cell transplantation (ASCT) as upfront or salvage therapy for noncutaneous T-cell lymphoma (TCL): The University of Texas M. D. Anderson Cancer Center (MDACC) experience. J Clin Oncol 2011 ASCO Annual Meeting 29(15_suppl):6565, 2011. e-Pub 2011.
200. Khouri IF, Saliba R, Korbling M, Alousi AM, Popat UR, Anderlini P, Kebriaei P, Qazilbash M, Champlin RE, Bassett RL. Bendamustine in combination with fludarabine and rituximab: A novel nonmyeloablative conditioning for allogeneic stem cell transplantation (AST) in patients with lymphoid malignancies. J Clin Oncol 2011 ASCO Annual Meeting 29(15_suppl):e18511, 2011. e-Pub 2011.
201. Aung FM, Lichtiger B, Alousi A, Hosing C, Qazilbash M, de Lima M, Kebriaei P, Khouri I, Champlin RC, Popat U. The Incidence and Natural History of Pure Red Cell Aplasia in Major ABO Mismatched Hematopoietic Stem Cell Transplantation in Patients Receiving Modern Reduce Intensity and Reduced Toxicity Regimens. Biol Blood Marrow Transplant 2011 BMT Meetings 17(2, Supplement):S153, 2011. e-Pub 2011.
202. Tang X, de Lima M, Wei W, Chiattone A, Thall PF, Medeiros LJ, Rondon G, Shpall EJ, Jones RB, Nieto Y, Alousi A, Champlin RE, Andersson BS. Early Mixed Chimerism Does Not Alter Long-Term Prognosis for Patients Receiving IV Busulfan-Fludarabine (Iv Bu-Flu) With Allogeneic Stem Cell Transplantation for AML/MDS. Biol Blood Marrow Transplant 2011 BMT Tandem Meetings 17(2, Supplement):S304, 2011. e-Pub 2011.
203. Ciurea SO, Saliba RM, Rondon G, Sharma M, Montes N, Bosque D, McMannis J, Fernandez-Vina M, Xie S, Konopleva M, Parmar S, Nieto Y, Kebriaei P, Qazilbash M, Alousi A, Popat U, Hosing CM, Shpall EJ, Khouri IF, de Lima M, Champlin RE. Haploidentical Stem Cell Transplantation for Minorities. Biol Blood Marrow Transplant 2011 BMT Tandem Meetings 17(2, Supplement):S227, 2011. e-Pub 2011.
204. Saliba RM, de Lima M, McMannis J, Robinson S, Shpall E, Champlin RE, Bosque DM, Parmar S, Rondon G, Simmons P, Alousi A. Dynamics of Recovery in Double Umbilical Cord Blood Transplantation With an ex-vivo Mesenchymal Cell Expanded Unit: Faster Recovery With Engraftment of the Expanded Unit. Biol Blood Marrow Transplant 2011 BMT Tandem Meetings 17(2, Supplement):S318, 2011. e-Pub 2011.
205. Leen AM, Saliba R, Maewal I, Ku S, Katari U, Tripic T, de Lima M, Alousi A, Shpall EJ, Bollard CM. Immune Reconstitution and Infectious Complications in Cord Blood Transplant Patients. Biol Blood Marrow Transplant 2011 BMT Tandem Meetings 17(2, Supplement):S232, 2011. e-Pub 2011.
206. Andersson BS, Valdez BC, Thall PF, Wang X, Worth LL, Popat U, Alousi A, Hosing C, Jones RB, Shpall EJ, de Lima M, Champlin RE. Clofarabine ± Fludarabine and IV Busulfan With Allogeneic Stem Cell Transplantation for Advanced Myeloid Leukemia (ML) and MDS. Biol Blood Marrow Transplant 2011 BMT Tandem Meetings 17(2, Supplement):S293, 2011. e-Pub 2011.
207. Konopleva M, Zhihong Z, Wang RY, Thall PF, McCormick G, Lu H, Chen JJ, Shpall EJ, Ciurea SO, Kebriaei P, Alousi AM, Popat U, Anderlini P, Nieto Y, Parmar S, McMullin B, Rondon G, Schober WD, Gulbis, Cool R, Lin E, Andreeff M, Champlin R. A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogenic Stem Cell Transplantation. Blood 52nd ASH Annual Meeting 116(21):2358, 2010. e-Pub 2010.
208. Nieto Y, Anderlini P, Popat U, Liu P, Andersson BS, Shpall EJ, Kebriaei P, Hosing C, Alousi AM, Qazilbash MH, Ciurea SO, Parmar S, Champlin RE, Jones R. Gemcitabine, Busulfan and Melphalan (GemBuMel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity In Refractory Hodgkin’s Lymphoma (HL) Patients Receiving An Autologous Stem-Cell Transplant (ASCT): A Contemporaneous Comparison with BEAM and Busulfan/Melphalan (BuMel). Blood 52nd ASH Annual Meeting 116(21):690, 2010. e-Pub 2010.
209. Kebriaei P, Ledesma C, Culotta K, Shpall EJ, Ciurea SO, Alousi A, de Lima M, Popat U, Thomas DA, Champlin RE, Andersson BS. Clofarabine (Clo) and Busulfan (Bu) as a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) In Patients (pts) with Acute Lymphoblastic Leukemia (ALL). Blood 52nd ASH Annual Meeting 116(21):3484, 2010. e-Pub 2010.
210. Ciurea SO, Aung FL, de Lima M, Thall PF, Rondon G, Kebriaei P, Alousi A, Shpall EJ, Hosing C, Khouri IF, Champlin RE, Fernandez-Vina M. Anti-HLA Antibodies and Graft Rejection In Hematopoietic Stem Cell Transplantation. Blood 52nd ASH Annual Meeting 116(21):519, 2010. e-Pub 2010.
211. Tang XW, de Lima M, Wei W, Chiattone A, Thall PF, Jeffrey M, Rondon G, Chen JJ, Shpall EJ, Jones R, Nieto Y, Alousi AM, Champlin RE, Andersson BS. Early Mixed Chimerism After Allogeneic Stem Cell Transplantation with the Reduced-Toxicity IV Busulfan-Fludarabine (BuFlu) Regimen Does Not Independently Affect Long-Term Prognosis for Patients with AML/MDS. Blood 52nd ASH Annual Meeting 116(21):3446, 2010. e-Pub 2010.
212. Okoroji GJ, Silva LD, Saliba RM, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriaei P, Popat U, Qazilbash M, Fayad L, Samaniego F, Fowler N, Champlin R, Hagemeister F, Khouri IF. Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy. Blood 52nd ASH Annual Meeting 116(21):3510, 2010. e-Pub 2010.
213. Champlin R, Lee DA, Fernandez-Vina M, Rondon G, McAdams P, Chen J, Qazilbash MH, Kebriaei P, Parmar S, Shpall EJ, Popat U, Alousi A, Ciurea SO, Cooper L, Peter T, McMannis J. Alloreactive Nk Cells to Augment Antileukemia Cytotoxicity with Allogeneic Stem Cell Transplantation for Aml/Mds: A Phase I Study. Blood 52nd ASH Annual Meeting 116(21):489, 2010. e-Pub 2010.
214. Alousi AM, Andersson BS, Saliba RM, Botnick W, Rondon G, Shpall EJ, de Lima M, Popat U, Hosing C, Kebriaei P, Khouri I, Qazilbash MH, Anderlini P, Nieto Y, Ciurea S, Jones R, Champlin R. Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies. Blood 52nd ASH Annual Meeting 116(21):2341, 2010. e-Pub 2010.
215. de Lima M, Robinson S, McMannis J, Alousi AM, Saliba RM, Munsell M, Kebriaei P, Hosing C, Parmar S, Cooper L, Shah N, Kelly SS, Rondon G, Fernandez-Vina M, Maewall I, Bosque D, Bollard CM, Chen JJ, McNiece IK, Komanduri KV, Nieto Y, Jones R, Andersson BS, Popat U, Champlin RE, Simmons PJ, Shpall EJ. Mesenchymal Stem Cell (MSC) Based Cord Blood (CB) Expansion (Exp) Leads to Rapid Engraftment of Platelets and Neutrophils. Blood 52nd ASH Annual Meeting 116(21):362, 2010. e-Pub 2010.
216. Williams LA, Couriel DR, Mendoza TR, McCarthy PL, Neumann JL, White MH, Mobley GM, Kapoor S, Hernandez L, Alousi AM, Cleeland CS. A New Measure Of Symptom Burden In Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant 2010 BMT Meetings 16(2, Supplement):S177, 2010. e-Pub 2010.
217. Jacobson PA, Juang J, Kim M, Logan B, Alousi A, Grimley M, Bolanos-Meade J, Ho V, Levine JE, Weisdorf D. Mycophenolate Pharmacokinetics And Association With Response To Acute Graft vs Host Disease (GVHD) Treatment. Biol Blood Marrow Transplant 2010 BMT Meetings 16(2, Supplement):S299-S300, 2010. e-Pub 2010.
218. Andersson BS, de Lima M, Valdez BC, Thall PF, Worth LL, Popat U, Jones RB, Shpall EJ, Madden T, McAdams PL, Alousi AM, Rondon G, Kebriaei P, Champlin RE. Clofarabine±Fludarabine With IV Busulfan And Allogeneic Stem Cell Transplantation For Relapsed, Refractory Myeloid Leukemia (ML) And MDS. Biol Blood Marrow Transplant 2010 BMT Meetings 16(2, Supplement):S271-S272, 2010. e-Pub 2010.
219. Sharma M, Qazilbash MH, Hosing CM, Thall PF, Mendoza FL, Han E, Wang M, Shah J, Alousi AM, Anderlini P, Kebriaei P, Khouri IF, Popat UR, de Lima M, Champlin RE, Giralt SA. Addition Of Bortezemib To High Dose Melphalan Does Not Improve Response Rate Or Progression-Free Survival. Biol Blood Marrow Transplant 2010 BMT Meetings 16(2, Supplement):S200-S201, 2010. e-Pub 2010.
220. Ciurea SO, Cano P, de Lima M, Thall PF, Rondon G, Kebriaei P, Alousi A, Hosing C, Khouri IF, Champlin RE, Fernandez-Vina M. The Role Of Donor-Specific Anti-HLA Antibodies (DSA) In Hematopoietic Stem Cell Transplantation From Matched Unrelated Donors. Biol Blood Marrow Transplant 2010 BMT Meetings 16(2, Supplement):S158, 2010. e-Pub 2010.
221. Popat U, Hosing C, Fanale M, Medeiros LJ, Alousi AM, Giralt SA, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson B, Champlin R, Anderlini P. Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Blood 51st ASH Annual Meeting 114(22):2310, 2009. e-Pub 2009.
222. Sharma M, Thall P, Wang X, Hosing C, Mendoza FL, Han E, Wang M, Weber D, Shah J, Alousi A, Anderlini P, Kebriaei P, Khouri IF, Popat U, de Lima M, Champlin RE, Giralt S, Qazilbash M. A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. Blood 51st ASH Annual Meeting 114(22):2309, 2009. e-Pub 2009.
223. Alousi AM, Rondon G, Okoroji GJ, Popat U, Silva LD, Hymes S, Neumann J, Brunelle NM, Kebriaei P, Hosing C, Khouri IF, Shpall EJ, Qazilbash MH, Giralt S, Champlin R, Saliba RM. Co-Morbidity Score at the Time of Transplant Determines Prognosis in Older Patients Who Develop Acute Graft-Vs.-Host Disease (GVHD). Blood 51st ASH Annual Meeting 114(22):2244, 2009. e-Pub 2009.
224. Qureshi S, Sharma M, Hosing C, Mendoza FL, Shah J, Alousi A, Anderlini P, Kebriaei P, Khouri IF, Popat U, de Lima M, Champlin RE, Giralt S, Qazilbash MH. Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Blood 51st ASH Annual Meeting 114(22):4354, 2009. e-Pub 2009.
225. Leandro DS, Saliba R, McCormick D, Okoroji GJ, Alousi A, Anderlini P, Ciurea S, Hosing C, Kebriaei P, Popat U, Qazilbash M, Ueno N, McMannis J, Champlin R, Pro B, Khouri IF. Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL). Blood 51st ASH Annual Meeting 114(22):3213, 2009. e-Pub 2009.
226. Okoroji GJ, Jr BR, Alousi A, Anderlini P, De Lima M, Giralt S, Hosing C, Kebriaei P, Popat U, Qazilbash M, Ueno N, Stachowiak AM, Erwin B, Fayad L, Pro B, Fowler N, McLaughlin P, Neelapu S, Younes A, Champlin R, Podoloff D. Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies. Issa F Khouri, Robyn Harrell, Rosamar Valverde, Martin Korbling, Taghi Manshouri, Barry Samuels,. Blood 51st ASH Annual Meeting 114(22):868, 2009. e-Pub 2009.
227. Popat U, Rondon G, Alousi A, Anderlini P, Andersson B, Hosing C, de Lima M, Ciurea S, Giralt S, Kebriaei P, Nieto Y, Khouri I, Qazilbash MH, Jones R, Champlin R. Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis. Blood 51st ASH Annual Meeting 114(22):2283, 2009. e-Pub 2009.
228. de Lima M, McMannis JD, Hosing C, Kebriaei P, Robinson S, Kelly S, Silva LD, Fernandez-Vina M, Chiattone A, Bosque D, Rondon G, Giralt S, Cooper L, Chen JJ, Parmar S, Jones R, Andersson B, Worth L, Alousi A, McNiece IK, Komanduri KV, Simmons PJ, Champlin RE, Shpall EJ. Rapid Engraftment of Neutrophils and Platelets with Mesenchymal Stem Cell Based Cord Blood (CB) Expansion (EXP). Blood 51st ASH Annual Meeting 114(22):3394, 2009. e-Pub 2009.
229. Shah N, Ahmed KF, Qureshi S, Shah J, Orlowski RZ, Weber DM, Hosing C, Popat U, Alousi A, Champlin RE, Giralt S, Qazilbash M. Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma. Blood 51st ASH Annual Meeting 114(22):1227, 2009. e-Pub 2009.
230. Bashir Q, Thall P, Hosing C, Mendoza FL, Han E, Wang M, Shah J, Alousi A, Anderlini P, Kebriaei P, Khouri IF, Popat U, de Lima M, Champlin R, Giralt SA, Qazilbash MH. Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of First Autograft in Patients with Multiple Myeloma. Blood 51st ASH Annual Meeting 114(22):1186, 2009. e-Pub 2009.
231. Stolar KR, Neumann J, Popat UR, Alousi AM. Identifying And Addressing the Long Term Needs Of the Adult Allogeneic Stem Cell Transplant (SCT) Recipient Through A Survivorship Clinical Program. Biol Blood Marrow Transplant 2009 BMT Meetings 15(2, Supplement):144-145, 2009. e-Pub 2009.
232. Kazmi SMA, Parikh GC, Lahoti A, Mendoza F, Hosing C, Popat U, Alousi AM, Weber DM, Wang M, Champlin RE. Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients With Multiple Myeloma. Biol Blood Marrow Transplant 2009 BMT Tandem Meetings 15(2, Supplement):41, 2009. e-Pub 2009.
233. Ciurea SO, de Lima M, Giralt S, Alousi A, Kebriaei P, Khouri IF, Anderlini P, Andersson BS, Hosing CM, Champlin RE, Popat U. Outcomes Of Allogeneic Stem Cell Transplantation for Patients With Acute Leukemia Transformed from Myelofibrosis. Biol Blood Marrow Transplant 2009 BMT Meetings 15(2, Supplement):62, 2009. e-Pub 2009.
234. Efebera Y, Saliba RM, Thandi RS, Popat U, De Lima M, Alousi A, Hosing C, Ledford M, Champlin R, Giralt S. Impact of Pre-stem Cell Transplant Ferritin Levels on Late Transplant Complications. A Landmark Analysis to Determine Potential Role of Iron Chelation in Improving Transplant Outcomes. Biol Blood Marrow Transplant 2009 BMT Meetings 15(2, Supplement):92-93, 2009. e-Pub 2009.
235. Pelosini M, Mendoza F, Hosing C, Popat UR, Anderlini P, Alousi AM, Kebriaei P, Weber DM, Wang M, Champlin RE, Giralt SA, Qazilbash MH. Improved Outcome for Allogeneic Transplantation Performed After January 2000. Biol Blood Marrow Transplant 2009 BMT Meetings 15(2, Supplement):68-69, 2009. e-Pub 2009.
236. Ciurea SO, Kebriaei P, Khouri I, Qazilbash M, Jones R, Petropoulos D, Worth LL, Alousi A, Hosing C, Cano P, McMannis J, Giralt S, Fernandez-Vina M, Shpall EJ, de Lima M. Fludarabine, Melphalan and Thiotepa Conditioning for Unrelated Donor Cord Blood Transplantation. Biol Blood Marrow Transplant 2009 BMT Meetings 15(2, Supplement):48-49, 2009. e-Pub 2009.
237. Alatrash G, Pelosini M, Saliba R, Rondon G, Zhang W, Giralt S, Kebriaei P, Alousi A, Khouri I, Champlin R, de Lima M. Post-Hematopoietic Stem Cell Transplantation (HSCT) Outcomes in Patients With AML Transplanted Prior to Achieving Platelet Recovery. Biol Blood Marrow Transplant 2009 BMT Meetings 15(2, Supplement):58, 2009. e-Pub 2009.
238. Walters KH, Hosing C, Smith VR, Rhodes BA, Thompson RC, Qazilbash MH, McMannis JD, Alousi A, De Lima M, Kebriaei P, Giralt S, Khouri I, Champlin RE, Popat UR. An Analysis of the Charges Associated With Peripheral Blood Hematopoietic Progenitor Cell (HPC) Mobilization, Collection and Cryopreservation In Patients With Lymphomas Undergoing Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant 2009 BMT Meetings 15(2, Supplement):71-72, 2009. e-Pub 2009.
239. Saliba RM, Komanduri KV, Koca E, Alousi AM, Giralt S, Andersson BS, Zhang W, Rondon G, Neumann J, Popat UR, Kebriaei P, de Lima M, Champlin RE. High Rate Of De Novo Chronic Graft-Versus-Host (cGVHD) Following Busulfan-Fludarabine Conditioning And Allogeneic Stem Cell Transplantation From A Matched-Sibling Donor (MSD) For AML/MDS. Biol Blood Marrow Transplant 2009 BMT Meetings 15(2, Supplement):S122, 2009. e-Pub 2009.
240. Andersson BS, de Lima M, Popat U, Jones RB, Shpall EJ, Hosing C, McAdams PL, Alousi AM, Kebriaei P, Champlin RE, Worth LL, Madden TL, Kazerooni R. Allogeneic Stem Cell Transplantation (Allo-SCT) For Relapsed, Refractory Myeloid Leukemia and Mds Using Clofarabine (Clo) ± Fludarabine (Flu) with IV Busulfan (Bu) As Conditioning Therapy. Biol Blood Marrow Transplant 2009 BMT Meetings 15(2, Supplement):86-87, 2009. e-Pub 2009.
241. de Lima M, McNiece I, McMannis J, Hosing C, Kebriaei P, Komanduri K, Worth L, Staba S, Cooper L, Petropolous D, Lee D, Jones R, Nieto Y, Andersson B, Korbling M, Alousi A, Qazilbash M, Popat U, Khouri I, Bollard C, Leen A, Rondon G, Molldrem J, Champlin R, Simmons P, Shpall E. Double Cord Blood Transplantation (CBT) With Ex-Vivo Expansion (EXP) of One Unit Utilizing A Mesenchymal Stromal Cell (MSC) Platform. Biol Blood Marrow Transplant 2009 BMT Meetings 15(2, Supplement):47-48, 2009. e-Pub 2009.
242. Ciurea SO, De Lima M, Giralt SA, Qazilbash MH, Alousi A, Kebriaei P, Khouri IF, Anderlini P, Andersson B, Hosing C, Verstovsek S, Kantarjian H, Champlin R, Popat U. Allogeneic Stem Cell Transplantation for Patients with Acute Leukemia Transformed from Myelofibrosis. Blood 50th ASH Annual Meeting 112(11):3293, 2008. e-Pub 2008.
243. Silva LD, Cortes J, Jabbour E, Giralt S, Kebriaei P, O’Brien S, Alousi A, Qazilbash M, Rondon G, Ravandi F, Ribeiro R, Hosing C, Kantarjian H, Champlin R, De Lima M. Novel Tyrosine Kinase Inhibitor Therapy Before Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia. Blood 50th ASH Annual Meeting 112(11):2154, 2008. e-Pub 2008.
244. Giralt S, Saliba RM, Rondon G, Silva LD, Alousi AM, Popat U, De Lima M, Andersson B, Kebriaei P, Anderlini P, Hosing C, Jones R, Shpall EJ, Champlin RE, Khouri IF. Outcomes of Allogeneic Stem Cell Transplant in Patients with Myeloid Leukemias Over 65 Years of Age. Rationale for Aggressive Therapy with Curative Intent. Blood 50th ASH Annual Meeting 112(11):2153, 2008. e-Pub 2008.
245. Joseph, Jr RW, Komanduri KV, Saliba RM, Alousi A, Giralt S, Rondon G, Neumann J, Trevino C, Couriel DR, Champlin R, Popat U. High Prevalence of Vitamin D Deficiency in Allogeneic Stem Cell Transplant Recipients. Blood 50th ASH Annual Meeting 112(11):2138, 2008. e-Pub 2008.
246. Tam CS, Bassett R, Ledesma C, Korbling MJ, Okoroji GJ, Harrell R, Hsu Y, Silva LD, Alousi AM, Hosing CM, Kebriaei P, Rondon G, Giralt S, De Lima M, Anderlini P, Popat U, Qazilbash MH, Samuels B, Champlin RE, Khouri IF. Rituximab Containing Autologous Stem Cell Transplantation May Be Curative in Mantle Cell Lymphoma for Patients in First Remission, but Not for Patients with Recurrent Disease. Blood 50th ASH Annual Meeting 112(11):1142, 2008. e-Pub 2008.
247. Khouri IF, Lopez A, Okoroji GJ, Korbling M, McCormick G, Hsu Y, de Padua L, Alousi AM, Hosing CM, Kebriaei P, Rondon G, Giralt SA, de Lima MJ, Anderlini P, Popat UR, Qazilbash MH, Champlin RE, Pro B. Myeloablative Chemotherapy for T-Cell Lymphoma: a Case for Autologous Stem Cell Transplantatin (Auto) in First Remission. Blood 50th ASH Annual Meeting 112(11):1141, 2008. e-Pub 2008.
248. Khouri IF, Bassett R, Samuels B, Maadani F, Okoroji FJ, Harrell R, Korbling M, Silva LD, Alousi A, Hosing C, Giralt S, de Lima M, Anderlini P, Popat U, Valverde R, Hsu Y, Hagemeister F, McLaughlin P, Medeiros LJ. Addition of Rituximab to Mobilization and Conditioning Overcomes the Predictive Value of Follicular Lymphoma International Prognostic Index (FLIPI) Score in Patients with Relapsed FL Undergoing Autologous Stem Cell Transplantation (AUTO). Blood 50th ASH Annual Meeting 112(11):1140, 2008. e-Pub 2008.
249. De Lima M, Silva LD, Giralt S, Komanduri K, Andersson BS, Hosing C, Qazilbash M, Shpall E, Thall P, Zhang W, McCormick G, Wang X, Popat U, Soriano A, Alousi A, Champlin R, Garcia-Manero G. Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study. Blood 50th ASH Annual Meeting 112(11):1134, 2008. e-Pub 2008.
250. Popat U, de Lima MJ, Ativitavas T, Rondon G, de Padua Silva L, Koca E, Zhang W, Alousi A, Anderlini P, Giralt SA, Hosing CM, Jones R, Kebriaei P, Khouri I, Nieto Y, Qazilbash MH, Andersson BS, Champlin R. Allogeneic Transplantation (HCT) for Myelodysplastic Syndrome:Recent MDACC Experience. Blood 50th ASH Annual Meeting 112(11):1131, 2008. e-Pub 2008.
251. Khouri I, Bassett RL, Hsu Y, Dickason T, Acholonu S, Harrell R, Okoroji GJ, Silva LD, Korbling MJ, Alousi AM, Hosing C, Popat U, Giralt SA, Kebriaei P, Qazilbash MH, Ledesma C, Keating MJ, Champlin RE, Bueso-Ramos C. Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival. Blood 50th ASH Annual Meeting 112(11):1128, 2008. e-Pub 2008.
252. Popat U, Saliba R, Silva LD, Andersson BS, Alousi AM, Anderlini P, de Lima M, Okoroji GJ, Hosing CM, Jones RB, Kebriaei P, Khouri I, Nieto Y, Qazilbash MH, Champlin R, Giralt SA. Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS. Blood 50th ASH Annual Meeting 112(11):799, 2008. e-Pub 2008.
253. Khalili JS, Saliba RM, St John L, Alousi A, Wieder ED, De Lima M, Champlin R, Molldrem JJ, Shpall EJ, McMannis J, Komanduri KV. Regulatory and Naïve T Cells in Unmanipulated Donor Grafts Are Not Associated with Acute Graft Vs Host Disease in Matched Sibling Transplants for AML. Blood 50th ASH Annual Meeting 112(11):719, 2008. e-Pub 2008.
254. De Lima M, McMannis JD, Saliba R, Worth L, Kebriaei P, Popat U, Qazilbash M, Jones R, Giralt S, Silva LD, Cooper L, Petropoulos D, Lee D, Kelly S, Thall P, Robinson S, Khouri I, Hosing C, Korbling M, Alousi A, Rondon G, Andersson BS, Nieto Y, Ciurea S, Komanduri K, Champlin RE, Shpall E. Double Cord Blood Transplantation (CBT) with and without Ex-Vivo Expansion (EXP): A Randomized, Controlled Study. Blood 50th ASH Annual Meeting 112(11):154, 2008. e-Pub 2008.
255. Alousi A, Weisdorf DJ, Logan BR, Bolanos-Meade J, Goldstein SC, Ho VT, Hayes-Lattin B, Wingard JR, Horowitz MM, Levine JE. BMT CTN 0302: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox, and Pentostatin in Combination with Corticosteroids in 180 Patients (pts) with Newly Diagnosed Acute Graft Vs. Host Disease (aGVHD). Blood 50th ASH Annual Meeting 112(11):55, 2008. e-Pub 2008.
256. Qazilbash MH, Saliba RM, Pelosini M, Hosing CM, Mendoza FL, Han E, Wang M, Weber DM, Alousi AM, Anderlini P, Kebriaei P, Khouri IF, Popat UR, De Lima M, Orlowski RZ, Champlin RE, Giralt SA. A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. Blood 50th ASH Annual Meeting 112(11):3320, 2008. e-Pub 2008.
257. Cole SM, Saliba R, Pelosini M, Mendoza FL, Weber D, Wang M, Thomas S, Orlowski RZ, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma. Blood 50th ASH Annual Meeting 112(11):3298, 2008. e-Pub 2008.
258. Kebriaei P, Giralt S, Jones D, Gutierrez K, De Lima M, Korbling M, Khouri IF, Popat U, Qazilbash MH, Alousi A, Ciurea SO, Cooper L, Shpall E, Champlin R. Addition of Umbilical Cord Blood (UCB) Unit to Reduced Intensity Conditioning (RIC) Regimen to Augment Graft Versus Tumor (GVT) in Patients (pts) with Advanced Hematologic Malignancies. Blood 50th ASH Annual Meeting 112(11):3297, 2008. e-Pub 2008.
259. Ciurea SO, Kebriaei P, Khouri IF, Qazilbash MH, Jones RB, Petropoulos D, Worth LL, Alousi AM, Hosing CM, Patah P, Cano P, McMannis J, Giralt SA, Fernandez-Vina M, Champlin RE, Shpall EJ, De Lima M. High Rate of Engraftment and Low Regimen-Related Toxicity Using Fludarabine, Melphalan and Thiotepa Conditioning for Unrelated Donor Cord Blood Transplantation. Blood 50th ASH Annual Meeting 112(11):4414, 2008. e-Pub 2008.
260. Andersson BS, de Lima M, Worth LL, Popat U, Jones RB, Shpall EJ, Hosing C, Madden T, Kazerooni R, McAdams P, Alousi A, Kebriaei P, Champlin RE. Clofarabine (Clo) +/– Fludarabine (Flu) with IV Busulfan (Bu) and Allogeneic Stem Cell Transplantation (Allo-SCT) for Relapsed, Refractory Myeloid Leukemia (ML) and MDS. Blood 50th ASH Annual Meeting 112(11):4390, 2008. e-Pub 2008.
261. Hosing C, Smith VR, Rhodes BA, Walters KH, Qazilbash MH, McMannis JD, Alousi AM, De Lima M, Kebriaei P, Giralt S, Khouri I, Champlin R, Popat U. An Analysis of the Costs Associated with Peripheral Blood Hematopoietic Progenitor Cell Mobilization, Collection and Cryopreservation in Patients with Lymphomas Undergoing Autologous Stem Cell Transplantation. Blood 50th ASH Annual Meeting 112(11):2377, 2008. e-Pub 2008.
262. Saliba RM, Komanduri KV, Koca E, Alousi AM, Giralt S, Andersson BS, Zhang W, Rondon G, Popat UR, Kebriaei P, de Lima M, Champlin RE. Donor Type Impacts the Incidence of Severe Acute but Not Chronic Graft- Versus-Host Disease (GVHD) after Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation (ASCT) for Treatment of AML/MDS. Blood 50th ASH Annual Meeting 112(11):2227, 2008. e-Pub 2008.
263. Alatrash G, Pelosini M, Saliba RM, Rondon G, Zhang W, Giralt S, Kebriaei P, Alousi A, Khouri IF, Champlin RE, De Lima M. Platelet Recovery Prior to Stem Cell Transplantation Predicts for Post- Transplant Outcomes in Patients with AML. Blood 50th ASH Annual Meeting 112(11):3000, 2008. e-Pub 2008.
264. Popat U, Saliba R, Ahlawat S, Okoroji GJ, Alousi A, Anderlini P, Andersson B, de Lima M, Jones R, Kebriaei P, Korbling M, Nieto Y, Qazilbash M, Shpall EJ, Khouri I, Giralt S, Champlin R, Hosing C. Incidence and Factors Influencing Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD). Biol Blood Marrow Transplant 2008 BMT Meetings 14(2, Supplement):37-38, 2008. e-Pub 2008.
265. Petropoulos D, Giralt SA, Andersson BS, Chan KW, Rondon G, Popat UR, Hosing C, Alousi AM, Champlin RE, de Lima MJ. Central Nervous System (CNS) Involvement at Diagnosis does not Adversely Affect the Outcome of High-Dose Chemotherapy and Transplant for Patients with Acute Myeloid Leukemia (AML). Biol Blood Marrow Transplant 2008 BMT Meetings 14(2, Supplement):61-62, 2008. e-Pub 2008.
266. Ramos CA, Saliba RM, Khorshid O, de Padua L, Giralt S, Andersson BS, Ueno NT, Shpall EJ, Khouri IF, Hosing C, Alousi A, Nieto Y, Qureshi SR, Champlin RE, de Lima M. Hepatitis C (HC) Virus Infection Is Associated with Worse Survival after Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) for Hematological Malignancies. Blood 49th ASH Annual Meeting 110(11):48, 2007. e-Pub 2007.
267. Qazilbash MH, Saliba RM, Parikh GC, Hosing C, Mendoza F, Weber DM, Wang M, Thomas SK, Flosser TS, Kebriaei P, Popat U, Alousi AM, de Lima M, Champlin RE, and Giralt SA. A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma. Blood 49th ASH Annual Meeting 110(11):3032, 2007. e-Pub 2007.
268. Patah P, Fernandez-Vina M, Stastny P, Liu P, Cano P, Pesoa S, Shpall EJ, Giralt S, Khouri I, Anderlini P, Alousi A, Padua L, Ramos C, Rondon G, Nieto Y, Champlin R, and de Lima M. Mismatches in Low Expression HLA Class II Loci and MIC-A in Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT). Blood 49th ASH Annual Meeting 110(11):3050, 2007. e-Pub 2007.
269. Popat UR, Rondon G, Alousi AM, Anderlini P, Andersson BS, de Lima MJ, Giralt SA, Hosing CM, Kebriaei P, Jones R, Nieto Y, Shpall EJ, Verstovesek S, Qazilbash MH, and Champlin R. Myelofibrosis and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RISCT). Blood 49th ASH Annual Meeting 110(11):3062, 2007. e-Pub 2007.
270. Tam CS, Ledesma C, Korbling M, Fayad LE, Wang M, Alousi A, Hosing C, Kebriaei P, Rondon G, Giralt SA, Anderlini P, Popat U, Couriel D, Pro B, Samuels B, Hagemeister F, Champlin RE, and Khouri IF. Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center. Blood 49th ASH Annual Meeting 110(11):484, 2007. e-Pub 2007.
271. Chu DT, Saliba R, Qureshi S, Alousi A, Anderlini P, Bukhari F, de lima M, Giralt SA, Kebriaei P, Khouri IF, Parik G, Popat U, Shpall EJ, Yusuf WS, Champlin RE, Qazilbash MH, and Hosing C. Cardiac Toxicity and Non-Relapse Mortality in Patients with Low Left Ventricular Ejection Fraction Undergoing Stem Cell Transplantation. Blood 49th ASH Annual Meeting 110(11):3002, 2007. e-Pub 2007.
272. Qazilbash MH, Saliba RM, Parikh G, Hosing C, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel DR, Kebriaei P, Popat U, Alousi A, de Lima M, Champlin RE, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan Is Safe and Effective for Autotransplantation for Multiple Myeloma. Blood 49th ASH Annual Meeting 110(11):942, 2007. e-Pub 2007.
273. Westin JR, Saliba RM, de Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Champlin R, Couriel DR. Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD). Blood 49th ASH Annual Meeting 110(11):5015, 2007. e-Pub 2007.
274. Alousi AM, Hosing C, Saliba RM, Valverde RB, Maadani F, Korbling M, Okoroji GJ, Fayad LE, Stachowiak AM, Erwin WD, Anderlini P, de Lima MJ, Giralt SA, Popat UR, Kebriaei P, Ueno NT, McLaughlin PW, Pro B, Wang M, Rodriguez A, Hagemeister FB, Macapinlac HA, Podoloff DA, Champlin RE, and Khouri IF. Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status. Blood 49th ASH Annual Meeting 110(11):620, 2007. e-Pub 2007.
275. Silva LD, Saliba RM, de Lima M, Okoroji GJ, Alousi AM, Andersson B, Hosing C, Sphall E, Khouri I, Qazilbash M, Anderlini P, Kebriaei P, Champlin RE, Jones R, Giralt S, and Popat U. Obesity Does Not Impact Outcome in Patients with AML/MDS Undergoing Allogeneic Transplantation. Blood 49th ASH Annual Meeting 110(11):1989, 2007. e-Pub 2007.
276. Giralt S, Saliba RM, Mendoza F, Parikh G, Qureshi S, Zhang W, Popat U, Qazilbash M, Khouri I, Hosing C, Alousi A, Anderlini P, Andersson B, Jones R, Shpall E, Kebriaei P, Nieto Y, Ueno N, Champlin R, and de Lima M. Pre Transplant Values of C Reactive Protein (CRP) and Brain Natriuretic Peptide (BNP) as Predictors of Transplant Outcomes in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndromes (AML/MDS) Undergoing Allogeneic Stem Cell Transplantation (AlloSCT). Blood 49th ASH Annual Meeting 110(11):1984, 2007. e-Pub 2007.
277. Hosing C, Munsell M, Popat U, Körbling M, Valverde R, Maadani F, Kebriaei P, Alousi A, deLima M, McMannis J, Shpall EJ, Qazilbash MH, Anderlini P, Giralt S, Champlin R, and Khouri I. Chemotherapy with Granulocyte Colony Stimulating Factor (G-CSF) Alone Versus Granulocyte Colony Stimulating Factor (G-CSF) Plus Granulocyte-Macrophage Stimulating Factor (GM-CSF) for Hematopoietic Progenitor Cell Mobilization in Patients with Relapsed Non-Hodgkin’s Lymphomas (NHLs). Blood 49th ASH Annual Meeting 110(11):1900, 2007. e-Pub 2007.
278. Parikh GC, Saliba RM, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi A, Champlin RE, Giralt SA, Qazilbash MH. Autotransplantation in Patients with Multiple Myeloma and Concurrent Renal Failure Is Safe and Feasible and Associated with Recovery of Renal Function in > 30% of Patients. Blood 49th ASH Annual Meeting 110(11):5126, 2007. e-Pub 2007.
279. Patah P, Saliba R, Fernandez-Vina M, Cano P, Pesoa S, Rondon G, Andersson B, Giralt S, Kebriaei P, Hosing C, Anderlini P, Couriel D, Alousi A, Padua L, Ramos C, Champlin R, de Lima M. A Comparison of 1 Antigen-Mismatched Related and Matched Unrelated Transplants. Blood 49th ASH Annual Meeting 110(11):3051, 2007. e-Pub 2007.
280. Popat UR, de Lima M, Anderlini P, Andersson B, Couriel D, Hosing C, Kebriaei P, Qazilbash M, Alousi A, Champlin R, Giralt S. Long-term survival of patients with AML in remission after reduced intensity allogeneic hematopoietic stem cell transplantation (RISCT). J Clin Oncol 2007 ASCO Annual Meeting 25(17_suppl):7002, 2007. e-Pub 2007.
281. Qazibalsh MH, Jindani S, Gul Z, Saliba R, Hosing C, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel DP, Kebriaei P, Popat U, Alousi AM, De Lima M, Champlin RE, Giralt SA. Arsenic trioxide with ascorbic acid and high-dose melphalan for autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2007 BMT Meetings 13(2, Supplement):9-10, 2007. e-Pub 2007.
282. Qazilbash MH, Gul Z, Jindani S, Saliba R, Hosing C, Medoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel DP, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation for elderly patients with multiple myeloma. Biol Blood Marrow Transplant 2007 BMT Meetings 13(2, Supplement):10, 2007. e-Pub 2007.
283. Ahmed B, Saliba RM, Ashraf N, Mendoza F, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Deletion of the Short Arm of Chromosome 1 (del 1p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. Blood 48th ASH Annual Meeting 108(11):3101, 2006. e-Pub 2006.
284. Qazilbash MH, Saliba RM, Davis MS, Mendoza FL, Hosing C, Couriel DR, de Lima M, Kebriaei P, Weber DM, Wang M, Alousi AM, Matthes SG, Jones RB, Champlin RE, Giralt SA. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Blood 48th ASH Annual Meeting 108(11):3090, 2006. e-Pub 2006.
285. Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, de Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation for elderly patients with multiple myeloma. Blood 48th ASH Annual Meeting 108(11):5422, 2006. e-Pub 2006.
286. Alousi AM, Saliba RM, Okoroji GJ, Hosing C, Samuels BI, Champlin RE, Khouri IF. The Influence of PET/Gallium (PET/Gal) Status and High-Dose Rituximab (HDR) in Patients with Aggressive, Large, B-Cell Lymphoma (LBCL) Receiving Autologous Stem Cell Transplants (ASCT). Blood 48th ASH Annual Meeting 108(11):3058, 2006. e-Pub 2006.
287. Kebriaei P, Detry M, Carrasco-Yalan A, Anagnostopoulos A, Couriel D, Khouri I, Anderlini P, Hosing C, Alousi A, Giralt S, Champlin R, de Lima M. Long-Term Follow-Up of Allogeneic Stem Cell Transplantation (SCT) with Reduced Intensity Conditioning (RIC) for Patients (pts) with Chronic Myeloid Leukemia (CML). Blood 48th ASH Annual Meeting 108(11):2898, 2006. e-Pub 2006.
288. Heath EI, Alousi A, Eder JP, Valdivieso M, Vasist LS, Appleman L, Bhargava P, Colevas AD, Lorusso PM, Shapiro G. A phase 1 dose escalation trial of ispinesib (SB-715992) administered days 1-3 of a 21-day cycle in patients with advanced solid tumors. J Clin Oncol 2006 ASCO Annual Meeting 24(18_suppl):2026, 2006. e-Pub 2006.
289. Alousi A, Saliba RM, Okoroji G, Hosing C, Samuels BI, Champlin RE, Khouri IF. The Influence of PET/Gallium (P/G) Status and High-Dose Rituximab (HDR) in Patients with Aggressive, Large, B-cell Lymphoma Receiving Autologous Stem Cell Transplant (ASCT). J Clin Oncol 2006 ASCO Annual Meeting 24(18_suppl):6518, 2006. e-Pub 2006.
290. Alousi AM, Parchment R, Bionpally R, Gadgeel S, Weigand R, McCormick J, LoRusso. Phase 1 Clinical Trial of XK469 in patients with chemo-refractory solid tumors. J Clin Oncol 2004 ASCO Annual Meeting 22(14_suppl):2020, 2004. e-Pub 2004.
291. Alousi A, Klein J, Hamm C, Dansey R, Abella E, Zonder J, Dudley A, Baynes R. Myelo-ablative Conditioning with Busulphan, Cyclophosphamide and Cytarabine for AML and MDS Followed by Allogeneic Transplantation. Blood 98, 2001. e-Pub 2001.

Book Chapters

1. Mehta, RS, Alousi, AM. Graft-Versus-Host Disease, 453-479, 2023.
2. Mehta, RS, Sheshadri, A, Alousi, AM. An Overview of Graft-Versus-Host Disease, 17-44, 2023.
3. de Lima M, Alousi A, Giralt S. Preparative Regimens for Stem Cell Transplantation. In: Hematology: Basic Principals and Practice. 5th. Churchill Livingstone, 2008.
4. Alousi AM, Giralt SA. Hematopoietic Progenitor Cells: Allogeneic. In: Rossi’s Principles of Transfusion Medicine. 4th. Wiley-Blackwell, 542-558, 2008.
5. Alousi A, de Lima M. Ablative Preparative Regimens. In: Stem Cell Transplantation for Hematologic and Other Disorders. 2nd. Humana Press, 2008.
6. Alousi A. Graft-Versus-Host Disease: Prevention and Treatment / Transfusion Support. In: Supportive Care Manual for Blood and Marrow Transplantation. 1st. Summit, 97-138; 171-183, 2007.
7. Alousi A. Disseminated Intravascular Coagulation / Fever in the Neutropenic Patient. In: Pediatric Acute Care. 2nd. Lippincott Williams & Wilkins, 74-75; 82 and 84-85, 2001.

Letters to the Editor

1. Marvin-Peek, J, Kantarjian, HM, Jen, WY, Daver, N, Short, NJ, Borthakur, G, Bazinet, A, Maiti, A, Abbas, HA, Yilmaz, M, Issa, GC, Macfarland, M, Alvarado, Y, Garcia-Manero, G, Alousi, AM, Popat, UR, Shpall, E, Ravandi-Kashani, F, DiNardo, C, Kadia, TM. Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AML. American journal of hematology 101: 917-922, 2026.
2. Rafaeli, N, Costa, DM, Ledesma, C, Jain, N, Tewari, P, Khouri, IF, Al-Atrash, G, Short, NJ, Jabbour, EJ, Rezvani, K, Alousi, AM, Popat, UR, Champlin, RE, Shpall, E, Kebriaei, P. Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 25: e374-e377, 2025.